WO2009090054A1 - Substituted sulfonamide derivatives - Google Patents

Substituted sulfonamide derivatives Download PDF

Info

Publication number
WO2009090054A1
WO2009090054A1 PCT/EP2009/000190 EP2009000190W WO2009090054A1 WO 2009090054 A1 WO2009090054 A1 WO 2009090054A1 EP 2009000190 W EP2009000190 W EP 2009000190W WO 2009090054 A1 WO2009090054 A1 WO 2009090054A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
pyrazin
dihydropyrrolo
methoxy
oxoethoxy
Prior art date
Application number
PCT/EP2009/000190
Other languages
French (fr)
Inventor
Beatrix Merla
Stefan OBERBÖRSCH
Ruth Jostock
Michael Engels
Stefan Schunk
Melanie Reich
Sabine Hees
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Priority to CA2712265A priority Critical patent/CA2712265A1/en
Priority to JP2010542577A priority patent/JP2011509961A/en
Priority to EP09702327A priority patent/EP2229395A1/en
Publication of WO2009090054A1 publication Critical patent/WO2009090054A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to substituted sulfonamide derivatives, processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments.
  • the bradykinin 1 receptor (BlR) is not expressed, or is only weakly expressed in most tissues.
  • BlR the expression of BlR can be induced in various cells.
  • IL-I interleukin-1
  • tumour necrosis factor alpha The cytokines interleukin-1 (IL-I) and tumour necrosis factor alpha
  • BlR antagonists in acute and in particular chronic-inflammatory diseases.
  • diseases of the respiratory tract include diseases of the respiratory tract (bronchial asthma, allergies, COPD (chronic obstructive pulmonary disease), cystic fibrosis, etc.), inflammatory intestinal diseases (ulcerative colitis, CD (Crohn's disease), etc.), neurological diseases (multiple sclerosis, neurodegeneration, etc.), inflammations of the skin (atopic dermatitis, psoriasis, bacterial infections, etc.) and mucous membranes (M. Behcet, pelvitis, prostatitis), rheumatic diseases
  • bradykinin (receptor) system is also involved in the regulation of angiogenesis (potential as an angiogenesis inhibitor in cancer and also macular degeneration of the eye) and BlR knockout mice are protected against the danger of becoming overweight due to a particularly fat-rich diet (Pesquero et al . , Biol. Chem. 2006, 387, 119-126) . BlR antagonists are therefore also suitable for treating obesity.
  • BlR antagonists are in particular suitable for treating pain, in particular inflammatory pain and neuropathic pain (Calixto et al . Br. J. Pharmacol 2004, 1-16), in this connection in particular diabetic neuropathy (Gabra et al . , Biol. Chem. 2006, 387, 127-143) . Furthermore they are suitable for the treatment of migraine.
  • An object of the present invention was accordingly to provide new compounds that are suitable in particular as pharmacological active constituents in medicaments, preferably in medicaments for treating disorders or diseases that are at least partially mediated by BlR receptors .
  • the present invention provides substituted sulfonamide derivatives of the general formula I
  • n and n independently of one another, in each case denote 0, 1 or 2; p denotes 1 or 2 ; Q denotes -O- or -CH 2 -;
  • R 2 denotes H, Ci_ 6 -alkyl, aryl or heteroaryl; or an aryl or heteroaryl bonded via a Ci- 6 -alkylene group, C 2 -6-alkenylene group or C 2 - 6 ⁇ alkinylene group;
  • R 3 denotes H, Ci- 6 -alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C 2 -6 ⁇ alkenylene group or C 2 - 6 ⁇ alkinylene group;
  • R 4 denotes H, halogen, CN, NO 2 , Ci- 6 -alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci- 6 -alkylene group, C 2 -6 ⁇ alkenylene group or C 2 - 6 ⁇ alkinylene group;
  • R 5 , R 6 and R 7 independently of one another in each case denote H, halogen, CN, Ci- 6 -alkyl, -NH (Ci_ 6 -alkyl) , -N(Ci- 6 - alkyl) 2 , -Ci- 6 -alkylene-NH (Ci- 6 -alkyl) , -Ci- 6 -alkylene-N (Ci- 6 - alkyl) 2 , C3-8-cycloalkyl, heterocyclyl, aryl or heteroaryl; or denote a C 3 - 8 -cycloalkyl, heterocyclyl, aryl or heteroaryl bonded via a Ci_ 6 -alkylene group, C 2 - 6 -alkenylene group or C 2 - 6 ⁇ alkinylene group;
  • radicals C ⁇ _ 6 -alkyl, Ci- 6 ⁇ alkylene, C 2 - 6 -alkenylene, C 2 -6-alkinylene, C 3 - 8 -cycloalkyl, heterocyclyl, aryl and heteroaryl can in each case be unsubstituted or monosubstituted or polysubstituted with identical or different radicals, and the abovementioned radicals Ci-6-alkyl, Ci-6-alkylene, C 2 -6 ⁇ alkenylene, and C 2 - 6 ⁇ alkinylene can in each case be branched or unbranched; in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in each case in the form of their bases and/or physiologically compatible salts.
  • halogen preferably denotes the radicals F, Cl, Br and I, and particularly preferably the denotes radicals F, Cl and Br.
  • Ci- 6 -alkyl includes within the context of the present invention acyclic saturated hydrocarbon radicals with 1, 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals.
  • the alkyl radicals can be selected from the group consisting of methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n- pentyl, iso-pentyl, neo-pentyl and hexyl.
  • Particularly preferred alkyl radicals can be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl.
  • C3-8-cycloalkyl denotes cyclic saturated hydrocarbons with 3, 4, 5, 6, 7 or 8 carbon atoms, which can be unsubstituted or monosubstituted or polysubstituted on one or more ring members, for example with 2, 3, 4 or 5 identical or different radicals.
  • C 3 - 8 -cycloalkyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl .
  • heterocyclyl denotes in the context of the present invention monocyclic or polycyclic, in particular mono-, bi- or tricyclic organic radicals, in which at least one cycle contains 1 heteroatom or 2, 3, 4 or 5 identical or different heteroatoms, which is/are preferably selected from the group consisting of N, 0 and S.
  • Each heterocyclyl radical can be unsubstituted or monosubstituted or polysubstituted on one or more ring members, for example with 2, 3, 4 or 5 identical or different radicals.
  • Saturated or unsaturated heterocyclyl are understood in particular to denote monocyclic 5-membered or 6-membered radicals with at least one heteroatom selected from the group consisting of N, O and S, wherein a further 5- membered or 6-membered, saturated, unsaturated or aromatic cycle, which likewise can contain at least one heteroatom selected from the group consisting of N, O and S, can be condensed onto these radicals .
  • Examples are the benzo- condensed or pyridino-condensed analogues of the aforementioned monocyclic 5- or 6-membered compounds.
  • a saturated or unsaturated heterocyclyl radical can be selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazolinyl, morpholinyl, tetrahydropyranyl, dioxanyl, dioxolanyl, indolinyl, isoindolinyl and
  • substitution with a heterocyclyl radical can take place at any suitable position of the heterocyclyl radical.
  • aryl denotes in the context of the present invention aromatic hydrocarbons, in particular phenyls and naphthyls .
  • the aryl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems.
  • Each aryl radical can be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, in which the aryl substituents can be identical or different and can be in any arbitrary and possible position of the aryl.
  • aryl can be selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl, which can in each case be unsubstituted or monosubstituted or polysubstituted, for example with 2, 3, 4 or 5 radicals.
  • heteroaryl denotes in the context of the present invention a 5-, 6- or 7-membered cyclic aromatic radical, which contains at least 1, possibly also 2, 3, 4 or 5 heteroatoms , in which the heteroatoms can be identical or different and the heteroaryl can be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals.
  • the substituents can be bonded in any arbitrary and possible position of the heteroaryl.
  • the heterocycle can also be part of a bicyclic or polycyclic, in particular of a monocyclic, bicyclic or tricyclic system, which can then overall contain more than 7 members, preferably up to 14 members.
  • heteroatoms are selected from the group consisting of N, O and S.
  • the heteroaryl radical can preferably be selected from the group consisting of pyrrolyl, indolyl, furyl, (furanyl), benzofuranyl, thienyl ( thiophenyl) , benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzodioxolanyl, benzodioxanyl, benzooxazolyl, benzooxadiazolyl, imidazothiazolyl, dibenzofuranyl, dibenzothienyl, phthalazinyl, pyrazolyl, imidazolyl, thiazolyl, oxadiazolyl, isoxazoyl, pyridinyl (pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indazolyl, purin
  • C ⁇ - 6 -alkylene group includes in the context of the present invention acyclic saturated hydrocarbon radicals with 1, 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure.
  • the alkylene groups can be selected from the list consisting of -CH 2 -, -CH 2 -CH 2 -, -CH(CH 3 )-, -CH 2 -CH 2 -CH 2 -, -CH (CH 3 ) -CH 2 -, -CH(CH 2 CH 3 )-, -CH 2 -(CH 2 J 2 -CH 2 -, -CH (CH 3 ) -CH 2 -CH 2 -, -CH 2 -CH(CH 3 J-CH 2 -,
  • the alkylene groups can be selected from the list consisting of -CH 2 -, -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -.
  • C 2 - 6 ⁇ alkenylene group includes in the context of the present invention acyclic, monosubstituted or polysubstituted, for example 2, 3 or 4 times, unsaturated hydrocarbon radicals with 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure.
  • C 2 - 6 -alkinylene group includes in the context of the invention acyclic, monosubstituted or polysubstituted, for example 2, 3 or 4 times, unsaturated hydrocarbon radicals with 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure.
  • the alkinylene groups contain at least one C ⁇ C triple bond.
  • aryl or heteroaryl bonded via a Ci_ 6 - alkylene group, C 2 -6 ⁇ alkenylene group or C 2 - 6 -alkinylene group denotes in the context of the present invention that the Ci_ 6 -alkylene groups, C 2 -6-alkenylene groups or C 2 - 6 ⁇ alkinylene groups as well as aryl and/or heteroaryl have the meanings given above and the aryl and/or heteroaryl is/are bonded via a Ci-6-alkylene group, C 2 -6 ⁇ alkenylene group or C 2 - 6 -alkinylene group to the overarching general structure.
  • Benzyl, phenethyl and phenylpropyl may be mentioned by way of example.
  • C 3 _ 8 -cycloalkyl and heterocyclyl bonded via a Ci- 6 -alkylene group, C 2 - 6 -alkenylene group or C 2 -6- alkinylene group denotes in the context of the present invention that the Ci- 6 -alkylene group, C 2 - 6 ⁇ alkenylene group, C 2 -6 ⁇ alkinylene group, C 3 - 8 ⁇ cycloalkyl and heterocyclyl have the meanings given above and C 3 - 8 - cycloalkyl and heterocyclyl are bonded via a Ci- 6 -alkylene group, C2-6 ⁇ alkenylene group or C 2 -6 ⁇ alkinylene group to the overarching general structure.
  • aryl and heteroaryl can take place with identical or different substituents.
  • Preferred substituents for aryl and heteroaryl can be selected from the group consisting of -O- Ci- 3 -alkyl, Ci- 6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl, in particular from the group consisting of F, Cl, Br, CF 3 , CH 3 and OCH 3 .
  • physiologically compatible salt is understood in the context of the present invention to denote preferably salts of the compounds according to the invention with inorganic or organic acids that are physiologically compatible, especially when used in humans and/or mammals.
  • suitable acids are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, 1, 1-dioxo-l, 2-dihydrol ⁇ 6 -benzo [d] isothiazol-3-one (saccharinic acid) , monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4- aminobenzoic acid, 2 , 4 , 6-trimethylbenzoic acid, ⁇ -lipoic acid, acetylgly
  • the radical R 1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably denotes phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, thiophenyl, pyridiny
  • the radical R 1 denotes phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals selected from the group consisting of methyl, methoxy, CF 3 , OCF 3 , F, Cl and Br.
  • the radical R 1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2 , 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2, 3, 5-trimethylphenyl, 2, 4 , 6-trimethylphenyl, 2-chloro-6- methylphenyl, 2 , 4 , 6-trichlorophenyl, 2-chloro-6- (trifluoromethyl) phenyl, 2 , 6-dichloro-4-methoxyphenyl, 2- methylnaphthyl, 2-chloronaphthyl, 2-fluoronaphthyl, 2- chloro-4- ( trifluoromethoxy) phenyl, 4-chloro-2, 5- dimethylphenyl, 2 , 3-dichlorophenyl, 3, 4-dichlorophenyl, 2- (trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl
  • the radical R 1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2 , 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2, 3, 5-trimethylphenyl, 2 , 4 , 6-trimethylphenyl, 4-chloro-2 , 5- dimethylphenyl, 2 , 3-dichlorophenyl, 3, 4-dichlorophenyl, 2- ( trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl, A- ( trifluoromethyl) phenyl, 1-naphthyl and 2-naphthyl.
  • radical R 1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2, 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2 , 3, 5-trimethylphenyl, 2 , 4 , 6-trimethylphenyl, 1-naphthyl and 2-naphthyl.
  • R 2 in the sulfonamide derivatives according to the invention denotes H, Ci- ⁇ -alkyl or aryl; or denotes an aryl bonded via a Cx-g-alkylene group, C 2 - 6 ⁇ alkenylene group or C 2 - 6 ⁇ alkinylene group, wherein the aryl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci_ 6 -alkyl, Ci- 6 -alkyl- O-, F, Cl, Br, I CF 3 , OCF 3 , OH and SH.
  • R 2 denotes H, Ci_ 6 - alkyl or phenyl; or denotes a phenyl bonded via a Ci_6 ⁇ alkylene group, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH.
  • R 2 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, benzyl or phenethyl.
  • R 3 in the sulfonamide derivatives according to the invention can denote H, Ci- 6 -alkyl or aryl; or can denote an aryl bonded via a Ci- 6 -alkylene group, C 2 - 6 ⁇ alkenylene group or C 2 - 6 ⁇ alkinylene group, the aryl in each case being unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci- 6 ⁇ alkyl, Ci- 6 -alkyl-O-, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH.
  • R 3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH.
  • R 3 denotes H or unsubstituted phenyl.
  • p denotes 1.
  • R 4 denotes H, Ci- 6 ⁇ alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci- 6 -alkylene group, C 2 - 6 -alkenylene group or C 2 - 6 -alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or polysubstituted by identical or different substituents, the aryl and/or heteroaryl is/are preferably selected from the group consisting of phenyl, naphthyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_ 3 -alkyl, unsubstituted Ci- 6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH.
  • R 4 denotes H, Ci-6- alkyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a C3.-3- alkylene group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted or monosubstituted or polysubstituted by identical or different substituents, the substituents, being selected from the group consisting of -O-Ci- 3 -alkyl, unsubstituted Ci- 6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH, SH.
  • R 4 denotes a radical selected from the group consisting of H, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert- butyl, phenyl, 2 , 3-dimethylphenyl, 3, 4-dimethylphenyl, 2- tert-butylphenyl, 3-tert-butylphenyl, 4-tert-butylphenyl, 2- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2- fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3- difluorophenyl, 3, 4-difluorophenyl, 2- (trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl, 4-
  • X denotes N
  • Y denotes CR 6
  • Z denotes CR 7 .
  • X denotes N
  • Y denotes N
  • Z denotes CR 7
  • X denotes CR 5
  • Y denotes CR 6
  • Z denotes CR 7 .
  • R 5 , R 6 and R 7 independently of one another in each case denote H, halogen, Ci-e-alkyl, -N (Ci- 6 -alkyl) 2 , -Ci-6 ⁇ alkylene-N (Ci_6 ⁇ Alkyl) 2 , 5-, 6- or 7-membered heterocyclyl, 5- or 6-membered heteroaryl or denote a 5- or 6-membered heteroaryl or a 5-, 6- or 7-membered heterocyclyl bonded via a Ci-6-alkylene group, wherein heterocyclyl comprises one or two identical or different heteroatoms selected from the group consisting of N and O and is unsubstituted or is monosubstituted or identically or differently polysubstituted with Ci_ 6 -alkyl.
  • R 5 , R 6 and R 7 independently of one another in each case denote H, F, Cl, Br, I, Ci-6-alkyl or denote a radical which is selected from the group consisting of
  • R 8 and R 9 independently of one another denote in each case a Ci- 6 -alkyl radical, j in each case is 1, 2 or 3, and
  • R 10 denotes a radical that is selected from the group consisting of H, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl
  • M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH.
  • R 5 in the compounds according to the invention denotes H.
  • R 6 denotes H or a radica selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a Ci_ 6 -alkyl radical
  • j is in each case 1, 2 or 3
  • M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH.
  • R 7 denotes H, F, Cl, Br, I, Ci- 6 ⁇ alkyl or denotes a radical selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a Ci_ 6 -alkyl radical
  • j is in each case 1, 2 or 3 and M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH.
  • substituted sulfonamide derivatives according to the invention in accordance with one or more of the preceding claims, wherein
  • n and n in each case independently of one another is 0 or 1; p is 1;
  • Q denotes -O- or -CH 2 ;
  • X denotes N or CR 5 ;
  • Y denotes N or CR 6 ;
  • Z denotes N or CR 7 ;
  • R 1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, and particularly preferably denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or polysubstituted with identical or different substituent
  • R 2 denotes H, Ci- 6 -alkyl or aryl; or denotes an aryl bonded via a Ci- 6 -alkylene group, C 2 - 6 -alkenylene group or C 2 - 6 - alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci- 6 -alkyl, Ci-6-alkyl- O-, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH;
  • R 3 denotes H, Ci- 6 -alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C 2 -6-alkenylene group or C 2 -6 ⁇ alkinylene group, the aryl being in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci- 6 -alkyl, Ci_ 6 -alkyl-O-, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH;
  • R 4 denotes H, C ⁇ - 6 -alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci- 6 ⁇ alkylene group, C 2 - 6 - alkenylene group or C 2 - 6 ⁇ alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the aryl or heteroaryl is preferably selected from the group consisting of phenyl, napththyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_ 3 - alkyl, unsubstituted Ci- 6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH;
  • R 5 , R 6 and R 7 independently of one another in each case denote H, halogen, C ⁇ -6-alkyl, -N (Ci-6-alkyl) 2 , -Ci-6-alkylene- N (Ci-6-alkyl) 2 / 5- or 6-membered heterocyclyl, 5- or 6- membered heteroaryl or denote a 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclyl bonded via a Ci- ⁇ -alkylene group, wherein heterocyclyl comprises 1 or 2 identical or different heteroatoms selected from the group consisting of N and O and is unsubstituted or is monosubstituted or identically or differently polysubstituted with Ci_ 6 -alkyl;
  • R 1 denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or identically or differently polysubstituted, wherein the substituents are selected from the group consisting of methyl, methoxy, CF 3 , F, Cl and Br;
  • R 2 denotes H, Ci- 6 -alkyl or phenyl; or denotes a phenyl bonded via a Ci- 6 -alkylene group, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH;
  • R 3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, methoxy, F, Cl, Br, I, CF3, OCF 3 and OH;
  • R 4 denotes H, Ci- ⁇ -alkyl, phenyl, furyl, thienyl or pyridxnyl; or denotes a phenyl, furyl, thienyl or pyridmyl bonded via a Ci_ 3 -alkylene group, wherein the phenyl, furyl, thienyl or pyridinyl are in each case unsubstituted or monosubstituted or identically or differently polysubstituted, the substituents being selected from the group consisting of -O-Ci- 3 -alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH, SH;
  • R 5 denotes H
  • R 6 denotes H or a radical that is selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a C ⁇ - 6 -alkyl radical
  • j is in each case 1, 2 or 3 and M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH
  • R 7 denotes H, F, Cl, Br, I, Ci- 6 -alkyl, or denotes a radical that is selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a Ci- 6 -alkyl radical
  • j is in each case 1, 2 or 3
  • X denotes N or CR 5 ;
  • Y denotes N or CR 6 ;
  • Z denotes N or CR 7 ;
  • R 1 denotes phenyl or naphthyl, which is unsubstituted or is monosubstituted or identically or differently disubstituted, trisubstituted, quadruply substituted or pentasubstituted, wherein the substituents can be selected from the group consisting of methyl, methoxy, CF 3 , F, Cl and Br;
  • R 2 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, or phenyl; or denotes a phenyl bonded via a -CH 2 -, -(CH 2 J 2 - or -(CH 2 ) 3- group, wherein the phenyl is in each case unsubstituted or is monosubstituted or disubstituted, trisubstituted, tetrasubstituted or pentasubstituted with identical or different radicals, which are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH
  • R 3 denotes H or unsubstituted phenyl
  • R 4 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a -(CH 2 )-, -(CH 2 ) 2- or -(CH 2 ) 3- group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted or is monosubstituted, disubstituted or trisubstituted with substituents selected independently of one another from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, methyl, ethyl, n-propyl, iso- propyl, n
  • R 5 denotes H
  • R 6 denotes H or a radical that is selected from the group consisting of
  • R 8 and R 9 in each case denote a methyl radical
  • j is in each case 1, 2 or 3
  • M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH;
  • R 7 denotes H, F, Cl, Br, I methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl or a radical that is selected from the group consisting of
  • R 8 and R 9 in each case denote a methyl radical
  • j is in each case 1, 2 or 3
  • M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH.
  • X denotes N or CR ;
  • Y denotes N or CR 6 ;
  • Z denotes N or CR 7 ;
  • R denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl group bonded via a -(CH 2 )-, -(CH 2 ) 2 " or -(CH 2 ) 3- group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted, or is monosubstituted or identically or differently disubstituted or trisubstituted with substituents selected independently of one another from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl
  • R 5 denotes H
  • R 6 denotes H or a radical that is selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a methyl radical
  • j is in each case 1, 2 or 3 and M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH;
  • R 7 denotes H, F, Cl, Br, I, methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, or denotes a radical that is selected from the group consisting of
  • R 8 and R 9 independently of one another in each case denote a methyl radical
  • j is in each case 1, 2 or 3 and M 1 , M 2 und M 3 independently of one another each denote N or CH, whereby one of M 1 , M 2 and M 3 represents N and the other two of M 1 , M 2 and M 3 represent CH.
  • the compounds according to the invention exhibit an antagonistic action on the human BlR receptor or on the BlR receptor of rats.
  • the compounds according to the invention exhibit an antagonistic action on both the human BlR receptor (hBlR) and the BlR receptor of rats (rBlR) .
  • the agonistic or antagonistic action of compounds can be quantified on the bradykinin 1 receptor (BlR) of humans and rats with ectopically expressing cell lines (CHO Kl cells) and with the aid of a Ca 2+ -sensitive dye (Fluo-4) in the fluorescent imaging plate reader (FLIPR) .
  • the figure in percent activation refers to the Ca 2+ signal after addition of Lys-Des-Arg 9 -bradykinin (0.5 nM) and Des-Arg 9 -bradykinin (100 nM) .
  • Antagonists result in a suppression of the Ca 2+ inflow after the addition of the agonist. Percent inhibition values are given in comparison to the maximum achievable inhibition.
  • the compounds according to the invention act for example on the BlR relevant in connection with various diseases, which means that they are suitable as pharmaceutical active constituent in medicaments .
  • the present invention therefore also provides medicaments containing at least one substituted sulfonamide derivative according to the invention as well as optionally suitable additives and/or auxiliary substances and/or optionally further active substances.
  • These medicaments are particularly suitable for treating pain, in particular acute, visceral, neuropathic, chronic pain and/or inflammatory pain .
  • these medicaments are also suitable for treating diabetes, diseases of the respiratory tract, inflammatory intestinal diseases, neurological diseases, inflammation of the skin, rheumatic diseases, septic shock, reperfusion syndrome, obesity, and as an angiogenesis inhibitor.
  • the medicaments according to the invention contain, apart from at least one substituted sulfonamide derivative according to the invention, optionally also suitable additives and/or auxiliary substances, thus also carrier materials, fillers, solvents, diluents, colourants and/or binders, and can be administered as liquid medicament forms in the form of injections for solution, drops or juices, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols.
  • suitable additives and/or auxiliary substances thus also carrier materials, fillers, solvents, diluents, colourants and/or binders, and can be administered as liquid medicament forms in the form of injections for solution, drops or juices, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols.
  • suitable additives and/or auxiliary substances thus also carrier materials, fillers, solvents, dilu
  • the amounts thereof to be used depend on whether the medicament is to be administered orally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, nasally, buccally, rectally or topically, for example to the skin, mucous membranes or to the eyes.
  • suitable preparations in the form of tablets, pills, capsules, granules, drops, juices and syrups
  • suitable preparations are in the form of solutions, suspensions, easily reconstitutable dry preparations as well as sprays.
  • Sulfonamide derivatives according to the invention in depot form, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration of the skin, are suitable percutaneous application preparations. Orally or percutaneously usable preparation forms can provide for the delayed release of the substituted sulfonamide derivatives according to the invention.
  • the substituted sulfonamide derivatives according to the invention can also be used in parenteral long-term depot forms, such as for example implants or implanted pumps. In principle other active constituents known to the person skilled in the art can be added to the medicaments according to the invention.
  • the amount of active constituent to be administered to the patient varies depending on the patient's weight, type of application, medical indications and the severity of the illness. Normally 0.00005 to 50 mg/kg, in particular 0.01 to 5 mg/kg of at least one substituted sulfonamide derivative according to the invention are administered.
  • a contained substituted sulfonamide derivative according to the invention is present as a pure diastereomer and/or enantiomer, as a racemate, or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers .
  • substituted sulfonamide derivatives according to the invention can be used for the preparation of a medicament for treating pain, in particular acute, visceral, neuropathic or chronic pain.
  • the invention accordingly also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treating pain, in particular acute, visceral, neuropathic or chronic pain.
  • the present invention also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for the treatment of inflammatory pain.
  • the present invention also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treating diabetes, diseases of the respiratory tract, inflammatory intestinal diseases, neurological diseases, inflammation of the skin, rheumatic diseases, septic shock, reperfusion syndrome, obesity, and as an angiogenesis inhibitor.
  • an employed substituted sulfonamide derivative is present as a pure diastereomer and/or enantiomer, as a racemate, or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers.
  • the invention also provides a method for treating, in particular in one of the aforementioned medical indications, a non-human mammal or a person that requires treatment for pain, in particular chronic pain, by administration of a therapeutically active dose of a substituted sulfonamide derivative according to the invention or a medicament according to the invention.
  • the invention also provides a method for treating, in particular in one of the aforementioned medical indications, a non-human mammal or a person that requires treatment thereof, by administration of a therapeutically active dose of a substituted sulfonamide derivative according to the invention or a medicament according to the invention .
  • the invention also provides a method for the preparation of the substituted sulfonamide derivatives according to the invention as explained and illustrated in the following description, examples as well as the claims.
  • the carboxylic acids N are converted in an amide formation using primary or secondary amines O in the presence of water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound), TBTU, EDCI, PyBOP or PFPTFA, also in the presence of HOAt or HOBt and an organic base, for example DIPEA or pyridine, in an organic solvent such as THF, dichloromethane, diethyl ether, dioxane, DMF or acetonitrile, at temperatures from 0 0 C to the reflux temperature, to form the final products of the general formula P.
  • water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound), TBTU, EDCI, PyBOP or PFPTFA
  • HOAt or HOBt an organic base
  • an organic base for example DIPEA or
  • the sulfonylated aminoalcohols B are reacted in an alkylation reaction with halogenated ester derivatives using tetrobutylammonium chloride or bromide or tetrabutylammonium hydrogen sulfate in a phase transfer reaction using an organic solvent such as THF, toluene, benzene or xylene and inorganic bases such as potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate or in the presence of an organic or inorganic base, conventional inorganic bases being metal alcoholates such as sodium methanolate, sodium ethanolate, potassium tert-butylate, lithium or sodium bases such as lithium diisopropylamide, butyllithium, tert-butyllithium, sodium methylate or metal hydrides such as potassium hydride, lithium hydride, sodium hydride, conventional organic bases being diisopropylethylamine, triethylamine, in an organic solvent such
  • mesylates or alternative alkylation reagents optionally in the presence of an organic or inorganic base, for example sodium hydride, potassium carbonate, cesium carbonate, DBU or DIPEA, preferably in an organic solvent
  • Racemic (R and S configuration) or enantiomer-pure (R or S configuration) acids G are esterified using water-extracting reagents, for example inorganic acids such as H 2 SO 4 or phosphorus oxides or organic reagents such as thionyl chloride, in organic solvents such as THF, diethyl ether, methanol, ethanol or dichloromethane, to the stage H, at temperatures from room temperature to reflux temperatures.
  • water-extracting reagents for example inorganic acids such as H 2 SO 4 or phosphorus oxides or organic reagents such as thionyl chloride, in organic solvents such as THF, diethyl ether, methanol, ethanol or dichloromethane
  • an organic or inorganic base for example potassium carbonate, sodium carbonate, sodium hydrogen carbonate, diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine
  • the ester derivatives C and I are reacted in an ester cleavage using organic acids such as trifluoroacetic acid or aqueous inorganic acids such as hydrochloric acid, or using aqueous inorganic bases such as lithium hydroxide, potassium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate in organic solvents such as methanol, dioxane, dichloromethane, THF, diethyl ether or mixtures of these solvents, at 0°C to room temperature, to form the acid stages of the general formula D (acid building blocks S1-S8) .
  • organic acids such as trifluoroacetic acid or aqueous inorganic acids such as hydrochloric acid
  • aqueous inorganic bases such as lithium hydroxide, potassium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate in organic solvents such as methanol, dioxane, dichlor
  • Pyrrole A is dissolved in a suitable solvent, such as for example ethanol, methanol, 2-butanone, DMSO, diethyl ether, water, benzene, toluene, THF, DCM, acetonitrile, acetone, DMF or pentane or a mixture of these solvents, and a suitable base is added, such as for example potassium hydroxide, sodium hydroxide, optionally in aqueous or alcoholic solution, potassium carbonate, potassium hexamethyldisilazane, sodium hydride, potassium hydride, sodium methanolate, sodium ethanolate, sodium tert .butylate or diisopropylethylamine, optionally with the addition of an auxiliary substance such as for example 18-crown-6, 15- crown-5, tetrabutylammonium bromide or sulfate, benzyltriethylammonium chloride, l-n-butyl-3- methylimi
  • the ring closure to form the 1, 2 , 3, 4-tetrahydropyrrolo [ 1, 2- a]pyrazine C is carried out by reacting the 2- ( lH-pyrrol-1- yl) ethanamine with the corresponding aldehyde in solvents such as acetic acid, ethanol, methanol, pyridine, benzene, toluene, DCM or a mixture of these solvents, optionally with the addition of benzotriazole, aluminium trichloride or p-toluenesulfonic acid and optionally with removal by azeotropic distillation of the water formed in the reaction.
  • solvents such as acetic acid, ethanol, methanol, pyridine, benzene, toluene, DCM or a mixture of these solvents, optionally with the addition of benzotriazole, aluminium trichloride or p-toluenesulfonic acid and optionally with removal by azeotropic distillation of
  • the ring closure to form the 1, 2, 3, 4-tetrahydropyrrolo [ 1, 2- a]pyrazine stage C can however also be achieved by reacting the 2- ( lH-pyrrol-1-yl) ethanamine with the corresponding carboxylic acid followed by reduction of the initially formed cyclic imine D with reducing agents, such as for example sodium boron hydride.
  • reducing agents such as for example sodium boron hydride.
  • the introduction of the BOC protective group by means of di-tert . -butyl dicarbonate can be carried out in solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 0 0 C and 100 0 C.
  • solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 0 0 C and 100 0 C.
  • the Cbz protective group can be introduced by reacting benzyl chloroformate in solvents such as for example diethyl ether, THF, DMF, benzene, toluene, dioxane, water, acetone, ethyl acetate, DCM or chloroform, optionally with the addition of a base such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine, optionally with the addition of a coupling reagent, such as for example HOBt.
  • solvents such as for example diethyl ether, THF, DMF, benzene, toluene, dioxane, water, acetone, ethyl acetate, DCM or chloroform
  • a base such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine
  • a coupling reagent such as for example HOBt.
  • the Fmoc protective group is introduced by reacting 9H- fluoren-9-yl methylchloroformate in solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water, optionally with the addition of a base, such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
  • solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water
  • a base such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
  • the introduction of the amino methyl substituent on the pyrrole ring is carried out via an aminoalkylation to form the stages F.
  • the corresponding aromatic compound can be reacted with formaldehyde and the corresponding amine in ethanol or methanol.
  • a variant of this process uses the reaction of an iminium salt with the corresponding aromatic system to form the stage E.
  • the iminium salt is obtained for example by cleavage of the corresponding aminal .
  • the aminal is formed by reacting the corresponding amine with formaldehyde.
  • the reaction can be carried out in solvents such as for example water, methanol, ethanol, tert . -butanol, benzene, toluene, diethyl ether, dioxane, THF, chloroform, DCM, DMF, acetonitrile, dilute aqueous HCl solution or mixtures of these solvents, optionally with the addition of a base, such as for example potassium carbonate or sodium hydroxide.
  • solvents such as for example water, methanol, ethanol, tert . -butanol, benzene, toluene, diethyl ether, dioxane, THF, chloroform, DCM, DMF, acetonitrile, dilute aqueous HCl solution or mixtures of these solvents, optionally with the addition of a base, such as for example potassium carbonate or sodium hydroxide
  • the iminium salt is obtained by reacting the aminal with for example acetyl or benzoyl chloride, mesyl chloride, trimethylsilyl chloride or iodide, tetrachlorosilane or borone trifluoride etherate, in solvents such as for example carbon tetrachloride, chloroform, DCM, diethyl ether, DMF, acetonitrile, hexane or DME at a temperature between -80 0 C and +25°C.
  • solvents such as for example carbon tetrachloride, chloroform, DCM, diethyl ether, DMF, acetonitrile, hexane or DME at a temperature between -80 0 C and +25°C.
  • the subsequent aminoalkylation to the stages F can be carried out in solvents such as for example acetonitrile, THF, DCM, diethyl ether, toluene or benzene at temperatures between -78 0 C and room temperature.
  • solvents such as for example acetonitrile, THF, DCM, diethyl ether, toluene or benzene at temperatures between -78 0 C and room temperature.
  • the aminoalkylated 5, 6, 7 , 8-tetrahydropyrrolo [ 1 , 2-a] pyrazine derivative G used as building block is obtained by cleavage of the corresponding protective group.
  • BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF, at a temperature from 0 0 C to 110 0 C and a reaction time of 0.5 to 20 hours.
  • the Cbz protective group can be split off for example under acidic conditions.
  • This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol.
  • reagents such as for example MesSil in solvents such as for example DCM, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DCM and nitromethane, or triethylsilane/PdCl 2 in methanol with the addition of triethylamine .
  • a further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without the use of pressure, by means of catalysts such as for example Pd on charcoal, Pd(OH) 2 , PdCl 2 , Raney nickel or PtO 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • catalysts such as for example Pd on charcoal, Pd(OH) 2 , PdCl 2 , Raney nickel or PtO 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DMC or chloroform.
  • solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DMC or chloroform.
  • Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • Reagents such as for example Ag 2 ⁇ /Mel can however also be used.
  • the Vilsmeier reaction is carried out by reacting HCN and HCl in CHCI 3 or diethyl ether or a mixture of these solvents.
  • Further suitable reagents for the Vilsmeier reaction are DMF and oxalyl chloride or POCI 3 in solvents such as for example DCM or DCE, but also for example trimethoxyethane and TiCl 4 in DCM.
  • N- (chloromethylene) -N- methylmethane aminium chloride with the addition of NaOH can also be used.
  • the reduction of the double bond can be carried out hydrogenolytically or by adding suitable reducing agents.
  • Heterogeneous catalysts as well as homogeneous catalysts can be used in the hydrogenolysis .
  • Suitable heterogeneous catalysts are for example Pd on charcoal or Raney nickel in solvents such as for example methanol, ethanol, toluene, THF, ethyl acetate, acetic acid or in mixtures of these solvents, optionally with the addition of bases such as for example triethylamine .
  • the reaction can be carried out at atmospheric pressure or at elevated pressure.
  • a suitable homogeneous catalyst is for example (PPh 3 ) 3 RhCl in benzene or toluene .
  • a suitable reducing agent is for example NaBH 4 with the addition of NiCl 2 in the solvents such as for example methanol, ethanol, THF or mixtures of these solvents.
  • the reduction of the ester group for the preparation of the stages K can be carried out by reduction with reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
  • reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
  • the aldehyde is reacted with an amine and the imine thereby formed is then reduced to the amine.
  • Suitable reducing agents are for example NaBH 4 , NaBH(OAc) 3 , NaCNBH 3 , NH 4 CNBH 3 , polymer-bound cyanoboron hydride, borane-pyridine complex or triethylsilane.
  • the reaction can be carried out in solvents such as for example methanol, ethanol, DCM, DCE, acetonitrile, THF, toluene, water, DMSO, DMF, l-methyl-2- pyrrolidin-2-one or mixtures of these solvents.
  • Auxiliary reagents such as for example HCl (gaseous or as an aqueous solution), acetic acid, TFA, ZnCl 2 , 1, 3-dimethyl-2- imidazolidine, MgSO 4 , Na 2 SO 4 or molecular sieves are also used.
  • the imine that is formed can however also be converted to the amine by catalytic hydrogenation on catalysts such as for example PtO 2 or Pd/C in solvents such as for example methanol or ethanol.
  • the derivative M used as building block is obtained by cleavage of the corresponding protective group.
  • BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF at a temperature from 0°C to 110 0 C and a reaction time of 0.5 to 20 hours.
  • organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate
  • the Cbz protective group can be split off for example under acidic conditions.
  • This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol.
  • reagents such as for example Me3Sil in solvents such as for example DCM, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DCM and nitromethane or triethylsilane/PdCl 2 in methanol with the addition of triethylamine .
  • solvents such as for example DCM, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DCM and nitromethane or triethylsilane/PdCl 2 in methanol with the addition of triethylamine .
  • a further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without the use of pressure with the aid of catalysts such as for example Pd on charcoal, Pd(OH) 2 PdCl 2 , Raney nickel or PtO 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • catalysts such as for example Pd on charcoal, Pd(OH) 2 PdCl 2 , Raney nickel or PtO 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform.
  • solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform.
  • Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • Reagents such as for example Ag 2 O/Mel can however also be used.
  • Various protective groups such as for example the BOC, Cbz or Fmoc protective group, are suitable for this purpose.
  • the introduction of the BOC protective group by means of di-tert . -butyl dicarbonate can be carried out in solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 0 0 C and 100 0 C.
  • solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 0 0 C and 100 0 C.
  • the Cbz protective group can be introduced by the reaction of benzyl chloroformate in solvents such as for example diethyl ether, THF, DMF, benzene, tolulene, dioxane, water, acetone, ethyl acetate, DCM or chloroform, optionally with the addition of a base, such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine, optionally with the addition of a coupling reagent such as for example HOBt.
  • solvents such as for example diethyl ether, THF, DMF, benzene, tolulene, dioxane, water, acetone, ethyl acetate, DCM or chloroform
  • a base such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine
  • a coupling reagent such as for example HOBt.
  • the Fmoc protective group is introduced by reacting 9H- fluoren-9-yl methylchloroformate in solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water, optionally with the addition of a base, such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
  • solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water
  • a base such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
  • the reduction of the ester group for the preparation of the stages C can be carried out by reduction with reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
  • reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
  • the aldehyde is reacted with an amine and the formed imine is then reduced to the amine.
  • Suitable reducing agents are for example NaBH 4 , NaBH(OAc) 3 , NaCNBH 3 , NH 4 CNBH 3 , polymer-bound cyano boron hydride, borane-pyridine complex or triethylsilane .
  • the reaction can be carried out in solvents such as for example methanol, ethanol, DCM, DCE, acetonitrile, THF, toluene, water, DMSO, DMF, 1- methyl-2-pyrrolidin-2-one or mixtures of these solvents.
  • auxiliary reagents such as for example HCl (gaseous or as an aqueous solution), acetic acid, TFA, ZnCl 2 , 1,3- dimethyl-2-imidazolidine, MgSO 4 , Na 2 ⁇ O 4 or molecular sieves are also used.
  • the formed imine can however also be converted to the amine by catalytic hydrogenation on catalysts such as for example Pt ⁇ 2 or Pd/C in solvents such as for example methanol or ethanol .
  • the aminoalkylated derivative E used as building block is obtained by cleavage of the corresponding protective group.
  • BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF at a temperature from 0 0 C to 110 0 C and a reaction time of 0.5 to 20 hours.
  • organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate
  • the Cbz protective group can be split off for example under acidic conditions.
  • This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol .
  • reagents such as for example Me3Sil in solvents such as for example DCM, chloroform or acetonitrile, BF 3 etherate with addition of ethanethiol or Me 2 S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DMC and nitromethane, or triethylsilane/PdCl 2 in methanol with the addition of triethylamine .
  • a further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without pressure with the aid of catalysts such as for example Pd on charcoal, Pd (OH) 2 , PdCl 2 , Raney nickel or Pt ⁇ 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • catalysts such as for example Pd on charcoal, Pd (OH) 2 , PdCl 2 , Raney nickel or Pt ⁇ 2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform.
  • solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform.
  • Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • Reagents such as for example Ag 2 O/Mel can however also be used.
  • the agonistic or antagonistic action of substances can be determined on the bradykinin 1 receptor (BlR) of humans and rats by means of the following assay.
  • BlR bradykinin 1 receptor
  • the Ca 2+ inflow through the channel is quantified by means of a Ca 2+ -sensitive dye (Fluo-4 type, Molecular Probes Europe BV, Leiden, Netherlands), in a Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, USA) .
  • CHO Kl cells Chinese hamster ovary cells
  • hBlR cells stably transfected with the human BlR gene
  • rBlR cells rBlR cells, Axxam, Milan, Italy
  • hBlR cells stably transfected with the human BlR gene
  • rBlR cells rBlR cells, Axxam, Milan, Italy
  • hBlR cells stably transfected with the human BlR gene
  • rBlR cells the BlR gene of rats
  • rBlR cells rBlR cells, Axxam, Milan, Italy
  • rBlR cells rBlR cells, Axxam, Milan, Italy
  • FBS fetal bovine serum, Gibco Invitrogen GmbH, Düsseldorf, Germany
  • % FBS total bovine serum, Gibco Invitrogen GmbH, Düsseldorf, Germany
  • hBlR cells Nutrient Mixture Ham's F12, Gibco Invitrogen GmbH, Düsseldorf, Germany
  • rBlR cells D-MEM/F12, Gibco Invitrogen GmbH, Düsseldorf, Germany
  • HBSS buffer which additionally contains 0.1% BSA (bovine serum albumin; Sigma-Aldrich, Taufkirchen, Germany), 5.6 mM glucose and 0.05% gelatin (Merck KGaA, Darmstadt, Germany) .
  • BSA bovine serum albumin
  • the quantification is carried out by measuring the highest fluorescence intensity (FC, fluorescence counts) over time.
  • the FLIPR protocol consists of two substance additions. First of all test substances (10 ⁇ M) are pipetted onto the cells and the Ca 2+ inflow is compared with the control (hBlR: Lys-Des-Arg9-bradykinin 0.5 nM; rBlR: Des-Arg9- bradykinin 100 nM) . This gives the result in percent activation referred to the Ca 2+ signal after addition of Lys-Des-Arg9-bradykinin (0.5 nM) , calculating. Des-Arg9-bradykinin (100 nM) .
  • Antagonists lead to a suppression of the Ca 2+ inflow.
  • the percent inhibition compared to the maximum achievable inhibition is calculated.
  • the compounds show a good activity on both human and rat receptors.
  • HATU 0- (Benzotriazol-1-yl) -N, N, N' ,N' -tetramethyluronium hexafluorophosphate
  • Stage 1 A solution of 4-methoxy-2 , 3, 6- trimethylbenzenesulfonyl chloride (2.29 g, 9.19 mmole) in THF (30 ml) was added dropwise at 0 0 C to a solution of 2- methylaminoethanol (0.95 ml, 11.8 mmole) and triethylamine (5 ml) in THF (15 ml) . The mixture was then stirred for 5 hours at RT, concentrated by evaporation in vacuo, and the residue was taken up in NaHCO 3 solution and extracted with ethyl acetate (3 x 30 ml) . The combined organic phases were dried with Na 2 SO 4 and concentrated by evaporation in vacuo. Yield: 2.38 g, 90%.
  • Stage 2 NaOH solution (35%, 40 ml) was added at O 0 C to a solution of N- ( 2-hydroxyethyl) -4-methoxy-2 , 3, 6,N- tetramethylbenzenesulfonamide (2.34 g, 8.2 mmole) and tetra-n-butylammonium hydrogen sulfate (611 mg, 1.8 mmole) in toluene (40 ml) .
  • a solution of tert. -butyl bromoacetate (1.82 ml, 12.3 mmole) in toluene (35 ml) was then added dropwise to the vigorously stirred two-phase system.
  • Stage 1 Triethylamine (11.2 ml, 80 mmole) was added to a solution of 2-benzylaminoethanol (5.28 g, 35 mmole) in DCM (200 ml) and cooled using an icebath. 4-methoxy-2, 6- dimethylbenzene-1-sulfonyl chloride (7.5 g, 32 mmole) was then added and stirred for 5 hours at RT. After adding hydrochloric acid (0.5 M, 100 ml) the organic phase was separated, washed with water, dried over Na 2 SC M , filtered, and the solvent was distilled off. The crude product was used without further purification. Stage 2.
  • n-Bu 4 NCl (2.78 g, 10 mmole) was added to a solution of tert. -butyl bromoacetate (6.5 ml, 45 mmole) in toluene (125 ml), cooled to 0 0 C, and aqueous 35% NaOH (150 ml) was first added, followed by the dropwise addition of N-benzyl- N- (2-hydroxyethyl) -4-methoxy-2, 6-dimethylbenzenesulfonamide (10.4 g, 30 mmole) dissolved in toluene (25 ml) . The reaction mixture was stirred for 3 hours, then washed with water til neutral, dried with Na 2 SO 4 , and the organic solvent was distilled off. The crude product was used without further purification.
  • Triethylamine (42.4 ml, 302 mmole) was added to a solution of ethanolamine (8.01 ml, 133 mmole) dissolved in DCM (200 ml) .
  • the solution was cooled on an ice bath and 2 , 3, 6-trimethyl-4-methoxybenzenesulfonyl chloride (30 g, 121 mmole) dissolved in DCM (200 ml) was added dropwise.
  • the reaction mixture was stirred overnight at RT.
  • HCl solution (1 M, 125 ml) was then added, and the organic phase was separated, washed with water, dried over Na 2 SO 4 and concentrated by evaporation to dryness.
  • the crude product was used without further purification in the next stage .
  • the aqueous phase was extracted with DCM (100 ml) and ethyl acetate (150 ml) , The combined organic phases were dried over Na 2 SO 4 and concentrated. Remaining impurities were removed by repeated dissolution in diisopropyl ether and diethyl ether, followed by evaporation. Yield: 9.36g, 99%.
  • step-1 To a solution of (R) -ethyl 3-amino-3-phenylpropanoate hydrochloride (5.04 g, 21.9 mmol) and naphthalene-2- sulfonyl chloride (4.97 g, 21.9 mmol) in CH 2 Cl 2 (60 inL) was added a solution of Et 3 N (7.65 inL, 54.9 mmol) in CH 2 Cl 2 (60 mL) at 0 0 C over a period of 45 min. The reaction mixture was stirred at room temperature for 42 h and then washed with aqueous 1 M HCl (300 mL) . The organic layer was dried (Na 2 SO 4 ) and evaporated to dryness, which gave 8.05 g (96%) of S9-1 as a light pink solid.
  • the organic phase was washed firstly with 1 M NaOH and then with satd. NaCl solution.
  • the organic phase was dried over Na 2 SO 4 and then concentrated by evaporation to dryness . Purification was carried out if necessary by column chromatography by neutral AI 2 O 3 or silica gel.
  • the amine is commercially obtainable
  • Stage 1 A mixture of 2-aminopyrazin (25 g, 262.9 mmole) , chloroacetaldehyde (50% in water, 50 ml, 394 mmole) and NaHCO 3 (33.1 g, 394 mmole) was heated for 2 days at 100 0 C. The reaction mixture was then cooled to RT, satd. K 2 CO 3 solution (100 ml) was added, and the mixture was washed with DCM. The organic phase was dried over Na 2 SO 4 and then concentrated by evaporation to dryness. Purification was carried out by column chromatography on silica gel (DCM / methanol, 95:5 + 5% NH 4 OH [35%].
  • Stage 1 Method A.
  • the formaldehyde solution (37% in water, 119 ml, 1.6 mole) was placed in a reaction vessel, dimethylamine solution (40% in water, 405 ml, 3.2 mole) was added, and the mixture was then stirred overnight at RT.
  • Literature M. Gaudry, Y. Jasor, B. T. Khac, Org. Synth. 59, 153-158
  • Stage 1 Method B.
  • the formaldehyde solution (37% in water, 59.5 ml, 0.8 mole) was placed in a reaction vessel and the corresponding amine (1.6 mole) was added. The mixture was then stirred overnight at RT.
  • the reaction mixture was worked up by adding water (100 ml) and was extracted four times with 200 ml of ethyl acetate each time. The combined organic phases were dried over MgSO 4 and concentrated. The crude product could be used without further purification.
  • Stage 2 A reaction flask was heated and the aminal (60 mmole) was added and dissolved or suspended in diethyl ether (70 ml) .
  • Stage 1 Method A.
  • the corresponding 1-substituted 1, 2 , 3, 4-tetrahydropyrrolo [1, 2-a] pyrazine (1 equiv.) was dissolved in 2.5 ml/mmole DCM in a heated three-necked flask.
  • Di-tert-butyl dicarbonate (0.5 equiv.) was dissolved in 1.5 ml/mmole DCM and added dropwise within 30 minutes. The suspension was stirred overnight at RT.
  • the reaction mixture was worked up by adding satd. sodium carbonate solution and the organic phase was separated. The aqueous phase was then extracted twice with DCM.
  • the organic phases were combined, dried over magnesium sulfate and concentrated by evaporation.
  • the products were purified by column chromatography on silica gel.
  • the crude product was purified if necessary by column chromatography on silica gel (solvent: gradient: DCM/methanol 99:1 ⁇ 95:5).
  • Method B The aminoalkylated Boc-protected 1-substituted 1, 2 , 3, 4-tetrahydropyrrolo [1 , 2-a] pyrazine was dissolved in ethyl acetate (1 ml/mmole) and a satd. solution of HCl in ethyl acetate (3 ml/mmole) was added at 0 0 C. The reaction mixture was then heated to RT and stirred for 2 hours. The solvent was removed and the product was used without further purification.
  • Stage 1 A solution of oxalyl chloride (1 equiv.) in DCE (15 ml) was added to an ice-cooled solution of dry DCE (15 ml) and dry DMF (1 equiv.) and stirred for 15 minutes at RT. The solution was re-cooled to 0°C and a solution of tert-butyl 3, 4-dihydropyrrolo [1,2-] pyrazine-2 (IH) - carboxylate (5 g, 22.25 mmole) in DCE (15 ml) was added. The reaction solution was stirred for 30 minutes at this temperature (DC check) . Ice was then added, followed by aqueous NaOH solution (50%) .
  • the aqueous phase was extracted with DCM and the organic phase was then washed in succession with water and satd. NaCl solution. After drying over Na 2 SU 4 , the solvent was removed on a rotary evaporator. The crude product obtained was used without further purification in the next stage.
  • the aqueous phase was extracted with ethyl acetate.
  • the organic phase was then washed with water and satd. NaCl solution.
  • the organic phase was dried over Na 2 SO 4 and the solvent was removed on a rotary evaporator.
  • the crude product was purified by column chromatography on silica gel (solvent: DCM/ethyl acetate, 95:5) .
  • Stage 3 A solution of the ester (from Stage 2, 9.37 mmole) in methanol (150 ml) was firstly deoxygenated with argon over a period of 15 minutes and Pd/C (10%, 20 wt. %) was added. The reaction mixture was hydrogenolysed for 45 minutes under atmospheric pressure (LCMS check) . After completion of the reaction the reaction mixture was filtered through filter earth and washed with methanol. The combined organic phases were concentrated and the product obtained was used without further purification in the next stage.
  • Stage 2 The nitro compound from Stage 1 (32 mmole) was added to a mixture of methanol and DMF (2:1, 17.5 ml/mmole) and cooled to 0°C. NaBH 4 (48 mmole) was added in portions to this mixture. The reaction mixture was stirred for 30 minutes at 0°C (DC check). Water (14 ml/mmole) and 1 drop of acetic acid were then added. The product was extracted with DCM. The organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate, and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: hexane/ethyl acetate 9:1).
  • step-1 Compound A (3g, 13.5 mmol) was taken in dry toluene (30 ml) and to it was added zinc dust ( 3 eqv) under inert atmosphere. The resulting reaction mixture was stirred at 25°C for 5 minutes and then isonicotinoyl chloride hydrochloride (1.5 eqv) was added under stirring. Stirring was continued for further l ⁇ hrs. Reaction mixture was filtered through celite bed, diluted with ethyl acetate, organic layer was washed successively with water and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product that was purified by column chromatography (5% methanol in dichloromethane) Yield: 40%
  • step-2 2:1 mixture of AcOH-MeOH ( 36 ml) was added to the keto compound (3.6 iranol) and to it zinc dust (50 eqv) was added under stirring. The resulting reaction mixture was allowed to stir at 25°C for 16 hrs (monitored by LCMS) and filtered through celite bed. Solvent was completely evaporated, residue was taken in ethyl acetate, organic layer was washed successively with sodium bicarbonate and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography (5% methanol in dichloromethane) . Yield: 26%
  • step-4 To a solution of the alcohol obtained from step-2 (Ig, 2.91 mmol) in xylene (15 ml) wadded p-toluene sulfonic acid (0.05 eqv) and the resulting reaction mixture was refluxed using a dean-stark apparatus for 5 hrs ( monitored by TLC) . Reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed successively with saturated sodium bicarbonate solution, water and brine. Organic layer was dried over sodium sulfate evaporated under reduced pressure to get the crude product that was purified by column chromatography (2% methanol in dichloromethane) . Yield : 56% Procedure for step-4:
  • step-1 To a solution of 2-aminopyrazine (1.87g) in dry acetone (30 ml) was added potassium carbonate (3 eqv) , 4-bromoacetyl pyridine (2 eqv) and the resulting reaction mixture was heated at 6O 0 C for 20hrs. Reaction mixture was filtered through a celite bed, residue washed with DCM and combined organic layer was evaporated completely to get a brown residue. It was again dissolved in ethyl acetate, washed with water and brine and finally dried over sodium sulfate. Evaporation of organic layer gave the crude product which was purified by column chromatography (1% methanol in dichloromethane) .
  • step-6 A solution of the compound (1.38 mmol) obtained from step-5 was taken in methanol (15 ml) and deoxygenated with argon. To it was added 10% Pd-C (225mg) and the resulting reaction mixture was hydrogenated under atmospheric pressure for 3hrs . It was filtered through celite bed, residue washed with methanol and the combined organic layer was evaporated to dryness to get the crude product which was used directly in the next step without any further purification. Yield : 80% (crude)
  • step-1 To a solution of 5, 6, 7 , 8-tetrahydro- [1, 2, 4 ] triazolo [4 , 3- ajpyrazine hydrochloride (1.0 g, 6.23 mmol) in CH2CI2 (25 inL) were added Et 3 N (2.17 mL, 15.57 mmol) and BoC 2 O (1.52 inL, 6.54 mmol) and the reaction was stirred at room temperature overnight. The mixture was extracted with aqueous 0.25 M KHSO 4 (50 mL) . The organic layer was dried (Na 2 SCj) and evaporated to dryness to afford compound A48-1 (1.29 g, 92%) .
  • the carboxylic acids N are converted in an amide formation process using primary or secondary amines O in the presence of water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound) , TBTU, EDCI, PyBOP or PFPTFA also in the presence of HOAt or HOBt and an organic base, for example DIPEA or pyridine in an organic solvent such as THF, dichloromethane, diethyl ether, dioxane, DMF or acetonitrile, at temperatures from 0°C to the reflux temperature, to yield the final products of the general formula P.
  • water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound) , TBTU, EDCI, PyBOP or PFPTFA also in the presence of HOAt or HOBt and an organic base, for example DIPE
  • EDCI 1.5 equiv.
  • HOBt 1 equiv.
  • diisopropylethylamine 1.5 equiv.
  • the mixture was first of all diluted with DCM and then washed in succession with ammonium chloride solution, sodium carbonate solution and saturated NaCl solution, and dried over Na 2 SO 4 .
  • the solution was concentrated by evaporation to dryness.
  • the product was purified using a purification system from Biotage operating in parallel. Parallel synthesis method 3
  • the organic phase was washed in succession with aqueous ammonium chloride solution, aqueous sodium hydrogen carbonate solution and saturated NaCl solution.
  • the organic phase was dried over Na ⁇ SCU and concentrated by evaporation.
  • the crude product was purified using a parallel purification system from Biotage . BIOTAGE PURIFICATION OF LIBRARY COMPOUNDS
  • Step-1 Before purification all the crude compounds were analyzed to get LCMS data of each compound. Thus, it is possible to determine the polarity of compounds .
  • Step-2 Each compound was dissolved in minimum quantity of dichloromethane and loaded onto a Biotage column (Biotage Si 12+ M) and it was then placed in the 12 channel Biotage Quad-3 parallel purification system. At a time 12 compounds were purified.
  • Step-3 Depending on the polarity of the compound (TLC was used to determine the eluent) specific solvent mixtures were run in 12 channel Biotage
  • Step-4 Combined pure fractions from each column were evaporated under reduced pressure, transferred to pre-tared glass vials using acetonitrile as solvent and dried in Speed Vac Thermo explorer to get dry pure compound. These were then submitted for final analysis.
  • Example 1 N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3 , 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) - 4-methoxy-N, 2,3, 6- tetramethylbenzene sulfonamide
  • CDl (0.2 g, 1.23 mmole) was first added to a solution S3 (0.41 g, 1.18 mmole) in DCM (10 ml) and stirred for 1 hour at RT.
  • the amine A18 (0.3 G, 1.18 mmole) dissolved in DCM (10 ml) was then added at this temperature and stirred for a further 16 hours at RT.
  • After completion of the reaction the mixture was first washed with NH 4 Cl solution and then with saturated sodium carbonate solution. The organic phase was dried over Na 2 SO 4 , filtered, and the solvent was distilled off.
  • Example 2 Preparation of 4-methoxy-N, 2, 6- trimethyl-N- (2- (2-OXO-2- (2-piperidin-l-ylmethyl) -5, 6-dihydroimidazo [1, 2- a]pyrazin-7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide hydrochloride
  • Example No. 162 N- ( (IR) -3- (l-Ethyl-3 , 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene- 2- sulfonamide
  • Carboxylic acid S9 120 mg, 0.338 mmol
  • N-ethyl-N ' - (3- dimethylamino propyl) carbodiimide hydrochloride (EDCI) 96 mg, 0.507 mmol
  • CH 2 Cl 2 8 mL
  • HOBt 49 mg, 0.372 mmol
  • 1-ethyl-l, 2 , 3, 4-tetrahydropyrrolo [ 1, 2- alpyrazine (76 mg, 0.507 mmol) and DIPEA 146 ⁇ L, 0.845 mmol
  • Example No. 163 4-Methoxy-N, 2, 6- trimethyl-N- (2- (2-oxo-2- (3- (piperidin-1-ylmethyl) -5, 6-dihydro- [1,2,4] triazolo [4,3- a]pyrazin-7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide
  • step-1 Boc-protected amine BB (1 eqv) was treated with 20% TFA in DCM (10ml/ mol) at 0 0 C and the resulting reaction mixture was allowed to stir at 25°C for 4 hrs ( monitored by TLC) . Solvent was completely evaporated, dried properly to remove traces of TFA and the residue was directly used in library synthesis.
  • step-2 To a dichloromethane solution (3 ml/mmol) of acid BBs (1 eqv) was added EDCI (1.5 eqv), HOBT (1 eqv), DIPEA (2.5 eqv) and the resulting reaction mixture was allowed to stir for 15 minutes at 25°C.
  • Boc deprotected amine BB 1.5 eqv in dichloromethane (1 ml/ mmol) was cooled in ice bath, treated with DIPEA (4 eqv) and it was added to the reaction mixture. Reaction mixture was allowed to stir at 25 0 C for 16 hrs and diluted with dichloromethane.
  • Example compounds 165-179 were obtained according to parallel synthesis method 4 :
  • the agonistic and antagonistic action of the compounds according to the invention on the bradykinin 1 receptor (BlR) of humans and rats were determined as described above .
  • Antagonists lead to a suppression of the Ca 2+ inflow.
  • the % inhibition compared to the maximum achievable inhibition was calculated.
  • the compounds according to the invention are highly effective on the human and rat receptor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to substituted sulfonamide derivatives of the general formula 1 processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments.

Description

Substituted sulfonamide derivatives
The present invention relates to substituted sulfonamide derivatives, processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments.
In contrast to the constitutive expression of the bradykinin 2 receptor (B2R) the bradykinin 1 receptor (BlR) is not expressed, or is only weakly expressed in most tissues. However, the expression of BlR can be induced in various cells. For example, in the course of inflammatory reactions there is a rapid and pronounced induction of BlR on neuronal cells but also on various peripheral cells such as fibroblasts, endothelial cells, granulocytes, macrophages and lymphocytes . In the course of inflammatory reactions there is thus a switch from a B2R to a BlR dominance on the involved cells. The cytokines interleukin-1 (IL-I) and tumour necrosis factor alpha
(TNFα) (Passos et al . J. Immunol. 2004, 172, 1839-1847) are significantly involved in this up-regulation . After activation with specific ligands, BlR-expressing cells can then themselves secrete inflammation-promoting cytokines such as IL-6 and IL-8 (Hayashi et al . Eur. Respir. J. 2000, 16, 452-458) . This leads to the inflow of further inflammatory cells, e.g. neutrophilic granulocytes (Pesquero et al . PNAS 2000, 97, 8140-8145). Via these mechanisms the bradykinin BIR system can contribute to the chronic condition of diseases. This is confirmed by a number of animal experiment investigations (reviews in Leeb-Lundberg et al . , Pharmacol Rev. 2005, 57, 27-77 and Pesquero et al . , Biol. Chem, 2006, 387, 119-126). An enhanced expression of BlR is also found in humans, for example on enterocytes and macrophages in the affected tissue of patients suffering from inflammatory intestinal diseases (Stadnicki et al . Am. J. Physio. Gastrointest . Liver Physiol. 2005, 289, G361-366) and on T lymphocytes of patients suffering from multiple sclerosis (Pratet et al . , Neurology, 1999, 53, 2087-2092) or an activation of the bradykinin B2R-B1R system during infections with Staphyloccocus aureus (Bengtson et al . , Blood 2006, 108, 2055-2063) . Infections with Staphyloccocus aureus are responsible for clinical conditions ranging from surface infections of the skin up to septic shock.
On account of the pathophysiological relationships outlined above there is therefore a great therapeutic potential for the use of BlR antagonists in acute and in particular chronic-inflammatory diseases. These include diseases of the respiratory tract (bronchial asthma, allergies, COPD (chronic obstructive pulmonary disease), cystic fibrosis, etc.), inflammatory intestinal diseases (ulcerative colitis, CD (Crohn's disease), etc.), neurological diseases (multiple sclerosis, neurodegeneration, etc.), inflammations of the skin (atopic dermatitis, psoriasis, bacterial infections, etc.) and mucous membranes (M. Behcet, pelvitis, prostatitis), rheumatic diseases
(rheumatoid arthritis, osteoarthritis, etc.), septic shock, and reperfusion syndrome (after heart attacks and strokes) .
In addition the bradykinin (receptor) system is also involved in the regulation of angiogenesis (potential as an angiogenesis inhibitor in cancer and also macular degeneration of the eye) and BlR knockout mice are protected against the danger of becoming overweight due to a particularly fat-rich diet (Pesquero et al . , Biol. Chem. 2006, 387, 119-126) . BlR antagonists are therefore also suitable for treating obesity.
BlR antagonists are in particular suitable for treating pain, in particular inflammatory pain and neuropathic pain (Calixto et al . Br. J. Pharmacol 2004, 1-16), in this connection in particular diabetic neuropathy (Gabra et al . , Biol. Chem. 2006, 387, 127-143) . Furthermore they are suitable for the treatment of migraine.
In the development of BlR modulators there is the problem however that the human and rat BlR receptors differ so greatly that many compounds that are good BlR modulators on the human receptor have only a poor affinity or no affinity at all for the rat receptor. This significantly complicates animal pharmacological investigations since many investigations are normally carried out on rats. If however a compound has no effect on the rat receptor, then neither the action nor side effects on rats can be investigated. This has already led to the creation of transgenic animals with human Bl receptors for animal pharmacological investigations (Hess et al . , Biol. Chem 2006; 387 (2) : 195-201) . Working with transgenic animals is however more costly than working with unaltered animals. Since long-term toxicity investigations on rats are in particular part of the routine investigations in drug research and development however, these are not practicable if the compound is ineffective on the receptor, and an important established tool for checking safety is therefore lacking in the development of such compounds. There is therefore a need for new BlR modulators, in which connection BlR modulators that bind to the rat receptor as well as to the human receptor offer particular advantages.
An object of the present invention was accordingly to provide new compounds that are suitable in particular as pharmacological active constituents in medicaments, preferably in medicaments for treating disorders or diseases that are at least partially mediated by BlR receptors .
This object is achieved by the substituted sulfonamide derivatives according to the invention.
The present invention provides substituted sulfonamide derivatives of the general formula I
Figure imgf000005_0001
wherein
m and n, independently of one another, in each case denote 0, 1 or 2; p denotes 1 or 2 ; Q denotes -O- or -CH2-;
X denotes N or CR5; Y denotes N or CR6; Z denotes N or CR7; R1 denotes aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group;
R2 denotes H, Ci_6-alkyl, aryl or heteroaryl; or an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6~alkinylene group;
R3 denotes H, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6~ alkenylene group or C2-6~alkinylene group;
R4 denotes H, halogen, CN, NO2, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~alkinylene group;
R5, R6 and R7 independently of one another in each case denote H, halogen, CN, Ci-6-alkyl, -NH (Ci_6-alkyl) , -N(Ci-6- alkyl)2, -Ci-6-alkylene-NH (Ci-6-alkyl) , -Ci-6-alkylene-N (Ci-6- alkyl)2, C3-8-cycloalkyl, heterocyclyl, aryl or heteroaryl; or denote a C3-8-cycloalkyl, heterocyclyl, aryl or heteroaryl bonded via a Ci_6-alkylene group, C2-6-alkenylene group or C2-6~alkinylene group;
wherein the aforementioned radicals Cχ_6-alkyl, Ci-6~ alkylene, C2-6-alkenylene, C2-6-alkinylene, C3-8-cycloalkyl, heterocyclyl, aryl and heteroaryl can in each case be unsubstituted or monosubstituted or polysubstituted with identical or different radicals, and the abovementioned radicals Ci-6-alkyl, Ci-6-alkylene, C2-6~alkenylene, and C2-6~ alkinylene can in each case be branched or unbranched; in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in each case in the form of their bases and/or physiologically compatible salts.
In the context of the present invention the term "halogen" preferably denotes the radicals F, Cl, Br and I, and particularly preferably the denotes radicals F, Cl and Br.
The expression "Ci-6-alkyl" includes within the context of the present invention acyclic saturated hydrocarbon radicals with 1, 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals. Preferably the alkyl radicals can be selected from the group consisting of methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n- pentyl, iso-pentyl, neo-pentyl and hexyl. Particularly preferred alkyl radicals can be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl.
In the context of the present invention the expression
"C3-8-cycloalkyl" denotes cyclic saturated hydrocarbons with 3, 4, 5, 6, 7 or 8 carbon atoms, which can be unsubstituted or monosubstituted or polysubstituted on one or more ring members, for example with 2, 3, 4 or 5 identical or different radicals. Preferably C3-8-cycloalkyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl . The expression "heterocyclyl" denotes in the context of the present invention monocyclic or polycyclic, in particular mono-, bi- or tricyclic organic radicals, in which at least one cycle contains 1 heteroatom or 2, 3, 4 or 5 identical or different heteroatoms, which is/are preferably selected from the group consisting of N, 0 and S. Each heterocyclyl radical can be unsubstituted or monosubstituted or polysubstituted on one or more ring members, for example with 2, 3, 4 or 5 identical or different radicals.
Saturated or unsaturated heterocyclyl are understood in particular to denote monocyclic 5-membered or 6-membered radicals with at least one heteroatom selected from the group consisting of N, O and S, wherein a further 5- membered or 6-membered, saturated, unsaturated or aromatic cycle, which likewise can contain at least one heteroatom selected from the group consisting of N, O and S, can be condensed onto these radicals . Examples are the benzo- condensed or pyridino-condensed analogues of the aforementioned monocyclic 5- or 6-membered compounds.
Preferably a saturated or unsaturated heterocyclyl radical can be selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazolinyl, morpholinyl, tetrahydropyranyl, dioxanyl, dioxolanyl, indolinyl, isoindolinyl and
Figure imgf000009_0001
Unless otherwise specified, the substitution with a heterocyclyl radical can take place at any suitable position of the heterocyclyl radical.
The term "aryl" denotes in the context of the present invention aromatic hydrocarbons, in particular phenyls and naphthyls . The aryl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems. Each aryl radical can be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, in which the aryl substituents can be identical or different and can be in any arbitrary and possible position of the aryl. Preferably aryl can be selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl, which can in each case be unsubstituted or monosubstituted or polysubstituted, for example with 2, 3, 4 or 5 radicals.
The term "heteroaryl" denotes in the context of the present invention a 5-, 6- or 7-membered cyclic aromatic radical, which contains at least 1, possibly also 2, 3, 4 or 5 heteroatoms , in which the heteroatoms can be identical or different and the heteroaryl can be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals. The substituents can be bonded in any arbitrary and possible position of the heteroaryl. The heterocycle can also be part of a bicyclic or polycyclic, in particular of a monocyclic, bicyclic or tricyclic system, which can then overall contain more than 7 members, preferably up to 14 members. Preferred heteroatoms are selected from the group consisting of N, O and S. The heteroaryl radical can preferably be selected from the group consisting of pyrrolyl, indolyl, furyl, (furanyl), benzofuranyl, thienyl ( thiophenyl) , benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzodioxolanyl, benzodioxanyl, benzooxazolyl, benzooxadiazolyl, imidazothiazolyl, dibenzofuranyl, dibenzothienyl, phthalazinyl, pyrazolyl, imidazolyl, thiazolyl, oxadiazolyl, isoxazoyl, pyridinyl (pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indazolyl, purinyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, carbazolyl, phenazinyl, phenothiazinyl and oxadiazolyl, wherein the bonding to the general structure I can take place via any arbitrary and possible ring member of the heteroaryl radical. Particularly preferably the heteroaryl radical can be selected from the group consisting of furyl, thienyl and pyridinyl.
The expression "Cχ-6-alkylene group" includes in the context of the present invention acyclic saturated hydrocarbon radicals with 1, 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure. Preferably the alkylene groups can be selected from the list consisting of -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH (CH3) -CH2-, -CH(CH2CH3)-, -CH2-(CH2J2-CH2-, -CH (CH3) -CH2-CH2-, -CH2-CH(CH3J-CH2-,
-CH(CH3) -CH(CH3) , -CH(CH2CH3) -CH2-, -C(CH3J2-CH2, -CH(CH2CH2CH3)-, -C(CH3) (CH2CH3)-, -CH2-(CH2J3-CH2-, -CH(CH3J-CH2-CH2-CH2-, -CH2-CH(CH3J-CH2-CH2-, -CH(CH3) -CH2-CH(CH3) -, -CH (CH3) CH (CH3) -CH2-,
-C (CH3) 2-CH2-CH2-, -CH2-C(CH3J2-CH2-, -CH(CH2CH3J-CH2-CH2), -CH2-CH (CH2CH3) -CH2-, -C (CH3) 2-CH (CH3) -, -CH (CH2CH3) -CH (CH3) -, -C (CH3) (CH2CH3) -CH2-, -CH(CH2CH2CH3) -CH2-, -C(CH2CH2CH3) -CH2-,
-CH(CH2CH2CH2CH3)-, -C(CH3) (CH2CH2CH3)-, -C(CH2CH3J2- and
-CH2- (CH2) 4-CH2-.
Particularly preferably the alkylene groups can be selected from the list consisting of -CH2-, -CH2-CH2- and -CH2-CH2-CH2-.
The expression "C2-6~alkenylene group" includes in the context of the present invention acyclic, monosubstituted or polysubstituted, for example 2, 3 or 4 times, unsaturated hydrocarbon radicals with 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure. In this connection the alkenylene groups contain at least one C=C double bond. Preferably the alkenylene groups can be selected from the list consisting of -CH=CH-, CH=CH-CH2-, -C(CHs)=CH2-, -CH=CH-CH2-CH2-, -CH2-CH=CH-CH2-, -CH=CH-CH=CH-, -C(CH3J=CH-CH2-, -CH=C (CH3) -CH2- , -C (CH3) =C (CH3)-, -C(CH2CH3J=CH-, -CH=CH-CH2-CH2-CH2-, -CH2CH=CH2-CH2-CH2-, -CH=CH=CH-CH2-CH2- and -CH=CH2-CH-CH=CH2- .
The expression "C2-6-alkinylene group" includes in the context of the invention acyclic, monosubstituted or polysubstituted, for example 2, 3 or 4 times, unsaturated hydrocarbon radicals with 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) as well as unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals, and which couple a corresponding radical to the overarching general structure. In this connection the alkinylene groups contain at least one C≡C triple bond.
Preferably the alkinylene groups can be selected from the list consisting of -C≡C-, -C=C-CH2-, -C=C-CH2-CH2-, -C≡C-CH (CH3)-, -CH2-C=C-CH2-, -C≡C-C≡C-, -C≡C-C (CH3J2-, -C=C-CH2-CH2CH2-, -CH2-C≡C-CH2-CH2-, -C≡C-C≡C-CH2- and -C=C-CH2-C=C-.
The expression "aryl or heteroaryl bonded via a Ci_6- alkylene group, C2-6~alkenylene group or C2-6-alkinylene group" denotes in the context of the present invention that the Ci_6-alkylene groups, C2-6-alkenylene groups or C2-6~ alkinylene groups as well as aryl and/or heteroaryl have the meanings given above and the aryl and/or heteroaryl is/are bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6-alkinylene group to the overarching general structure. Benzyl, phenethyl and phenylpropyl may be mentioned by way of example.
The expression "C3_8-cycloalkyl and heterocyclyl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6- alkinylene group" denotes in the context of the present invention that the Ci-6-alkylene group, C2-6~alkenylene group, C2-6~alkinylene group, C3-8~cycloalkyl and heterocyclyl have the meanings given above and C3-8- cycloalkyl and heterocyclyl are bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~alkinylene group to the overarching general structure.
In connection with "alkyl", "alkylene", "alkenylene",
"alkinylene" and "cycloalkyl" the term "substituted" is understood in the context of the present invention to denote the substitution of a hydrogen atom by F, Cl, Br, I, CN, NH2, NH-Ci-6-alkyl, NHCi-6-alkylene-OH, Ci-6-alkyl, N(Ci-6- alkyl) 2, N (Ci-6-alkylene-OH) 2, NO2, SH, S-C i_6-alkyl, S- benzyl, O-Ci-δ-alkyl, OH, O-Ci-6-alkylene-OH, =0, 0-benzyl, C (=0) Ci-6-alkyl, CO2H, CO2-Ci-6-alkyl, or benzyl wherein polysubstituted radicals are understood to be those radicals that are substituted either on different or on identical atoms several times, for example twice or three times, for example three times on the same C atom as in the case of CF3 or CH2CF3, or on different sites as in the case of CH(CI)-CH=CH-CHCI2. The polysubstitution can be carried out with identical or different substituents, as for example in the case of CH(OH)-CH=CH-CHCI2. In connection with "heterocyclyl" the term "substituted" is understood to denote the substitution of a hydrogen atom on one or more ring members by F, Cl, Br, I, -CN, NH2, NH-Ci-6-alkyl, NH-Ci-6-alkylene-OH, Ci-6-alkyl, N (Cx-g-alkyl) 2, N (Ci-6-alkylene-OH) 2, pyrrolinyl, piperazinyl, morpholinyl, NO2, SH, S-Ci-6-alkyl, S-benzyl, O-Ci-e-alkyl, OH, O-Ci-6- alkylene-OH, =0, O-benzyl, C (=0) Ci-6-alkyl, CO2H, CO2-Ci-6- alkyl or benzyl. The polysubstitution can be carried out with identical or different substituents . In particular the hydrogen bonded to a N-heteroatom can be substituted by a Ci-6-alkyl group.
With regard to "aryl" and "heteroaryl", in the context of the present invention the term "substituted" is understood to denote monosubstitution or polysubstitution, for example 2, 3, 4 or 5 times, of one or more hydrogen atoms of the corresponding ring system by F, Cl, Br, I, CN, NH2, NH-Ci-6-alkyl, NH-Ci-6-alkylene-OH, N (Ci-e-alkyl) 2, N(Ci-6-alkylene-OH)2, NH-aryl1, N (aryl1) 2, N (Ci-6-alkyl ) aryl1, pyrrolinyl, piperazinyl, morpholinyl, NO2, SH, S-Ci-6-alkyl, OH, O-Ci-6-alkyl, O-Ci-6-alkyl-OH, C (=0) Ci-6-alkyl, NHSO∑Ci-e-alkyl, NHCOCi-6-alkyl, CO2H, CH2SO2-phenyl, CO2-Ci-6-alkyl, OCF3, CF3, -0-CH2-O-, -0-CH2-CH2-O-, -0-C(CH3) 2-CH2-, unsubstituted Ci-6-alkyl, pyrrolidinyl, imidazolyl, piperidinyl, benzyloxy, phenoxy, phenyl, naphthyl, pyridinyl, -Ci-s-alkylene-aryl1, benzyl, thienyl, furyl, wherein aryl1 denotes phenyl, furyl, thienyl or pyridinyl, on one or various atoms, wherein the aforementioned substituents - unless otherwise specified - may optionally for their part be substituted by the aforementioned substituents. The polysubstitution of aryl and heteroaryl can take place with identical or different substituents. Preferred substituents for aryl and heteroaryl can be selected from the group consisting of -O- Ci-3-alkyl, Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl, in particular from the group consisting of F, Cl, Br, CF3, CH3 and OCH3.
In the context of the present invention the symbol
Figure imgf000015_0001
used in the formulae denotes a coupling of a corresponding radical to the respective overarching general structure.
The expression "physiologically compatible salt" is understood in the context of the present invention to denote preferably salts of the compounds according to the invention with inorganic or organic acids that are physiologically compatible, especially when used in humans and/or mammals. Examples of suitable acids are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, 1, 1-dioxo-l, 2-dihydrolλ6-benzo [d] isothiazol-3-one (saccharinic acid) , monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4- aminobenzoic acid, 2 , 4 , 6-trimethylbenzoic acid, α-lipoic acid, acetylglycine, hippuric acid, phosphoric acid and/or aspartic acid. Particularly preferred are the salts of hydrochloric acid (hydrochlorides) as well as of citric acid (citrates) . In a preferred embodiment of the present invention, in the substituted sulfonamide derivatives according to the invention the radical R1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably denotes phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, and particularly preferably denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or polysubstituted with identical or different substituents, wherein the substituents are preferably selected from the group consisting of -O-Ci-3-alkyl, Ci-β-alkyl, F, Cl, Br, I CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl .
In a further preferred embodiment of the present invention, in the substituted sulfonamide derivatives according to the invention the radical R1 denotes phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, with identical or different radicals selected from the group consisting of methyl, methoxy, CF3, OCF3, F, Cl and Br.
In a further preferred embodiment the radical R1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2 , 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2, 3, 5-trimethylphenyl, 2, 4 , 6-trimethylphenyl, 2-chloro-6- methylphenyl, 2 , 4 , 6-trichlorophenyl, 2-chloro-6- (trifluoromethyl) phenyl, 2 , 6-dichloro-4-methoxyphenyl, 2- methylnaphthyl, 2-chloronaphthyl, 2-fluoronaphthyl, 2- chloro-4- ( trifluoromethoxy) phenyl, 4-chloro-2, 5- dimethylphenyl, 2 , 3-dichlorophenyl, 3, 4-dichlorophenyl, 2- (trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl, A- (trifluoromethyl) phenyl, 1-naphthyl and 2-naphthyl.
In a further preferred embodiment the radical R1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2 , 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2, 3, 5-trimethylphenyl, 2 , 4 , 6-trimethylphenyl, 4-chloro-2 , 5- dimethylphenyl, 2 , 3-dichlorophenyl, 3, 4-dichlorophenyl, 2- ( trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl, A- ( trifluoromethyl) phenyl, 1-naphthyl and 2-naphthyl.
In a further preferred embodiment the radical R1 in the sulfonamide derivatives according to the invention is selected from the group consisting of 4-methoxy-2, 3, 6- trimethylphenyl, 4-methoxy-2 , 6-dimethylphenyl, 4-methoxy- 2 , 3, 5-trimethylphenyl, 2 , 4 , 6-trimethylphenyl, 1-naphthyl and 2-naphthyl.
Preferably R2 in the sulfonamide derivatives according to the invention denotes H, Ci-β-alkyl or aryl; or denotes an aryl bonded via a Cx-g-alkylene group, C2-6~alkenylene group or C2-6~alkinylene group, wherein the aryl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci_6-alkyl, Ci-6-alkyl- O-, F, Cl, Br, I CF3, OCF3, OH and SH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R2 denotes H, Ci_6- alkyl or phenyl; or denotes a phenyl bonded via a Ci_6~ alkylene group, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R2 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, benzyl or phenethyl.
Preferably R3 in the sulfonamide derivatives according to the invention can denote H, Ci-6-alkyl or aryl; or can denote an aryl bonded via a Ci-6-alkylene group, C2-6~ alkenylene group or C2-6~alkinylene group, the aryl in each case being unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci-6~ alkyl, Ci-6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R3 denotes H or unsubstituted phenyl.
In a further preferred embodiment of the sulfonamide derivatives according to the invention, for
Q= -O- m and n are in each case equal to 1, and for Q= -CH2- the sum of m+n = 0 or 1.
In a further preferred embodiment of the sulfonamide derivatives according to the invention, for
Q= -0- m and n are in each case equal to 1, and for Q= -CH2- the sum of m+n = 0.
In a further preferred embodiment of the substituted sulfonamide derivatives according to the invention p denotes 1.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R4 denotes H, Ci-6~ alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6-alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or polysubstituted by identical or different substituents, the aryl and/or heteroaryl is/are preferably selected from the group consisting of phenyl, naphthyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_3-alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH and SH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R4 denotes H, Ci-6- alkyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a C3.-3- alkylene group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted or monosubstituted or polysubstituted by identical or different substituents, the substituents, being selected from the group consisting of -O-Ci-3-alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R4 denotes a radical selected from the group consisting of H, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert- butyl, phenyl, 2 , 3-dimethylphenyl, 3, 4-dimethylphenyl, 2- tert-butylphenyl, 3-tert-butylphenyl, 4-tert-butylphenyl, 2- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2- fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3- difluorophenyl, 3, 4-difluorophenyl, 2- (trifluoromethyl) phenyl, 3- (trifluoromethyl) phenyl, 4-
( trifluoromethyl) phenyl, 2-fluoro-4 (trifluoromethyl) phenyl, 3-fluoro-4- (trifluoromethyl ) phenyl, benzyl, phenethyl, thienyl, pyridyl and 6-chloropyridin-3-yl .
In a further preferred embodiment of the present invention, in the substituted sulfonamide derivatives according to the invention X denotes N, Y denotes CR6 and Z denotes CR7.
In a further embodiment of the present invention, in the substituted sulfonamide derivatives according to the invention X denotes N, Y denotes N and Z denotes CR7. In a further embodiment of the present invention, in the substituted sulfonamide derivatives according to the invention X denotes CR5, Y denotes CR6 and Z denotes CR7.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R5, R6 and R7 independently of one another in each case denote H, halogen, Ci-e-alkyl, -N (Ci-6-alkyl) 2, -Ci-6~alkylene-N (Ci_6~ Alkyl)2, 5-, 6- or 7-membered heterocyclyl, 5- or 6-membered heteroaryl or denote a 5- or 6-membered heteroaryl or a 5-, 6- or 7-membered heterocyclyl bonded via a Ci-6-alkylene group, wherein heterocyclyl comprises one or two identical or different heteroatoms selected from the group consisting of N and O and is unsubstituted or is monosubstituted or identically or differently polysubstituted with Ci_6-alkyl.
In a further preferred embodiment of the sulfonamide derivatives according to the invention R5, R6 and R7 independently of one another in each case denote H, F, Cl, Br, I, Ci-6-alkyl or denote a radical which is selected from the group consisting of
Figure imgf000022_0001
-J-(CH2J1-Nx J . -HCH2)j-Nv /
Figure imgf000022_0002
f
Figure imgf000022_0003
wherein R8 and R9 independently of one another denote in each case a Ci-6-alkyl radical, j in each case is 1, 2 or 3, and
R10 denotes a radical that is selected from the group consisting of H, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
Preferably R5 in the compounds according to the invention denotes H.
In a further preferred embodiment of the compounds according to the invention R6 denotes H or a radica selected from the group consisting of
Figure imgf000023_0001
wherein R8 and R9 independently of one another in each case denote a Ci_6-alkyl radical, j is in each case 1, 2 or 3, and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
In a further preferred embodiment of the compounds according to the invention R7 denotes H, F, Cl, Br, I, Ci-6~ alkyl or denotes a radical selected from the group consisting of
Figure imgf000023_0002
wherein R8 and R9 independently of one another in each case denote a Ci_6-alkyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH. Also preferred are substituted sulfonamide derivatives according to the invention in accordance with one or more of the preceding claims, wherein
m and n in each case independently of one another is 0 or 1; p is 1;
Q denotes -O- or -CH2;
X denotes N or CR5; Y denotes N or CR6; Z denotes N or CR7;
R1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, and particularly preferably denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or polysubstituted with identical or different substituents, wherein the substituents are preferably selected from the group consisting of -O-Ci_3-alkyl, Ci-6-alkyl, F, Cl, Br, I CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl;
R2 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6- alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci-6-alkyl, Ci-6-alkyl- O-, F, Cl, Br, I, CF3, OCF3, OH and SH;
R3 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6~ alkinylene group, the aryl being in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of Ci-6-alkyl, Ci_6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH;
R4 denotes H, Cχ-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6~alkylene group, C2-6- alkenylene group or C2-6~alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, the aryl or heteroaryl is preferably selected from the group consisting of phenyl, napththyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_3- alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH and SH;
R5, R6 and R7 independently of one another in each case denote H, halogen, Cχ-6-alkyl, -N (Ci-6-alkyl) 2, -Ci-6-alkylene- N (Ci-6-alkyl) 2/ 5- or 6-membered heterocyclyl, 5- or 6- membered heteroaryl or denote a 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclyl bonded via a Ci-β-alkylene group, wherein heterocyclyl comprises 1 or 2 identical or different heteroatoms selected from the group consisting of N and O and is unsubstituted or is monosubstituted or identically or differently polysubstituted with Ci_6-alkyl;
in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in the form of their bases and/or physiologically compatible salts.
In addition substituted sulfonamide derivatives according to the invention are preferred in which
for Q = -O- m and j are in each case 1, and for Q = -CH2- the sum of m+n = 0 or 1 ; p is 1;
R1 denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or identically or differently polysubstituted, wherein the substituents are selected from the group consisting of methyl, methoxy, CF3, F, Cl and Br;
R2 denotes H, Ci-6-alkyl or phenyl; or denotes a phenyl bonded via a Ci-6-alkylene group, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH;
R3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH;
R4 denotes H, Ci-β-alkyl, phenyl, furyl, thienyl or pyridxnyl; or denotes a phenyl, furyl, thienyl or pyridmyl bonded via a Ci_3-alkylene group, wherein the phenyl, furyl, thienyl or pyridinyl are in each case unsubstituted or monosubstituted or identically or differently polysubstituted, the substituents being selected from the group consisting of -O-Ci-3-alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH;
R5 denotes H;
R6 denotes H or a radical that is selected from the group consisting of
Figure imgf000027_0001
wherein R8 and R9 independently of one another in each case denote a Cχ-6-alkyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH, R7 denotes H, F, Cl, Br, I, Ci-6-alkyl, or denotes a radical that is selected from the group consisting of
Figure imgf000028_0001
-S-(CH2J1-N- /° -1-(CH2)J-N /N"
Figure imgf000028_0002
wherein R8 and R9 independently of one another in each case denote a Ci-6-alkyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
According to a further embodiment of the present invention substituted sulfonamide derivatives are preferred in which
m = 1, n = 1 and Q denotes -O- , m = 1, n = 0 and Q denotes -CH2-, m = 0, n = 1 and Q denotes -CH2- or m = 0, n = 0 and Q denotes -CH2-; p denotes 1;
X denotes N or CR5;
Y denotes N or CR6;
Z denotes N or CR7; R1 denotes phenyl or naphthyl, which is unsubstituted or is monosubstituted or identically or differently disubstituted, trisubstituted, quadruply substituted or pentasubstituted, wherein the substituents can be selected from the group consisting of methyl, methoxy, CF3, F, Cl and Br;
R2 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, or phenyl; or denotes a phenyl bonded via a -CH2-, -(CH2J2- or -(CH2) 3- group, wherein the phenyl is in each case unsubstituted or is monosubstituted or disubstituted, trisubstituted, tetrasubstituted or pentasubstituted with identical or different radicals, which are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH,
R3 denotes H or unsubstituted phenyl,
R4 denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a -(CH2)-, -(CH2) 2- or -(CH2) 3- group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted or is monosubstituted, disubstituted or trisubstituted with substituents selected independently of one another from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, F, Cl, Br, I, CF3, OCF3, OH and SH,
R5 denotes H; R6 denotes H or a radical that is selected from the group consisting of
Figure imgf000030_0001
-(CH2WN O -1-(CH2)J-NN N-
Figure imgf000030_0002
wherein R8 and R9 in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH;
R7 denotes H, F, Cl, Br, I methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl or a radical that is selected from the group consisting of
Figure imgf000030_0003
Figure imgf000030_0005
and
Figure imgf000030_0004
' wherein R8 and R9 in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
Also preferred are sulfonamide derivatives according to the invention of the general formula Ib
Figure imgf000031_0001
Ib wherein
X denotes N or CR ; Y denotes N or CR6; Z denotes N or CR7;
R denotes H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl group bonded via a -(CH2)-, -(CH2) 2" or -(CH2) 3- group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted, or is monosubstituted or identically or differently disubstituted or trisubstituted with substituents selected independently of one another from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, F, Cl, Br, I CF3, OCF3, OH and SH;
R5 denotes H;
R6 denotes H or a radical that is selected from the group consisting of
-1-(CH2)J-NN , -j-(CH2)j- \
Figure imgf000032_0001
Figure imgf000032_0002
wherein R8 and R9 independently of one another in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH;
R7 denotes H, F, Cl, Br, I, methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, or denotes a radical that is selected from the group consisting of
Figure imgf000033_0001
O
-(CH2).—N / !-(CH2)J-NN N'
wherein R8 and R9 independently of one another in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
In a further preferred embodiment of the present invention the sulfonamide derivatives according to the invention can be selected from the group consisting of
(1) N- (2- (2- (6- ( (dimethylammo) methyl) -l-phenyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 6- tetramethylbenzenesulfonamide,
(2) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (piperidm-1- ylmethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide,
(3) N- (2- (2- (5, 6-dihydro-[l, 2, 4] triazolo [4, 3-a] pyrazin-7 (8H) - yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide, (4) (R) -N- (3-oxo-l-phenyl-3- (2- (piperidin-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazin-7 (8H) -yl) propyl) naphthalene- 2-sulfonamide,
(5) (R) -N- (3- (3-chloro-2- (piperidin-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazin-7 (8H) -yl) -3-oxo-l- phenylpropyl) naphthalene-2-sulfonamide,
(6) N- (2- (2- (3-chloro-2- (piperidin-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazin-7 (8H) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(7) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (morpholinomethyl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(8 ) N- (3-oxo-l-phenyl-3- ( 6- (pyrrolidin-1-ylmethyl) -3,4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) propyl) naphthalene- 2-sulfonamide,
(9) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- ( (4-methylpiperazin- l-yl)methyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) - 2-oxoethoxy) ethyl) benzenesulfonamide,
(10) N- (3- (6- (morpholinomethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene-2- sulfonamide,
(11) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyrrolidin-1- ylmethyl) -3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide, (12) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (3- (4- methylpiperazin-1-yl) propyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(13) N- (3- (6- (3- (4-methylpiperazin-l-yl) propyl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -3-oxo-l- phenylpropyl) naphthalene-2-sulfonamide,
(14) N- (2- (2- (6- ( (dimethylamino)methyl) -l-phenyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(15) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- ( l-phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(16) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (l-phenyl-6-
(piperidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 ( IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(17) N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2 , 6- trimethylbenzenesulfonamide,
(18) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2
(IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(19) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1-
(pyridin-3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide, (20) N- (2- (2- (1- (β-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2 -a]pyrazm-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(21) N- (2- (2-(5, 6-dihydroimidazo[l,2-a]pyrazm-7 (8H) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2 ,3,6- trimethylbenzenesulfonamide,
(22) N-isobutyl-4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) -2, 3, 6-trimethylbenzenesulfonamide,
(23) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-3, 4-dihydropyrrolo [1, 2-a] pyrazm-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(24) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [ 1, 2- a] pyrazm-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulonamide,
(25) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1-
(thiophen-2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazm-2 (IH) - yl ) ethoxy) ethyl) benzenesulfonamide,
(26) N-isobutyl-4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) -2, 3, β-trimethylbenzenesulfonamide,
(27) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [ 1, 2-a]pyrazm- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide, (28) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(29) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (pyridin- 3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(30) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3,
5-tetramethylbenzenesulfonamide,
(31) 4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) -N, 2,3, 5-tetramethylbenzenesulfonamide,
(32) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(33) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 5-tetramethylbenzenesulfonamide,
(34) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 5-tetramethylbenzenesulfonamide,
(35) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 5-tetramethylbenzenesulfonamide, (36) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen- 2-yl) -3, 4-dihydropyrrolo[l, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(37) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (3- (trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(38) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo[l, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 3, 5-tetramethylbenzenesulfonamide,
(39) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(40) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(41) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1-
(pyridin-3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(42) N-benzyl-N- (2- (2- ( 1- ( 6-chloropyridin-3-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(43) N-benzyl-N- (2- (2- (5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide, (44) N-benzyl-N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo
[1, 2-a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy- 2, 6-dimethylbenzenesulfonamide,
(45) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(46) N-benzyl-N- (2- (2- (5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(47) N-benzyl-4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -2 , 6-dimethylbenzenesulfonamide,
(48) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(49) N-benzyl-N- (2- (2- (1- (3, 4-dimethylphenyl) -3, A- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(50) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-
(thiophen-2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (1 H) - yl) ethoxy) ethyl) benzenesulfonamide,
(51) N-benzyl-N- (2- (2-(l- (4-tert-butylphenyl) -3, A- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide, (52) N- (2- (2-(l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(53) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(54) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (pyridin-3- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(55) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo-
[1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy- N, 2, 6-trimethylbenzenesulfonamide,
(56) N- (2- (2- (5, 6-dihydroimidazo[l, 2-a] pyrazin-7 (8H) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2 , 6- trimethylbenzenesulfonamide,
(57) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(58) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(59) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide, (60) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (thiophen-2- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazxn-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(61) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (3-
(trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazm-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(62) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 6-trimethylbenzenesulfonamide,
(63) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2 , 6- trimethylbenzenesulfonamide,
(64) N- (2- (2- (1- (4-tert-butylphenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazm-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(65) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a]pyrazm- 2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(66) N, 2, 4, 6-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(67) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- ( 1- (pyridm-3-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazm-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide, (68) N- (2- (2-(l- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [ 1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(69) N- (2- (2- (1- (4-methoxyphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(70) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(71) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(72) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(73) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [ 1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(74) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl) benzenesulfonamide,
(75) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (1- (3- (trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide, (76) N- (2- (2- (1- (3-methoxyphenyl) -3, 4-dihydropyrrolo [ 1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(77) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 ( IH) -yl) -2- oxoethoxy) ethyl) -N, 2 , 4, 6-tetramethylbenzenesulfonamide,
(78) N- (2- (2- (1- (4-tert-butylphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(79) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide,
(80) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(81) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- (pyridin- 3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(82) N- (2- (2- (1- ( 6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(83) 4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 3, 6-tetramethylbenzenesulfonamide, (84) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl ) ethoxy) ethyl ) benzenesulfonamide,
(85) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(86) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3,
6-tetramethylbenzenesulfonamide,
(87) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(88) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen- 2-yl) -3, 4-dihydropyrrolo [1,2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(89) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1,2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 3, 6-tetramethylbenzenesulfonamide,
(90) N- (2- (2- (l-(4-tert-butylphenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(91) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide, (92) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(93) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (piperidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(94) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2- ( 6- (morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(95) N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(96) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(97) N- (2- (2- (l-butyl-6- ( (dimethylamino)methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(98) N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(99) N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(100) N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH)- yl) -2-oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(101) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- propyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(102) N-isobutyl-N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(103) N- (2- (2- (l-ethyl-6-methyl-3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(104) N-isobutyl-N- (2- (2- (l-isopropyl-6-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(105) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(106) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (1 H) -yl) ethoxy) ethyl) benzenesulfonamide, (107) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [ 1, 2-a]pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(108) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2- (6-
(morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1,2- a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(109) N- (2- (2- (l-benzyl-6-( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(110) N- (2- (2- (6- ( (dimethylamino)methyl) -l-phenethyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(111) N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(112) N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen-2-yl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(113) N- (2- (2- (6- ( (dimethylamino)methyl) -l-ethyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide, (114) N-(2-(2-(l-ethyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) ■ yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(115) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2-( 1-propyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(116) N-benzyl-4-methoxy-2, 3, β-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (pyrrolidin-1-ylmethyl) -3 , 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(117) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2- (6- (morpholinomethyl) -1-phenyl-3, 4-dihydropyrrolo [1,2- a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(118) N-benzyl-N- (2- (2- (l-benzyl-6- ( (dimethylamino)methyl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(119) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -1-phenethyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(120) N-benzyl-N- (2- (2- (l-butyl-6- ( (dimethylamino)methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) - ethyl) -4-methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(121) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen- 2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzesulfonamide,
(122) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolol [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethyl) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(123) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- propyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl ) benzenesulfonamide,
(124) N-benzyl-N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(125) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1- phenethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(126) N-benzyl-N- (2- (2- (6- ( (dimethylamino)methyl) -1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(127) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(128) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 6- (piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide, (129) N-benzyl-N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2- ( IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(130) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen- 2-yl)-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(131) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(132) N-benzyl-N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(133) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1-phenethyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(134) N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(135) N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide, (136) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (l-propyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(137) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(138) N- (2- (2- (l-ethyl-6-methyl-3, 4-dihydropyrrolo [1,2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(139) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(140) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6-
(pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(141) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6-
(piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(142) N, 2, 4, 6-tetramethyl-N- (2- (2- (6- (morpholinomethyl) -1- phenyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 ( IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(143) N- (2- (2- (l-benzyl-6- ( (dimethylamino)methyl) -3, 4- dihydropyrrolo[l, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide, (144) N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen-2-yl) - 3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2 - oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(145) N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(146) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-propyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(147) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(148) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- phenethyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(149) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(150) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2- (6-
(morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(151) N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide, (152) N- (2- (2-(l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide,
(153) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [ 1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 6- tetramethylbenzenesulfonamide,
(154) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-propyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(155) N-benzyl-N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(156) N- (3- (6- (2- (4-methylpiperazin-l-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -3-oxo-l- phenylpropyl) naphtha1in-2-sulfonamide,
(157) N- (3- (6- (2-morpholinoethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalin-2- sulfonamide,
(158) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyrrolidin-1-yl) ethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(159) N- (3-oxo-l-phenyl-3- (6- (2- (pyrrolidin-1-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(160) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (2- (4- methylpiperazin-1-yl) ethyl) -3, 4-dihydropyrrolo [1,2- a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(161) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (2- morpholinoethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(162) N- ( (IR) -3- (l-Ethyl-3, 4-dihydropyrrolo [ 1 , 2-a] pyrazin- 2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene-2- sulfonamide, (163) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (3- (piperidin-1- ylmethyl) -5, 6-dihydro- [l,2,4]triazolo[4,3-a] pyrazin- 7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide,
(164) (R) -N- (3-oxo-l-phenyl-3- (3- (piperidin-1-ylmethyl) -5, 6- dihydro- [1, 2, 4]triazolo[4, 3-a] pyrazin-7 (8H) - yl) propyl) naphthalene-2-sulfonamide,
(165) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-4- ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(166) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-3- yD-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH)- yl) ethoxy) ethyl) benzenesulfonamide,
(167) N- (3-Oxo-l-phenyl-3- (6- (pyridin-3-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide, (168) N- (3-Oxo-l-phenyl-3- ( 6- (pyridin-4-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(169) N- (3-Oxo-l-phenyl-3- (6- (pyridin-4-ylmethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) propyl) naphthalene-2-sulfonamide,
(170) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyridin- 3-yl) ethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide, (171) N- (3-Oxo-l-phenyl-3- (6- (2- (pyridin-3-yl) ethyl) -3,4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(172) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyridin- 4-yl) ethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(173) N- (3-Oxo-l-phenyl-3- (6- (2- (pyridin-4-yl) ethyl) -3,4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide, (174) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-3- ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(175) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (pyridin-4- yl) -5, 6-dihydroimidazo [1, 2-a]pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide,
(176) N- (3-Oxo-l-phenyl-3- (6- (pyridin-3-ylmethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(177) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-4- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(178) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (2- (pyridin- 4-yl) ethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide and (179) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (pyridin-4- ylmethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide
in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers or diastereomers, in each case in the form of their bases and/or physiologically compatible salts.
The numbering adopted above of the individual embodiments of the compounds according to the invention is retained in the following discussions of the present invention, in particular in the description of the examples.
The compounds according to the invention exhibit an antagonistic action on the human BlR receptor or on the BlR receptor of rats. In a preferred embodiment of the invention the compounds according to the invention exhibit an antagonistic action on both the human BlR receptor (hBlR) and the BlR receptor of rats (rBlR) .
Particularly preferred are compounds which at a concentration of 10 μM in the FLIPR assay exhibit an inhibition on the human BlR receptor and/or on the BlR receptor of rats of at least 15%, preferably at least 25%, more preferably at least 50%, still more preferably at least 70%, most preferably at least 80% and especially preferably at least 90%.
Particularly preferred are compounds that in a concentration of 10 μM exhibit an inhibition on the human BlR receptor and on the BlR receptor of rats of at least 70%, especially at least 80% and particularly preferably at least 90%.
The agonistic or antagonistic action of compounds can be quantified on the bradykinin 1 receptor (BlR) of humans and rats with ectopically expressing cell lines (CHO Kl cells) and with the aid of a Ca2+-sensitive dye (Fluo-4) in the fluorescent imaging plate reader (FLIPR) . The figure in percent activation refers to the Ca2+ signal after addition of Lys-Des-Arg9-bradykinin (0.5 nM) and Des-Arg9-bradykinin (100 nM) . Antagonists result in a suppression of the Ca2+ inflow after the addition of the agonist. Percent inhibition values are given in comparison to the maximum achievable inhibition.
The compounds according to the invention act for example on the BlR relevant in connection with various diseases, which means that they are suitable as pharmaceutical active constituent in medicaments .
The present invention therefore also provides medicaments containing at least one substituted sulfonamide derivative according to the invention as well as optionally suitable additives and/or auxiliary substances and/or optionally further active substances. These medicaments are particularly suitable for treating pain, in particular acute, visceral, neuropathic, chronic pain and/or inflammatory pain .Moreover, these medicaments are also suitable for treating diabetes, diseases of the respiratory tract, inflammatory intestinal diseases, neurological diseases, inflammation of the skin, rheumatic diseases, septic shock, reperfusion syndrome, obesity, and as an angiogenesis inhibitor.
The medicaments according to the invention contain, apart from at least one substituted sulfonamide derivative according to the invention, optionally also suitable additives and/or auxiliary substances, thus also carrier materials, fillers, solvents, diluents, colourants and/or binders, and can be administered as liquid medicament forms in the form of injections for solution, drops or juices, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols. The choice of the auxiliary substances, etc. as well as the amounts thereof to be used depend on whether the medicament is to be administered orally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, nasally, buccally, rectally or topically, for example to the skin, mucous membranes or to the eyes. For oral application suitable are preparations in the form of tablets, pills, capsules, granules, drops, juices and syrups, while for parenteral, topical and inhalative application suitable preparations are in the form of solutions, suspensions, easily reconstitutable dry preparations as well as sprays. Sulfonamide derivatives according to the invention in depot form, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration of the skin, are suitable percutaneous application preparations. Orally or percutaneously usable preparation forms can provide for the delayed release of the substituted sulfonamide derivatives according to the invention. The substituted sulfonamide derivatives according to the invention can also be used in parenteral long-term depot forms, such as for example implants or implanted pumps. In principle other active constituents known to the person skilled in the art can be added to the medicaments according to the invention.
The amount of active constituent to be administered to the patient varies depending on the patient's weight, type of application, medical indications and the severity of the illness. Normally 0.00005 to 50 mg/kg, in particular 0.01 to 5 mg/kg of at least one substituted sulfonamide derivative according to the invention are administered.
In a preferred form of the medicament a contained substituted sulfonamide derivative according to the invention is present as a pure diastereomer and/or enantiomer, as a racemate, or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers .
BlR is involved in particular in the phenomenon of pain. Accordingly, the substituted sulfonamide derivatives according to the invention can be used for the preparation of a medicament for treating pain, in particular acute, visceral, neuropathic or chronic pain.
The invention accordingly also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treating pain, in particular acute, visceral, neuropathic or chronic pain. Moreover, the present invention also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for the treatment of inflammatory pain.
The present invention also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treating diabetes, diseases of the respiratory tract, inflammatory intestinal diseases, neurological diseases, inflammation of the skin, rheumatic diseases, septic shock, reperfusion syndrome, obesity, and as an angiogenesis inhibitor. In this connection it may be preferred in one of the above uses if an employed substituted sulfonamide derivative is present as a pure diastereomer and/or enantiomer, as a racemate, or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers.
The invention also provides a method for treating, in particular in one of the aforementioned medical indications, a non-human mammal or a person that requires treatment for pain, in particular chronic pain, by administration of a therapeutically active dose of a substituted sulfonamide derivative according to the invention or a medicament according to the invention.
The invention also provides a method for treating, in particular in one of the aforementioned medical indications, a non-human mammal or a person that requires treatment thereof, by administration of a therapeutically active dose of a substituted sulfonamide derivative according to the invention or a medicament according to the invention .
The invention also provides a method for the preparation of the substituted sulfonamide derivatives according to the invention as explained and illustrated in the following description, examples as well as the claims.
General process for the preparation of the substituted sulfonamide derivatives according to the invention:
Figure imgf000061_0001
N O P
The carboxylic acids N are converted in an amide formation using primary or secondary amines O in the presence of water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound), TBTU, EDCI, PyBOP or PFPTFA, also in the presence of HOAt or HOBt and an organic base, for example DIPEA or pyridine, in an organic solvent such as THF, dichloromethane, diethyl ether, dioxane, DMF or acetonitrile, at temperatures from 00C to the reflux temperature, to form the final products of the general formula P.
General process for the preparation of the acids N
Method I Method II Method III
Figure imgf000062_0001
Figure imgf000062_0002
Figure imgf000062_0003
In Method I the racemic (R and S configuration) or enantiomer-pure (R or S configuration) aminoalcohols A are reacted in a sulfonylation with sulfonyl chlorides, bromides or pentafluorophenylate R1SC^X (X = Cl, Br, OPFP) , optionally in the presence of an organic or inorganic base, for example potassium carbonate, sodium carbonate, sodium hydrogen carbonate, diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine or DBU, preferably in an organic solvent, for example acetone, acetonitrile, dichloromethane or tetrahydrofuran and at a temperature from 0° to the reflux temperature, to form the sulfonylated aminoalcohols B.
The sulfonylated aminoalcohols B are reacted in an alkylation reaction with halogenated ester derivatives using tetrobutylammonium chloride or bromide or tetrabutylammonium hydrogen sulfate in a phase transfer reaction using an organic solvent such as THF, toluene, benzene or xylene and inorganic bases such as potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate or in the presence of an organic or inorganic base, conventional inorganic bases being metal alcoholates such as sodium methanolate, sodium ethanolate, potassium tert-butylate, lithium or sodium bases such as lithium diisopropylamide, butyllithium, tert-butyllithium, sodium methylate or metal hydrides such as potassium hydride, lithium hydride, sodium hydride, conventional organic bases being diisopropylethylamine, triethylamine, in an organic solvent such as dichloromethane, THF or diethyl ether, at 00C to the reflux temperature, to form the products of the general structure C.
In Method II the racemic (R and S configuration) or enantiomer-pure (R or S configuration) aminoalcohols E are reacted in a sulfonylation with sulfonyl chlorides, bromides or pentafluorophenolate R1SO2X (X = Cl, Br, OPFP) , optionally in the presence of an organic or inorganic base, for example potassium carbonate, sodium hydrogen carbonate, diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine or DBU, preferably in an organic solvent, for example acetone, acetonitrile, dichloromethane or tetrahydrofuran and at a temperature from 0° to the reflux temperature, to form the sulfonylated aminoalcohols F. The sulfonylated aminoalcohols F are then reacted in an alkylysation reaction with alkyl halides (RX, X = I, Br, Cl) , mesylates or alternative alkylation reagents, optionally in the presence of an organic or inorganic base, for example sodium hydride, potassium carbonate, cesium carbonate, DBU or DIPEA, preferably in an organic solvent, for example dimethylformamide, acetone, THF, acetonitrile, dioxane or mixtures of these solvents, at a temperature from 00C to the reflux temperature, to form the sulfonylated aminoalcohols B.
In Method III the racemic (R and S configuration) or enantiomer-pure (R or S configuration) acids G are esterified using water-extracting reagents, for example inorganic acids such as H2SO4 or phosphorus oxides or organic reagents such as thionyl chloride, in organic solvents such as THF, diethyl ether, methanol, ethanol or dichloromethane, to the stage H, at temperatures from room temperature to reflux temperatures. The amino acid esters H are reacted in a sulfonylation with sulfonyl chlorides, bromides or pentafluorophenolate R1SO2X (X = Cl, Br, OPFP) , optionally in the presence of an organic or inorganic base, for example potassium carbonate, sodium carbonate, sodium hydrogen carbonate, diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine or DBU, preferably in an organic solvent, for example acetone, acetonitrile, dichloromethane or tetrahydrofuran and at a temperature from O0C to the reflux temperature, to form the sulfonylated aminoesters I.
In the Methods I-III the ester derivatives C and I are reacted in an ester cleavage using organic acids such as trifluoroacetic acid or aqueous inorganic acids such as hydrochloric acid, or using aqueous inorganic bases such as lithium hydroxide, potassium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate in organic solvents such as methanol, dioxane, dichloromethane, THF, diethyl ether or mixtures of these solvents, at 0°C to room temperature, to form the acid stages of the general formula D (acid building blocks S1-S8) .
General processes for preparing the amines O
Method I
Figure imgf000065_0001
Pyrrole A is dissolved in a suitable solvent, such as for example ethanol, methanol, 2-butanone, DMSO, diethyl ether, water, benzene, toluene, THF, DCM, acetonitrile, acetone, DMF or pentane or a mixture of these solvents, and a suitable base is added, such as for example potassium hydroxide, sodium hydroxide, optionally in aqueous or alcoholic solution, potassium carbonate, potassium hexamethyldisilazane, sodium hydride, potassium hydride, sodium methanolate, sodium ethanolate, sodium tert .butylate or diisopropylethylamine, optionally with the addition of an auxiliary substance such as for example 18-crown-6, 15- crown-5, tetrabutylammonium bromide or sulfate, benzyltriethylammonium chloride, l-n-butyl-3- methylimidazolium tetrafluoroborate or DMAP, followed by- reaction with the corresponding iodide, bromide or chloride compound to form the stage B.
The ring closure to form the 1, 2 , 3, 4-tetrahydropyrrolo [ 1, 2- a]pyrazine C is carried out by reacting the 2- ( lH-pyrrol-1- yl) ethanamine with the corresponding aldehyde in solvents such as acetic acid, ethanol, methanol, pyridine, benzene, toluene, DCM or a mixture of these solvents, optionally with the addition of benzotriazole, aluminium trichloride or p-toluenesulfonic acid and optionally with removal by azeotropic distillation of the water formed in the reaction. The reaction times can be between 1 and 48 hours and the reaction temperature can vary between 200C and 1100C.
The ring closure to form the 1, 2, 3, 4-tetrahydropyrrolo [ 1, 2- a]pyrazine stage C can however also be achieved by reacting the 2- ( lH-pyrrol-1-yl) ethanamine with the corresponding carboxylic acid followed by reduction of the initially formed cyclic imine D with reducing agents, such as for example sodium boron hydride.
Starting from 1, 2 , 3, 4-tetrahydropyrrolo [1, 2-a] pyrazines , for further derivatisations on the pyrrole part the nitrogen in the piperidine part must if necessary be protected. Various protective groups are suitable for this purpose, such as for example BOC, Cbz or Fmoc protective groups .
The introduction of the BOC protective group by means of di-tert . -butyl dicarbonate can be carried out in solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 00C and 1000C.
The Cbz protective group can be introduced by reacting benzyl chloroformate in solvents such as for example diethyl ether, THF, DMF, benzene, toluene, dioxane, water, acetone, ethyl acetate, DCM or chloroform, optionally with the addition of a base such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine, optionally with the addition of a coupling reagent, such as for example HOBt.
The Fmoc protective group is introduced by reacting 9H- fluoren-9-yl methylchloroformate in solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water, optionally with the addition of a base, such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
The introduction of the amino methyl substituent on the pyrrole ring is carried out via an aminoalkylation to form the stages F. For the aminoalkylation the corresponding aromatic compound can be reacted with formaldehyde and the corresponding amine in ethanol or methanol. A variant of this process uses the reaction of an iminium salt with the corresponding aromatic system to form the stage E. The iminium salt is obtained for example by cleavage of the corresponding aminal .
The aminal is formed by reacting the corresponding amine with formaldehyde. The reaction can be carried out in solvents such as for example water, methanol, ethanol, tert . -butanol, benzene, toluene, diethyl ether, dioxane, THF, chloroform, DCM, DMF, acetonitrile, dilute aqueous HCl solution or mixtures of these solvents, optionally with the addition of a base, such as for example potassium carbonate or sodium hydroxide.
The iminium salt is obtained by reacting the aminal with for example acetyl or benzoyl chloride, mesyl chloride, trimethylsilyl chloride or iodide, tetrachlorosilane or borone trifluoride etherate, in solvents such as for example carbon tetrachloride, chloroform, DCM, diethyl ether, DMF, acetonitrile, hexane or DME at a temperature between -800C and +25°C.
The subsequent aminoalkylation to the stages F can be carried out in solvents such as for example acetonitrile, THF, DCM, diethyl ether, toluene or benzene at temperatures between -780C and room temperature.
The aminoalkylated 5, 6, 7 , 8-tetrahydropyrrolo [ 1 , 2-a] pyrazine derivative G used as building block is obtained by cleavage of the corresponding protective group. BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF, at a temperature from 00C to 1100C and a reaction time of 0.5 to 20 hours.
The Cbz protective group can be split off for example under acidic conditions. This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol. Also suitable however are reagents such as for example MesSil in solvents such as for example DCM, chloroform or acetonitrile, BF3 etherate with the addition of ethanethiol or Me2S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DCM and nitromethane, or triethylsilane/PdCl2 in methanol with the addition of triethylamine . A further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without the use of pressure, by means of catalysts such as for example Pd on charcoal, Pd(OH)2, PdCl2, Raney nickel or PtO2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
The Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DMC or chloroform. Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH. Reagents such as for example Ag2θ/Mel can however also be used.
Method II
Figure imgf000070_0001
Starting from the protected 1,2,3,4- tetrahydropyrrolo [1, 2] a] pyrazine E an aldehyde function is first of all introduced in the pyrrole ring in a Vilsmeier reaction .
The Vilsmeier reaction is carried out by reacting HCN and HCl in CHCI3 or diethyl ether or a mixture of these solvents. Further suitable reagents for the Vilsmeier reaction are DMF and oxalyl chloride or POCI3 in solvents such as for example DCM or DCE, but also for example trimethoxyethane and TiCl4 in DCM. N- (chloromethylene) -N- methylmethane aminium chloride with the addition of NaOH can also be used.
The subsequent Wittig reaction to the stages I, using phosphorylidene and a strong base, for example potassium tert . -butylate, n-butyllithium, s-butyllithium, phenyllithium, lithium diisopropylamide or lithium hexamethyldisilazide in organic solvents such as THF, diethyl ether, cyclohexane, toluene or a mixture of these solvents at a temperature from -780C to +300C yields the corresponding unsaturated esters.
The reduction of the double bond can be carried out hydrogenolytically or by adding suitable reducing agents. Heterogeneous catalysts as well as homogeneous catalysts can be used in the hydrogenolysis . Suitable heterogeneous catalysts are for example Pd on charcoal or Raney nickel in solvents such as for example methanol, ethanol, toluene, THF, ethyl acetate, acetic acid or in mixtures of these solvents, optionally with the addition of bases such as for example triethylamine . The reaction can be carried out at atmospheric pressure or at elevated pressure. A suitable homogeneous catalyst is for example (PPh3)3RhCl in benzene or toluene .
A suitable reducing agent is for example NaBH4 with the addition of NiCl2 in the solvents such as for example methanol, ethanol, THF or mixtures of these solvents.
The reduction of the ester group for the preparation of the stages K can be carried out by reduction with reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
In the subsequent reductive amination to the stages L the aldehyde is reacted with an amine and the imine thereby formed is then reduced to the amine. Suitable reducing agents are for example NaBH4, NaBH(OAc)3, NaCNBH3, NH4CNBH3, polymer-bound cyanoboron hydride, borane-pyridine complex or triethylsilane. The reaction can be carried out in solvents such as for example methanol, ethanol, DCM, DCE, acetonitrile, THF, toluene, water, DMSO, DMF, l-methyl-2- pyrrolidin-2-one or mixtures of these solvents. Auxiliary reagents such as for example HCl (gaseous or as an aqueous solution), acetic acid, TFA, ZnCl2, 1, 3-dimethyl-2- imidazolidine, MgSO4, Na2SO4 or molecular sieves are also used. The imine that is formed can however also be converted to the amine by catalytic hydrogenation on catalysts such as for example PtO2 or Pd/C in solvents such as for example methanol or ethanol.
The derivative M used as building block is obtained by cleavage of the corresponding protective group.
BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF at a temperature from 0°C to 1100C and a reaction time of 0.5 to 20 hours.
The Cbz protective group can be split off for example under acidic conditions. This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol. Also suitable however are reagents such as for example Me3Sil in solvents such as for example DCM, chloroform or acetonitrile, BF3 etherate with the addition of ethanethiol or Me2S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DCM and nitromethane or triethylsilane/PdCl2 in methanol with the addition of triethylamine . A further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without the use of pressure with the aid of catalysts such as for example Pd on charcoal, Pd(OH)2 PdCl2, Raney nickel or PtO2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
The Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform. Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH. Reagents such as for example Ag2O/Mel can however also be used.
Method III
Figure imgf000074_0001
The nitrogen on the piperidine part of the alkyl 5,6,7,8- tetrahydroimidazo [ 1, 2 ] a] pyrazin-2-carboxylate of stage A first of all has to be protected for further reactions.
Various protective groups, such as for example the BOC, Cbz or Fmoc protective group, are suitable for this purpose.
The introduction of the BOC protective group by means of di-tert . -butyl dicarbonate can be carried out in solvents such as for example dioxane, DCM, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium hydrogen carbonate, sodium carbonate or DMAP at temperatures between 00C and 1000C.
The Cbz protective group can be introduced by the reaction of benzyl chloroformate in solvents such as for example diethyl ether, THF, DMF, benzene, tolulene, dioxane, water, acetone, ethyl acetate, DCM or chloroform, optionally with the addition of a base, such as for example sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide or triethylamine, optionally with the addition of a coupling reagent such as for example HOBt.
The Fmoc protective group is introduced by reacting 9H- fluoren-9-yl methylchloroformate in solvents such as for example DCM, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water, optionally with the addition of a base, such as for example diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine, sodium carbonate or sodium hydrogen carbonate and optionally under microwave irradiation.
The reduction of the ester group for the preparation of the stages C can be carried out by reduction with reducing agents such as for example DIBAHL-H in solvents such as for example THF, DCM, toluene or hexane at temperatures between -78 °C and room temperature.
In the subsequent reductive amination for the preparation of the stages D, the aldehyde is reacted with an amine and the formed imine is then reduced to the amine. Suitable reducing agents are for example NaBH4, NaBH(OAc)3, NaCNBH3, NH4CNBH3, polymer-bound cyano boron hydride, borane-pyridine complex or triethylsilane . The reaction can be carried out in solvents such as for example methanol, ethanol, DCM, DCE, acetonitrile, THF, toluene, water, DMSO, DMF, 1- methyl-2-pyrrolidin-2-one or mixtures of these solvents. Often auxiliary reagents such as for example HCl (gaseous or as an aqueous solution), acetic acid, TFA, ZnCl2, 1,3- dimethyl-2-imidazolidine, MgSO4, Na2≤O4 or molecular sieves are also used. The formed imine can however also be converted to the amine by catalytic hydrogenation on catalysts such as for example Ptθ2 or Pd/C in solvents such as for example methanol or ethanol .
The aminoalkylated derivative E used as building block is obtained by cleavage of the corresponding protective group.
BOC protective groups can be split off for example by reaction with HCl in organic solvents such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in dichloromethane or THF at a temperature from 00C to 1100C and a reaction time of 0.5 to 20 hours.
The Cbz protective group can be split off for example under acidic conditions. This acidic cleavage can be carried out for example by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCl in methanol or ethanol . Also suitable however are reagents such as for example Me3Sil in solvents such as for example DCM, chloroform or acetonitrile, BF3 etherate with addition of ethanethiol or Me2S in solvents such as for example DCM, a mixture of aluminium chloride/anisole in a mixture of DMC and nitromethane, or triethylsilane/PdCl2 in methanol with the addition of triethylamine . A further method is the hydrogenolytic cleavage of the protective group at elevated pressure or without pressure with the aid of catalysts such as for example Pd on charcoal, Pd (OH) 2, PdCl2, Raney nickel or Ptθ2 in solvents such as for example methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCl, formic acid or TFA.
The Fmoc protective group is as a rule split off under basic conditions in solvents such as for example acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, DCM or chloroform. Suitable bases are for example diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH. Reagents such as for example Ag2O/Mel can however also be used.
Pharmacological investigations
1. Functional investigation on the bradykinin 1 receptor
(BlR)
The agonistic or antagonistic action of substances can be determined on the bradykinin 1 receptor (BlR) of humans and rats by means of the following assay. According to this assay the Ca2+ inflow through the channel is quantified by means of a Ca2+-sensitive dye (Fluo-4 type, Molecular Probes Europe BV, Leiden, Netherlands), in a Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, USA) .
Method:
Chinese hamster ovary cells (CHO Kl cells) are used, which are stably transfected with the human BlR gene (hBlR cells, Euroscreen s.a., Gosselies, Belgium), or with the BlR gene of rats (rBlR cells, Axxam, Milan, Italy). For functional investigations these cells are plated out on black 96-well plates with a clear floor (BD Biosciences, Heidelberg, Germany) in a density of 20,000/25,000 cells/well. The cells are incubated overnight with 10 vol . % FBS (foetal bovine serum, Gibco Invitrogen GmbH, Karlsruhe, Germany) at 37°C and 5% CO2 in a culture medium (hBlR cells: Nutrient Mixture Ham's F12, Gibco Invitrogen GmbH, Karlsruhe, Germany; rBlR cells: D-MEM/F12, Gibco Invitrogen GmbH, Karlsruhe, Germany) . The following day the cells are charged for 60 minutes at 37 °C with 2.13 μM Fluo-4 (Molecular Probes Europe BV, Leiden, Netherlands) in HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH, Karlsruhe, Germany) together with 2.5 M probenecid (Sigma-Aldrich, Taufkirchen, Germany) and 10 mM HEPES (Sigma-Aldrich, Taufkirchen, Germany) .
The plates are then washed twice with HBSS buffer and HBSS buffer is added which additionally contains 0.1% BSA (bovine serum albumin; Sigma-Aldrich, Taufkirchen, Germany), 5.6 mM glucose and 0.05% gelatin (Merck KGaA, Darmstadt, Germany) . After further incubation for 20 minutes at room temperature the plates are used for the Ca2+ measurement in the FLIPR. The Ca2+-dependent fluorescence is measured both before and after the addition of substances (λex = 488 nm, λem = 540 nm) . The quantification is carried out by measuring the highest fluorescence intensity (FC, fluorescence counts) over time.
FLIPR assay:
The FLIPR protocol consists of two substance additions. First of all test substances (10 μM) are pipetted onto the cells and the Ca2+ inflow is compared with the control (hBlR: Lys-Des-Arg9-bradykinin 0.5 nM; rBlR: Des-Arg9- bradykinin 100 nM) . This gives the result in percent activation referred to the Ca2+ signal after addition of Lys-Des-Arg9-bradykinin (0.5 nM) , bzw. Des-Arg9-bradykinin (100 nM) .
After 10 minutes' incubation 0.5 nM Lys-Des-Arg9-bradykinin ((hhBBllRR)) aanndd 110000 nnMM DDeess--AArrgg99--bbrraaddyykkiinniinn ((rrBB:lR) are applied and the inflow of Ca2+ is likewise determined.
Antagonists lead to a suppression of the Ca2+ inflow. The percent inhibition compared to the maximum achievable inhibition is calculated. The compounds show a good activity on both human and rat receptors.
The invention is described in more detail hereinafter with the aid of examples, without however restricting the general scope of the invention.
Examples :
List of abbreviations :
Eq. Equivalent (s )
BOC2O Di-tert . -butyl dicarbonate
CDI 1 , 1' -carbonyl diimidazole d Day (s)
DCE 1, 2-dichloroethane
DCM Dichloromethane
DIBAL-H Diisobutyl aluminium hydride
DIPEA Diisopropylethylamine
DMF Dimethylformamide
DMAP 4-Dimethylaminopyridine
EDCI N- ( 3-Dimethylaminopropyl) -N' -ethyl-carbodiimide
Wt. % Weight percent h Hour (s)
HATU 0- (Benzotriazol-1-yl) -N, N, N' ,N' -tetramethyluronium hexafluorophosphate
HOAt 1-hydroxy-7-azabenzotriazole
HOBt 1-hydroxy-lH-benzotriazole i . vac . In vacuo
M Molar mbar Millibar min Minute (s )
N Normal
NaOH Sodium hydroxide
RT Room temperature
B. p. Boiling point
THF Tetrahydrofuran
TFA Trifluoroacetic acid
Ms Methanesulfonyl The following acid building blocks were used for the synthes is of the sul fonamide derivatives according to the invention :
Figure imgf000082_0001
Figure imgf000083_0001
Preparation of {2- [ (4-methoxy-2 , 6-dimethyl- benzenesulfonyl) -methyl -amino] -ethoxy}acetic acid Sl
Figure imgf000084_0001
Stage 1. A solution of 3, 5-dimethylanisole (102.5g, 753 mmole) in DCM (1000 ml) was cooled to 00C. A solution of chlorosulfonic acid (251 ml, 3763 mmole) in DCM (250 ml) was added dropwise to this solution. After 10 minutes' reaction time the reaction solution was poured into an icebath (1000 ml), and the phases were separated and extracted again with DCM (250 ml) . The combined organic phases were washed with water (1000 ml) and satd. NaCl solution (1000 ml), dried over Na2SO4 and concentrated by evaporation. The product was purified by column chromatography on silica gel (heptane/DCM 5:1) . Yield: 63.5 g, 36%.
Stage 2. 2- (methylamino) ethanol (3.8 ml), 46.9 mmole) was dissolved in DCM (200 ml) and triethylamine (15 ml,
107 mmole) was added. The solution was cooled to 00C, a solution of 4-methoxy-2 , 6-dimethylbenzene-l-sulfonyl chloride (10 g, 42.6 mmole) dissolved in DCM (100 ml) was added, and the whole was stirred for 1.5 hours at RT. After completion of the reaction HCl (0.5 M, 100 ml) was added, the phases were separated, washed with water, dried over Na2SO4 and concentrated by evaporation. The crude product was used without further purification in the next stage . Yield 12.2 g, > 100%.
Stage 3. n-Bu4NCl (3.95 g, 14.2 mmole) was added to a solution of N-2- (hydroxyethyl) -4-methoxy-N, 2 , 6- trimethylbenzenesulfonamide (12.2 max. 42.6 mmole) in toluene (250 ml) . The reaction solution was cooled to 00C and NaOH solution (35%, 250 ml) was added. Tert. -butyl bromoacetate (9.3 ml, 63.9 mmole) was added dropwise to this solution and then stirred for 3 hours at RT. The organic phase was separated and washed three times with water (300 ml), dried over Na2SO4 and concentrated by evaporation. The crude product was used without further purification in the next stage. Yield 17.95 g, > 100%.
Stage 4. The tert. -butyl 2- (2- (4-methoxy-N, 2, 6- trimethylphenylsulfonamido) ethoxy) acetate (17.95 g, max.
42.6 mmole) was stirred in a solution of TFA (30 ml) and DCM (200 ml) for 2 hours at RT. After completion of the reaction the solvent was removed on a rotary evaporator and the remaining TFA was removed by evaporating twice with toluene and once with diisopropyl ether.
Yield: 13.6 g, 96% over 3 stages. Preparation of {2- [methyl- (2, 4, 6-trimethyl- benzenesulfonyl) -amino] -ethoxy}acetic acid S2
Figure imgf000086_0001
Stage 1. 2- (methylamino) ethanol (6.4 ml, 79.8 mmole) was dissolved in DMC (500 ml) and triethylamine (13.3 ml, 95.9 mmole) was added. The solution was cooled to 00C and a solution of 2 , 3, 6-trimethylbenzene-l-sulfonyl chloride (21 g, 95.9 mmole) dissolved in DCM (65 ml) was added dropwise, and the whole was stirred for 4 hours at RT.
After completion of the reaction the reaction mixture was washed first with water and then with sodium carbonate solution, and the phases were separated and extracted three times with DCM. The combined organic phases were dried over Na2SC>4 and concentrated by evaporation. The crude product was purified by column chromatography (silica gel, diethyl ether / hexane 9:1) .
Stage 2. Tetra-n-butylammonium hydrogen sulfate (2.24 g, 6.6 mmole) was added to a solution of N- (2-hydroxyethyl) -
N, 2, 4 , 6-tetramethylbenzenesulfonamide (16.9 g, 66 mmole) in toluene (450 ml) and cooled to 00C. NaOH solution (50%, 445 ml) was then added, followed by the dropwise addition of tert. -butyl bromoacetate (20.3 ml, 138.5 mmole) . The mixture was then stirred for 3.5 hours at RT, following which the aqueous phase was separated and extracted twice with diethyl ether (450 ml) . The combined organic phases were dried over Na2SO4, concentrated by evaporation in vacuo, and the residue was purified by column chromatography on silica gel (ethyl acetate) . Yield: 15.2 g, 62%.
Stage 3. Tert-butyl (2- (2- (N, 2 , 4, 6- tetramethylphenylsulfonamido) ethoxy) acetate (15.2 g, 41 mmole) was stirred for 4 hours at RT in a solution of TFA (63 ml) and DCM (290 ml). After completion of the reaction the solvent was removed on a rotary evaporator and the remaining TFA was removed by evaporating twice with toluene (200 ml) .
Preparation of {2] [4-methoxy-2, 3 , 6-trimethyl- benzenesulfonyl) -methyl-amino] -ethoxy}acetic acid S3
Figure imgf000087_0001
Stage 1. A solution of 4-methoxy-2 , 3, 6- trimethylbenzenesulfonyl chloride (2.29 g, 9.19 mmole) in THF (30 ml) was added dropwise at 00C to a solution of 2- methylaminoethanol (0.95 ml, 11.8 mmole) and triethylamine (5 ml) in THF (15 ml) . The mixture was then stirred for 5 hours at RT, concentrated by evaporation in vacuo, and the residue was taken up in NaHCO3 solution and extracted with ethyl acetate (3 x 30 ml) . The combined organic phases were dried with Na2SO4 and concentrated by evaporation in vacuo. Yield: 2.38 g, 90%.
Stage 2. NaOH solution (35%, 40 ml) was added at O0C to a solution of N- ( 2-hydroxyethyl) -4-methoxy-2 , 3, 6,N- tetramethylbenzenesulfonamide (2.34 g, 8.2 mmole) and tetra-n-butylammonium hydrogen sulfate (611 mg, 1.8 mmole) in toluene (40 ml) . A solution of tert. -butyl bromoacetate (1.82 ml, 12.3 mmole) in toluene (35 ml) was then added dropwise to the vigorously stirred two-phase system. The mixture was then stirred for 2 hours at RT, following which the aqueous phase was separated and the organic phase was washed neutral with water (3 x 40 ml) . The organic phase was dried with Na∑SCi, concentrated by evaporation in vacuo and the residue was purified by flash chromatography with ethyl acetate/cyclohexane (1:3) . Yield: 2.50 g, 76%.
Stage 3. Triethylsilane (1.54 ml, 9.6 mmole) followed by
TFA (5 ml) were added to a solution of { 2- [ ( 4-methoxy-
2, 3, 6-trimethylbenzenesulfonyl ) -methylamino] -ethoxy} acetic acid tert-butyl acetate (2.48 g, 6.18 mmole) in DCM
(50 ml), and the whole was stirred for 5 hours at RT. The mixture was then concentrated by evaporation in vacuo and the residue was taken up several times in toluene and concentrated by evaporation each time. The crude product was dissolved in ethyl acetate and extracted with 5% NaHCO3 solution (3 x 50 ml) . The combined organic phases were adjusted to pH 1 with cone, hydrochloric acid and re- extracted with ethyl acetate (3 x 50 ml) . The combined organic phases were dried with Na2SO4 and concentrated by evaporation in vacuo. Yield 2.41 g, >99%.
Preparation of {2- [benzyl- (4-methoxy-2 , 3 , 6- trimethyl- benzenesulfonyl) -amino] -ethoxy}acetic acid S4
Figure imgf000089_0001
Stage 1. Triethylamine (11.2 ml, 80 mmole) was added to a solution of 2-benzylaminoethanol (5.28 g, 35 mmole) in DCM (200 ml) and cooled using an icebath. 4-methoxy-2 , 3, 6- trimethylbenzene-1-sulfonyl chloride (7.9 g, 32 mmole) was then added and stirred for 3 hours at RT. After adding hydrochloric acid (0.5 M, 100 ml) the organic phase was separated, washed with water, dried over Na∑SO,}, filtered, and the solvent was distilled off. The crude product was used without further purification.
Stage 2. n-Bu4NCl (2.78 g, 10 mmole) was added to a solution of tert. -butyl bromoacetate (6.5 ml, 45 mmole) in toluene (125 ml), cooled to 00C, and then aqueous 35% NaOH
(150 ml) was added followed by the dropwise addition of N- benzyl-N- (2-hydroxyethyl) -4-methoxy-2 , 3, 6- trimethylbenzenesulfonamide (10.8 g, 30 mmole) dissolved in toluene (25 ml) . The reaction mixture was stirred for 3 hours, then washed with water until neutral, dried with Na2SO4, and the organic solvent was distilled off. The crude product was used without further purification.
Stage 3. The tert. -butyl 2- (2-N-benzyl-4-methoxy-2, 6- dimethylphenylsulfonamido) ethoxy) -acetate (14.3 g, 30 mmole) was dissolved in DCM (200 ml) , TFA (30 ml) was added, and the reaction mixture was stirred for 2 hours at RT. The solvent was largely distilled off. The residue was taken up in toluene (300 ml) and concentrated by evaporation on a rotary evaporator. The crude product was purified by washing with diisopropyl ether.
Preparation of {2- [benzyl- (4-methoxy-2, 6-dimethyl- benzenesulfonyl) -amino] -ethoxy}acetic acid S5
Figure imgf000090_0001
Stage 1. Triethylamine (11.2 ml, 80 mmole) was added to a solution of 2-benzylaminoethanol (5.28 g, 35 mmole) in DCM (200 ml) and cooled using an icebath. 4-methoxy-2, 6- dimethylbenzene-1-sulfonyl chloride (7.5 g, 32 mmole) was then added and stirred for 5 hours at RT. After adding hydrochloric acid (0.5 M, 100 ml) the organic phase was separated, washed with water, dried over Na2SCM, filtered, and the solvent was distilled off. The crude product was used without further purification. Stage 2. n-Bu4NCl (2.78 g, 10 mmole) was added to a solution of tert. -butyl bromoacetate (6.5 ml, 45 mmole) in toluene (125 ml), cooled to 00C, and aqueous 35% NaOH (150 ml) was first added, followed by the dropwise addition of N-benzyl- N- (2-hydroxyethyl) -4-methoxy-2, 6-dimethylbenzenesulfonamide (10.4 g, 30 mmole) dissolved in toluene (25 ml) . The reaction mixture was stirred for 3 hours, then washed with water til neutral, dried with Na2SO4, and the organic solvent was distilled off. The crude product was used without further purification.
Stage 3. The tert. -butyl 2- (2-N-benzyl-4-methoxy-2 , 6- dimethylphenylsulfonamido) ethoxy) acetate (19.4 g, 41.8 mmole) was dissolved in a mixture of methanol
(150 ml), THF (165 ml) and aqueous NaOH solution (6 M, 150 ml, 900 mmole) and stirred for 1 hour at RT. After completion of the reaction the solution was concentrated and HCl (6 M, 155 ml) was added at 00C. The aqueous phase was extracted with ethyl acetate (2 x 150 ml) and the combined organic phases were dried over Na2SCj and concentrated . Yield: 17.05 g, 100%.
Preparation of 2- ( (4-methoxy-N, 2, 3 , 5- tetramethylphenylsulfonamido)methoxy) acetic acid S6
Figure imgf000092_0001
Stage 1. K2CO3 (102 g, 740 mmole) and methyl iodide (55.3 ml, 888 mmole) were added to a solution of 2,3,6- trimethylphenol (80.6 g, 740 mmole) in DMSO (90 ml) and stirred for 2 days at RT. The reaction mixture was added to water (750 ml) and extracted twice with heptane (500 ml and 300 ml) . The combined organic phases were washed with satd. NaCl solution, dried over Na∑SO,), and concentrated. The residue was taken up in heptane, washed with KOH solution (2 M), dried over Na∑SOή and concentrated. Yield: 76.26 g, 80%.
Stage 2. A solution of 2-methoxy-l, 3, 4-trimethylbenzene
(85.18 g, 532 mmole) in DCM (500 ml) was cooled to 00C. A solution of chlorosulfonic acid (38.9 ml, 585 mmole) was added dropwise to the solution and stirred overnight at RT. After completion of the reaction the reaction mixture was concentrated. The residue was taken up in heptane and vigorously stirred. The heptane was decanted and concentrated.
Yield: 14.3 g, 11%.
The still remaining solids were taken up in DCM. The organic phase was washed with water, dried over Na∑SC^ and concentrated. A further fraction was obtained in a yield of 38.6 g, 29%.
Stage 3. 2- (methylamino) ethanol (5.57 ml, 69.0 mmole) was dissolved in DCM (100 ml) and triethylamine (20.2 ml, 144 mmole) was added. The solution was cooled to O0C and a solution of 4-methoxy-2, 3, 5-trimethylbenzene-l-sulfonyl chloride (14.3 g, 57.5 mmole) dissolved in DCM (100 ml) was added dropwise and stirred for 3 hours at RT. After completion of the reaction HCl (0.5 M, 130 ml) was added, the phases were separated, washed with water, dried over Na2SC>4 and concentrated. The crude product was used without further purification in the next stage. Yield: 15.69 g, 95%.
Stage 4. Tetra-n-butylammonium chloride (5.06 g,
18.2 mmole) was added to a solution of N- (2-hydroxyethyl) -
4-methoxy-N, 2 , 3, 5-tetramethylbenzenesulfonamide (15.69 g, 54.6 mmole) in toluene (300 ml) and cooled to 00C. NaOH solution (35%, 300 ml) was first of all added, followed by the dropwise addition of tert. -butyl bromoacetate (11.9 ml, 81.9 mmole) . The mixture was then stirred for 3.5 hours at RT, following which the aqueous phase was separated and the organic phase was washed with water (3 x 300 ml) until neutral. The organic phase was dried with Na2SCM, concentrated by evaporation in vacuo, and the residue was purified by column chromatography on silica gel (heptane / ethyl acetate 4:1 → 2:1). Yield: 19.23 g, 88%.
Stage 5. An NaOH solution (6 M, 200 ml, 1.2 mole) was added to an ice-cooled solution of tert. -butyl 2-(2-(4- methoxy-N, 2,3, 5-tetramethylphenylsulfonamido) ethoxy) acetate (19.23 g, 47.89 mole) in THF (100 ml) and methanol (100 ml) and stirred overnight at RT. The reaction solution was then acidified with HCl (6 M, 250 ml) and extracted with DCM. The organic phase was washed with saturated NaCl solution, dried over Na2SO4 and concentrated by evaporation. Yield: 16.58 g, 100%.
Preparation of 2- (2- (N-isobutyl-4-methoxy-2, 3, 6- trimethylphenylsulfonamido) ethoxy) acetic acid S7
Figure imgf000094_0001
Stage 1. Triethylamine (42.4 ml, 302 mmole) was added to a solution of ethanolamine (8.01 ml, 133 mmole) dissolved in DCM (200 ml) . The solution was cooled on an ice bath and 2 , 3, 6-trimethyl-4-methoxybenzenesulfonyl chloride (30 g, 121 mmole) dissolved in DCM (200 ml) was added dropwise. The reaction mixture was stirred overnight at RT. HCl solution (1 M, 125 ml) was then added, and the organic phase was separated, washed with water, dried over Na2SO4 and concentrated by evaporation to dryness. The crude product was used without further purification in the next stage .
Stage 2. K2CO3 (11.11 g, 80.4 mmole) and l-bromo-2- methylpropane (43.7 ml, 402 mmole) were added in succession to a solution of N- (2-hydroxyethyl) -4-methoxy-2 , 3, 6- trimethylbenzenesulfonamide (11 g, max. 38.69 mmole) in acetonitrile (400 ml) and heated overnight under reflux. Further l-bromo-2-methylpropane (21.9 ml, 201 mmole) was added and heating was continued overnight under reflux.
After cooling to RT, the reaction mixture was first of all filtered through filter earth and the filtrate was then concentrated by evaporation to dryness. The crude product was purified by column chromatography (silica gel, heptane/ethyl acetate 2:1).
Yield: 8.30 g, 63% over 2 stages.
Stage 3. n-Bu4NCl (2.33 g, 8.4 mmole) was added to a solution of N- (2-hydroxyethyl) -N-isobutyl-4-methoxy-2 , 3, 6- trimethylbenzenesulfonamide (8.3 g, 25.19 mmole) in toluene (100 ml) and DCM (100 ml), cooled to O0C, after which aqueous 35% NaOH (175 ml) was first of all added, followed by the dropwise addition of tert. -butyl bromoacetate (5.51 ml, 37.8 mmole). The reaction solution was stirred for 3 hours at RT. After completion of the reaction the phases were first of all separated, then washed with water until neutral, dried with Na2SO4, and the organic solvent was distilled off. The crude product was purified by column chromatography (silica gel, heptane/ethyl acetate
4:1) .
Yield: 10.8 g, 97%.
Stage 4. The tert. -butyl 2- (2- (N-isobutyl-4-methoxy-2 , 3, 6- trimethylphenylsulfonamido) ethoxy) -acetate (10.8 g, 24.3 mmole) was dissolved in a mixture of methanol (100 ml), THF (100 ml) and aqueous NaOH solution (6 M, 100 ml, 600 mmole) and stirred for 1 hour at RT. After completion of the reaction the solution was concentrated and HCl (6 M, 125 ml) was added at 00C. The aqueous phase was extracted with DCM (100 ml) and ethyl acetate (150 ml) , The combined organic phases were dried over Na2SO4 and concentrated. Remaining impurities were removed by repeated dissolution in diisopropyl ether and diethyl ether, followed by evaporation. Yield: 9.36g, 99%.
Preparation of 3 - (naphthalene-2-sulfonamido) -3 phenylpropionic acid S8
Figure imgf000096_0001
Stage 1. Thionyl chloride (19.1 g, 162 mmole) was added dropwise to a solution, cooled to 00C, of 3-amino-3- phenylpropionic acid (8.9 g, 54 mmole) in methanol (3 ml/mmole) . The reaction mixture was then heated for 12 hours under reflux (DC check) . The solvent was completely removed and the residue was dried in vacuo. The crude product was used without further purification in the next stage .
Stage 2. Triethylamine (9.7 g, 96 mmole) was added to a solution, cooled to 0°C, of methyl 3-amino-3- phenylpropionate (5.73 g, 32 mmole) in DCM. Naphthalene-2- sulfonyl chloride (8.7 g, 38.4 mmole) dissolved in DCM (50 ml) was added to this reaction solution. The reaction mixture was stirred for 3 hours at RT (DC check) . After completion of the reaction the reaction mixture was diluted with DCM, washed with water and satd. NaCl solution and dried over Na2SO4. The solvent was removed and the crude product was purified by column chromatography (silica gel, ethyl acetate/hexane 3:7) .
Stage 3. LiOH x H2O (0.25 g, 18 mmole) was added at a reaction temperature of 0°C to a solution of methyl 3- (naphthalene-2-sulfonamido) -3-phenylpropionate (3.3 g, 9 mmole) in a methanol/water mixture (3:1, 90 ml) . The reaction mixture was stirred for 16 hours at RT. The solvent was removed under reduced pressure, and the residue was taken up in water and washed with DCM. The aqueous phase was then carefully acidified with HCl (1 N) and extracted with ethyl acetate. The organic phase was washed with water and satd. NaCl solution and dried over Na2SO4. The product was obtained in sufficient purity after removing the solvent.
Preparation of (R) -3- (Naphthalene-2-sulfonamido) -3- phenylpropanoic acid S9
Figure imgf000098_0001
Figure imgf000098_0002
Procedure for step-1 : To a solution of (R) -ethyl 3-amino-3-phenylpropanoate hydrochloride (5.04 g, 21.9 mmol) and naphthalene-2- sulfonyl chloride (4.97 g, 21.9 mmol) in CH2Cl2 (60 inL) was added a solution of Et3N (7.65 inL, 54.9 mmol) in CH2Cl2 (60 mL) at 0 0C over a period of 45 min. The reaction mixture was stirred at room temperature for 42 h and then washed with aqueous 1 M HCl (300 mL) . The organic layer was dried (Na2SO4) and evaporated to dryness, which gave 8.05 g (96%) of S9-1 as a light pink solid.
Procedure for step-2 :
To a solution of sulfonamide S9-1 (7.82 g, 20.39 mmol) in THF (100 mL) and MeOH (100 mL) was added aqueous 4 M NaOH (15.35 mL, 61.4 mmol) and the mixture was stirred at room temperature for 18 h. The reaction was not complete according to TLC. Therefore, more aqueous 4 M NaOH (6 mL, 24 mmol) was added. After stirring for another 6 h the organic solvents were evaporated and aqueous 1 M HCl (100 mL) was added at 0 0C. The aqueous layer was then extracted with CH2Cl2 (100 mL) ; the organic layer was dried (Na2SO4) and evaporated to dryness to afford carboxylic acid S9 (6.97 g, 96%) .
The following amine building blocks were used for the synthesis of the sulfonamide derivatives according to the invention:
Amine Structure Name building block
Al 1-ethyl-l, 2,3,4- tetrahydropyrrolo [1,2] a]pyrazine
A2 1- (4-methoxyphenyl) -1,2,3,4- tetrahydropyrrolo [1,2] a]pyrazine
A3 l-phenyl-1,2,3,4- tetrahydropyrrolo [1,2] a]pyrazine
A4 1- (3, 4-difluorophenyl) -1,2,3, 4- tetrahydropyrrolo [1 , 2-a]pyrazine
A5 l-(3,4-dimethylphenyl) -1,2,3,4- tetrahydropyrrolo [ 1 , 2-a] pyrazine
A6 1- (3-fluorophenyl)-l,2,3,4- tetrahydropyrrolo [1 , 2-a]pyrazine
A7 1- (thiophen-2-yl) -1,2,3, 4- tetrahydropyrrolo [ 1 , 2-a] pyrazine Amine Structure Name building block
A8 1- (3- (trifluoromethyl) -1, 2, 3, 4- tetrahydropyrrolo [1 , 2-a]pyrazine
A9 1- (3-methoxyphenyl) -1,2,3,4- tetrahydropyrrolo [1, 2-a]pyrazine
AlO l-(2-fluoro-4-
(trifluoromethyl) phenyl) -1,2,3,4- tetrahydropyrrolo [1, 2-a]pyrazine
All l-phenethyl-1,2,3, A- tetrahydropyrrolo [1, 2-a]pyrazine
A12 l-propyl-1,2,3,4- tetrahydropyrrolo [1, 2-a]pyrazine
A13 l-isopropyl-1,2, 3,4- tetrahydropyrrolo [1, 2-a]pyrazine
A14 l-ethyl-6-methyl-l,2,3, 4- tetrahydropyrrolo [ 1 , 2-a] pyrazine
Al 5 l-isopropyl-6-methyl-l , 2 , 3 , A- tetrahydropyrrolo [ 1 , 2-a ] pyrazine
Al 6 l-tert-butyl-1 , 2 , 3 , A- tetrahydropyrrolo [ 1 , 2-a ] pyrazine
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0002
Synthesis of the amine building blocks Al-17, A27-28, A34
Figure imgf000104_0001
Stage 1. NaOH (9.4 g, 0.23 mole) and tetrabutylammonium hydrogen sulfate (0.8 g, 2.36 mmole) were added to a solution of the corresponding pyrrole (0.06 mmole) in acetonitrile (33 ml) and stirred for 30 minutes at RT. After the addition of 2-chloroethylamine hydrochloride
(8.2 g, 0.07 mole) the reaction mixture was heated for 24 hours under reflux. After the reaction mixture had cooled the insoluble inorganic residue was filtered off and the solvent was removed under reduced pressure. The crude product was distilled in vacuo (35° - 370C, 0.037 mbar)
1H NMR (400 MHz, CDCl3) δ ppm 2.95 - 3.15 (m, 1 H) 3.89 - 4.00 (m, 1 H) 6.12 - 6.21 (m, 1 H) 6.64 - 6.73 (m, 1 H)
Literature: Cuadro A.M., Matia M. P., Garcia J. L., Vaquero J.J. and Alvarez-Builla J.: Synth. Corrmun . , 1991, 21(4), 535-544.
Stage 2, Method A. A solution of the 2- ( lH-pyrrol-1- yl) ethanamine (0.1 mole) and the corresponding aldehyde
(0.1 mole) in acetic acid (250 ml) was stirred for 48 hours at RT. After completion of the reaction the solvent was removed on a rotary evaporator and the residue was taken up in aqueous sodium carbonate solution (10%) and extracted with DCM. The organic phase was then dried over MgSO4 and concentrated by evaporation in vacuo. Purification was carried out by column chromatography on neutral AI2O3 or silica gel or by washing with 2-propanol or by crystallising from ethanol or 2-propanol / n-hexane
Literature: I. Jirkovski, R. Baudy, Synthesis 1981, 481-483 Stage 2, Method B. Acetic acid (0.3 ml) was added to a solution of the 2- ( lH-pyrrol-1-yl) ethanamine (0.05 mole) and the corresponding aldehyde (0.05 mole) in ethanol (25 ml) and heated for 10 minutes under reflux. The reaction mixture was then stirred for a further hour at RT. The reaction mixture was concentrated by evaporation on a rotary evaporator and taken up in ethyl acetate. The organic phase was washed with NaHCC>3 solution, dried over MgSO4 and concentrated by evaporation. Purification was carried out if necessary by column chromatography on neutral AI2O3 or silica gel.
Stage 2, Method C. Benzotriazole (54.5 mmole) and a spatula tip amount of p-toluenesulfonic acid were added to a solution of the 2- (IH-pyrrol-l-yl) ethanamine (54.5 mmole) and corresponding aldehyde (54.5 mmole) in toluene (500 ml) . The reaction mixture was heated overnight on a Dean-Stark water separator. After completion of the reaction first of all the solvent was removed on a rotary evaporator and the residue was taken up in ethyl acetate.
The organic phase was washed firstly with 1 M NaOH and then with satd. NaCl solution. The organic phase was dried over Na2SO4 and then concentrated by evaporation to dryness . Purification was carried out if necessary by column chromatography by neutral AI2O3 or silica gel.
Figure imgf000106_0001
Figure imgf000107_0001
The amine is commercially obtainable
The crude product was used without further purification
The crude product was recrystallised in ethanol. 5 , 6 , 7 , 8 - tetrahydroimidazo [ 1 , 2 - a] pyrazine A29
Figure imgf000108_0001
Stage 1. A mixture of 2-aminopyrazin (25 g, 262.9 mmole) , chloroacetaldehyde (50% in water, 50 ml, 394 mmole) and NaHCO3 (33.1 g, 394 mmole) was heated for 2 days at 1000C. The reaction mixture was then cooled to RT, satd. K2CO3 solution (100 ml) was added, and the mixture was washed with DCM. The organic phase was dried over Na2SO4 and then concentrated by evaporation to dryness. Purification was carried out by column chromatography on silica gel (DCM / methanol, 95:5 + 5% NH4OH [35%].
Stage 2. The imidazo [1, 2-a]pyrazine (7.2 g, 60.44 mmole) was dissolved in 2-methoxyethanol (100 ml) and PtO2 (1.2 g, 5.13 mmole) was added. The reaction mixture was stirred overnight at RT in an autoclave under a hydrogen atmosphere (4 bar) . The autoclave was then flushed with nitrogen, the reaction mixture was filtered through filter earth, concentrated, and the solvent residues were then extracted with toluene. Purification was carried out by column chromatography on silica gel (DCM / 7 N NH3 in methanol, 95:5) Synthesis of the amine building blocks A18-26, A30-A32
Synthesis of the aminals
Stage 1, Method A. The formaldehyde solution (37% in water, 119 ml, 1.6 mole) was placed in a reaction vessel, dimethylamine solution (40% in water, 405 ml, 3.2 mole) was added, and the mixture was then stirred overnight at RT.
After completion of the reaction K2CO3 was added to the reaction mixture until phase separation occurred. The phases were separated and dried over K2CO3. The product was purified by means of fractional distillation (b.p. 80- 84°C) .
1H NMR (300 MHz, CDCl3) δppm 2.23 (s, 12 H) 2.73 (s, 2 H).
Literature: M. Gaudry, Y. Jasor, B. T. Khac, Org. Synth. 59, 153-158
Stage 1, Method B. The formaldehyde solution (37% in water, 59.5 ml, 0.8 mole) was placed in a reaction vessel and the corresponding amine (1.6 mole) was added. The mixture was then stirred overnight at RT. The reaction mixture was worked up by adding water (100 ml) and was extracted four times with 200 ml of ethyl acetate each time. The combined organic phases were dried over MgSO4 and concentrated. The crude product could be used without further purification. Stage 2. A reaction flask was heated and the aminal (60 mmole) was added and dissolved or suspended in diethyl ether (70 ml) . Acetyl chloride (72 mmole) dissolved in diethyl ether (20 ml) was added dropwise while cooling with ice. The reaction mixture was then stirred overnight at RT. The precipitate that had formed was filtered off through a glass frit, quickly transferred to a round- bottomed flask and dried under an oil pump vacuum. The crude product was used without further purification.
Literature: G. Kienast, L. F. Tietze, Angew. Chemie 1976, 88, 8, 261-262
Figure imgf000110_0001
1,2,3, 4 -tetrahydropyrrole [1, 2-a]pyrazine
Figure imgf000111_0001
TFA (0.5 ml) was added to a solution of l-(2- aminoethyl) pyrrole (9 mmole) in ethanol (20 ml) and 37% formaldehyde (9 mmole) . The reaction mixture was stirred for 15 minutes at 500C. The reaction solution was then cooled to 250C and stirred for 4 hours at this temperature. The reaction solution was concentrated by evaporation under reduced pressure. The residue was taken up in ethyl acetate and washed with aqueous sodium carbonate solution. The organic phase was separated, dried over Na2SO4 and concentrated by evaporation to dryness. The product was used without further purification.
Aminoalkylation
Figure imgf000111_0002
Stage 1, Method A. The corresponding 1-substituted 1, 2 , 3, 4-tetrahydropyrrolo [1, 2-a] pyrazine (1 equiv.) was dissolved in 2.5 ml/mmole DCM in a heated three-necked flask. Di-tert-butyl dicarbonate (0.5 equiv.) was dissolved in 1.5 ml/mmole DCM and added dropwise within 30 minutes. The suspension was stirred overnight at RT. The reaction mixture was worked up by adding satd. sodium carbonate solution and the organic phase was separated. The aqueous phase was then extracted twice with DCM. The organic phases were combined, dried over magnesium sulfate and concentrated by evaporation.
The products were purified by column chromatography on silica gel.
Stage 1, Method B. Diisopropylethylamme (12.15 mmole) and di-tert-butyl dicarbonate (8.9 mmole) were added to a solution of the correspondingly 1-substituted 1,2,3,4- tetrahydropyrrolo [ 1, 2-a] pyrazme (8.1 mmole) in DCM. The reaction mixture was stirred for 16 hours at 25°C. The organic phase was then washed with sodium carbonate solution, water and satd. NaCl solution, dried over NaaSCU and concentrated by evaporation. The crude product was purified by column chromatography (silica gel, ethyl acetate/DCM, 99:1)
Figure imgf000112_0001
Figure imgf000113_0001
Stage 2. Methods for the aminoalkylation
Method A. The Boc-protected 1-substituted 1,2,3,4- tetrahydropyrrole [ 1, 2-a] pyrazine (1 equiv.) was dissolved in acetonitrile (5 ml/mmole) , the corresponding iminium salt (1 equiv.) was added and the reaction mixture was stirred overnight at RT. For the working-up the reaction mixture was first adjusted to pH 1 with IN HCl and then extracted three times with diethyl ether. The aqueous phase was then made alkaline with sodium hydrogen carbonate solution and extracted three times with diethyl ether. The combined organic phases were dried over magnesium sulfate and concentrated by evaporation on a rotary evaporator.
The crude product was purified if necessary by column chromatography on silica gel (solvent: gradient: DCM/methanol 99:1 → 95:5).
Method B. The Boc-protected 1-substituted 1,2,3,4- tetrahydropyrrolo [ 1 , 2-a] pyrazine (1 equiv.) was dissolved in acetonitrile (10 ml/mmole), the corresponding iminium salt (1 equiv.) was added, and the reaction mixture was stirred overnight at RT. For the working-up the reaction mixture was diluted with ethyl acetate and then washed with sodium hydrogen carbonate solution, water and satd. NaCl solution, dried over Na2SU4 and concentrated by evaporation. The crude product was purified by column chromatography (silica gel, DCM/methanol 95:5)
Stage 3: Methods for cleavage of the protective groups
Method A. The aminoalkylated Boc-protected 1-substituted 1, 2 , 3, 4-tetrahydropyrrolo [1 , 2-a] pyrazine was dissolved in DCM (7 ml/mmole) , TFA (10 equiv.) was added, and the reaction mixture was stirred overnight at RT. After completion of the reaction (DC check) the reaction mixture was made alkaline with sodium carbonate solution. The phases were separated and the aqueous phase was extracted three times with DCM. The combined organic phases were dried over magnesium sulfate and the solvent was removed on a rotary evaporator. The crude product could be used without further purification.
Method B. The aminoalkylated Boc-protected 1-substituted 1, 2 , 3, 4-tetrahydropyrrolo [1 , 2-a] pyrazine was dissolved in ethyl acetate (1 ml/mmole) and a satd. solution of HCl in ethyl acetate (3 ml/mmole) was added at 00C. The reaction mixture was then heated to RT and stirred for 2 hours. The solvent was removed and the product was used without further purification.
Figure imgf000115_0001
Figure imgf000116_0002
Preparation of the amine building blocks A33
Figure imgf000116_0001
Stage 1. A solution of oxalyl chloride (1 equiv.) in DCE (15 ml) was added to an ice-cooled solution of dry DCE (15 ml) and dry DMF (1 equiv.) and stirred for 15 minutes at RT. The solution was re-cooled to 0°C and a solution of tert-butyl 3, 4-dihydropyrrolo [1,2-] pyrazine-2 (IH) - carboxylate (5 g, 22.25 mmole) in DCE (15 ml) was added. The reaction solution was stirred for 30 minutes at this temperature (DC check) . Ice was then added, followed by aqueous NaOH solution (50%) . The aqueous phase was extracted with DCM and the organic phase was then washed in succession with water and satd. NaCl solution. After drying over Na2SU4, the solvent was removed on a rotary evaporator. The crude product obtained was used without further purification in the next stage.
Stage 2. A solution of triethylphosphonium acetate
(48.9 mmole) in dry THF (160 ml) was slowly added to a suspension of NaH (60%, 48.9 mmole) in dry THF (160 ml), cooled to 00C, and then stirred for 60 minutes at 25°C. The reaction mixture was then cooled to 0°C and the aldehyde (from Stage 1, 22.25 mmole) in dry THF (160 ml) was added dropwise, the temperature being maintained constant. The reaction mixture was then heated to 25 °C and stirred for 16 hours at this temperature until the reaction had gone to completion. The reaction mixture was hydrolysed first with ice and then with satd. NaCl solution. The aqueous phase was extracted with ethyl acetate. The organic phase was then washed with water and satd. NaCl solution. The organic phase was dried over Na2SO4 and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: DCM/ethyl acetate, 95:5) .
Stage 3. A solution of the ester (from Stage 2, 9.37 mmole) in methanol (150 ml) was firstly deoxygenated with argon over a period of 15 minutes and Pd/C (10%, 20 wt. %) was added. The reaction mixture was hydrogenolysed for 45 minutes under atmospheric pressure (LCMS check) . After completion of the reaction the reaction mixture was filtered through filter earth and washed with methanol. The combined organic phases were concentrated and the product obtained was used without further purification in the next stage.
Stage 4. DIBAL-H (1 equiv., 1.5 M in toluene) was added dropwise at -700C and under an argon atmosphere to a solution of the tert-butyl 6- (2-ethoxycarbonylethyl) -3, 4- dihydro-lH-pyrrolo [ 1, 2-a] pyrazine-2-carbonate (from Stage 3, 1 equiv.) in dry toluene (7 ml/mmole) . The reaction mixture was stirred for 1 hour at this temperature, after which the educt had completely reacted (DC check) . Methanol (30 ml) was added at -700C and the reaction mixture was heated to 25°C. Saturated NaCl solution (30 ml) was added. The reaction mixture was stirred for 30 minutes at this temperature and then filtered through filter earth. The reaction mixture was washed several times with ethyl acetate. The combined organic phases were washed with saturated NaCl solution and then dried over Na2SO4, and the solvent was removed on a rotary evaporator. The product obtained was used without further purification in the next stage .
Stage 5. The corresponding amine (1 equiv.) and glacial acetic acid (170 μl/mmole) were added to a solution of the aldehyde (from Stage 4, 1.5 equiv.) in DCM (20 ml/mmole) at 250C and stirred for 30 minutes at this temperature. Sodium triacetoxy boron hydride (4 equiv.) was added to the reaction mixture and stirred for 20 hours at 25°C (DC check) . The reaction mixture was then diluted with DCM and washed with saturated, aqueous sodium hydrogen carbonate solution. The reaction mixture was next dried over Na∑SC^ and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: DCM/methanol, 9:1).
Preparation of the amine building blocks A35 and A36
Figure imgf000119_0001
The synthesis of the aldehyde reacted in Stage 1 was carried out according to Stage 1 of the synthesis of the amine building block A33.
Stage 1. Ammonium acetate (0.45 equiv.) was added to a solution of the aldehyde (10.4 mmole) in nitromethane (14.5 ml) . The reaction mixture was then heated under reflux for 2 hours (DC check) . After completion of the reaction the nitromethane was carefully removed under reduced pressure. The residue was taken up in ethyl acetate and washed successively with water and saturated sodium chloride solution. The organic phase was dried over sodium sulfate and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: hexane/ethyl acetate 9:1) .
Stage 2. The nitro compound from Stage 1 (32 mmole) was added to a mixture of methanol and DMF (2:1, 17.5 ml/mmole) and cooled to 0°C. NaBH4 (48 mmole) was added in portions to this mixture. The reaction mixture was stirred for 30 minutes at 0°C (DC check). Water (14 ml/mmole) and 1 drop of acetic acid were then added. The product was extracted with DCM. The organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate, and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: hexane/ethyl acetate 9:1).
Stage 3. A solution of the nitro compound (3.5 g,
12 mmole) from Stage 2 in ethanol (60 ml) was cooled to 00C and zinc dust (10 equiv.) was added in portions. The reaction mixture was stirred at 00C for 12 hours and then filtered through celite. The filtrate was washed several times with ethanol. The combined organic phases were concentrated by evaporation. The brown residue was taken up in DCM and washed in succession with sodium carbonate solution and saturated sodium chloride solution. The residue was then dried over sodium sulfate and the solvent was removed on a rotary evaporator. The crude product was used without further purification.
Stage 4. The tert-butyl-6- (2-aminoethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazine-2 (IH) -carboxylate (1 equiv.) was dissolved in toluene (5 ml/mmole) and potassium carbonate (5 equiv.) was added. l-chloro-2- (2- chloroethoxy) ethane or 2-chloro-N- (2-chloroethyl ) -N-methyl- methanamine (1.5 equiv.) was then added at RT. The reaction mixture was heated for 16 hours at 1000C in a closed tube (DC check) . After completion of the reaction the mixture was cooled to RT, diluted with ethyl acetate, and washed in succession with water and saturated sodium chloride solution. The organic phase was dried over sodium sulfate and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: DCM/methanol, NRR' = morpholine: 98:2, NRR' = methylpiperazine : 94:6).
Preparation of the amine building block A37
MsO'
Figure imgf000121_0001
Stage 1. Butanediol (5 g, 56 mmole) was dissolved in DCM, triethylamine (280 mmole) was added and the mixture was cooled to 00C. Methanesulfonic acid chloride (140 mmole) was added at this temperature and stirred for 1 hour at 0°C. After completion of the reaction the mixture was diluted with DCM and washed in succession with water and saturated sodium chloride solution. The organic phase was dried over sodium sulfate and the solvent was removed on a rotary evaporator. The crude product was used without further purification.
Stage 2. The tert-butyl-6- (2-aminoethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazine-2 (IH) -carboxylate (1 equiv. ) was dissolved in toluene (5 ml/mmole) and potassium carbonate (5 equiv.) was added. Butane-1,4- diyldimethanesulfonate (1.5 equiv.) was then added at RT. The reaction mixture was heated for 16 hours at 100°C in a closed tube (DC check) . After completion of the reaction the mixture was cooled to RT, diluted with ethyl acetate, and washed in succession with water and saturated sodium chloride solution. The organic phase was dried over sodium sulfate and the solvent was removed on a rotary evaporator. The crude product was purified by column chromatography on silica gel (solvent: DCM/methanol) .
Preparation of the amine building block A39 tert-Butyl 6- (pyridin-4-yl) -3 , 4-dihydropyrrolo [1, 2- a] pyrazine-2 (IH) -carboxylate
Figure imgf000122_0001
Step-3
Procedure for step-1:
To a solution containing 4g (0.06 mol) of pyrrole in 33 ml of acetonitrile were added 9.4g ( 0.23 mol) of powdered sodium hydroxide and 0.8 g (2.36 mmol) of tetrabutylammonium hydrogensulfate . After the mixture was stirred at 25°C for 30 minutes, 2-chloroethylamine hydrochloride (8.2 g, 0.07 mol) was added. The reaction mixture was refluxed for 24 hrs, inorganic solid was filtered off and the solvent was removed under reduced pressure to get crudel- (2-aminoethyl) pyrrole . This was distilled under vacuum to get a colorless liquid that was used in the next step directly. Yield : 30 % (crude) Procedure for step-2:
To a ethanol solution (20 ml) of 1- (2-aminoethyl) pyrrole (9 mmol) and 37% formaldehyde ( 9 mmol) was added TFA (0.5 ml) and the resulting reaction mixture was allowed to stir at 50°C for 15 minutes. It was then cooled to come to 25°C and stirred at this temperature for 4 hrs . Solvent was removed under reduced pressure, residue was dissolved in ethyl acetate, basified with aqueous sodium carbonate solution, organic layer was separated and dried over sodium sulfate. Evaporation of the organic layer gave the crude 1,2,3,4- Tetrahydro-pyrrolo [ 1, 2-a] pyrazine which was dissolved in dichloromethane (90 ml) at to it DIPEA ( 12.15mmmol) and boc anhydride ( 8.9 mmol) were added at 00C. The resulting reaction mixture was allowed to stir for 16 hrs at 25°C. Organic layer was washed with sodium carbonate, water and brine and finally dried over sodium sulfate. Evaporation of the organic layer gave the crude product which was purified by column chromatography (1% ethyl acetate in dichloromethane) or (10% ethyl acetate in hexane) .
Procedure for step-3 :
To a solution of 3, 4-Dihydro-lH-pyrrolo [1, 2-a] pyrazine-2- carboxylic acid tert-butyl ester (200mg, 0.9 mmmol) obtained from step-2 in dry dimethyl acetamide (200 μL) was added cesium acetate (3 eqv) , diisopropyl amine (4 eqv) and 4-bromopyridine hydrochloride (2 eqv) under argon atmosphere. To this reaction mixture was then added Pd (OAc) 2 (0.15eqv) under inert atmosphere and the reaction was heated at 130°C for 16hrs. It was then diluted with ethyl acetate, filtered through celite bed and the organic layer was washed successively with water and brine. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography. Yield : 40%
Preparation of the amine building block A40 tert-Butyl 6- (pyridin-4-ylmethyl) -3, 4-dihydropyrrolo [1,2- a]pyrazine-2 (IH) -carboxylate
Figure imgf000124_0001
Procedure for step-1 : Compound A (3g, 13.5 mmol) was taken in dry toluene (30 ml) and to it was added zinc dust ( 3 eqv) under inert atmosphere. The resulting reaction mixture was stirred at 25°C for 5 minutes and then isonicotinoyl chloride hydrochloride (1.5 eqv) was added under stirring. Stirring was continued for further lβhrs. Reaction mixture was filtered through celite bed, diluted with ethyl acetate, organic layer was washed successively with water and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product that was purified by column chromatography (5% methanol in dichloromethane) Yield: 40%
Procedure for step-2 : 2:1 mixture of AcOH-MeOH ( 36 ml) was added to the keto compound (3.6 iranol) and to it zinc dust (50 eqv) was added under stirring. The resulting reaction mixture was allowed to stir at 25°C for 16 hrs (monitored by LCMS) and filtered through celite bed. Solvent was completely evaporated, residue was taken in ethyl acetate, organic layer was washed successively with sodium bicarbonate and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography (5% methanol in dichloromethane) . Yield: 26%
Preparation of the amine building block A41 tert-Butyl 6- (2- (pyridin-4-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazine-2 (IH) -carboxylate
Figure imgf000125_0001
Step-2
Figure imgf000125_0002
Procedure for step-1:
To an ice cold solution of dry DCE (15 ml) and dry DMF (1 eqv) was added a solution of oxalyl chloride (1 eqv) in dry DCE (15 ml) and the resulting reaction mixture was stirred at 250C for 15 minutes. Reaction was again cooled to 00C and to it was added a solution of 3, 4-Dihydro-lH-pyrrolo [ 1, 2- a] pyrazine-2-carboxylic acid tert-butyl ester (5 gm, 22.25 mmol) in dry DCE (15 ml) and the reaction was stirred at the same temperature for 30 minutes (monitored by TLC) . It was quenched with ice, 50% aqueous NaOH solution was then added, aqueous layer was extracted with DCM and the organic layer was washed successively with water and brine. After drying over sodium sulfate, organic layer was evaporated under reduced pressure to get the crude product which was used immediately in the next step without any further purification . Yield : 60% (crude)
Procedure for step-2:
To a solution of 4-picoline (4 iranol) in dry THF (10 ml) was added n-BuLi (1.57M, 2.5ml, 4 mmol) at -780C and the resulting reaction mixture was allowed to stir at 25°C for 1 hr. It was again cooled to 0°C and the aldehyde obtained from step-1 (Ig, 4 mmol) was added to the reaction mixture drop wise. After stirring at 25°C for 3 hrs, reaction mixture was quenched with water ( 5ml), extracted with ethyl acetate and the combined organic layer was washed with brine. After drying over sodium sulfate, organic layer was evaporated under reduced pressure to get the crude alcohol that was purified by column chromatography (2 % methanol in dichloromethane) . Yield : 48%
Procedure for step-3:
To a solution of the alcohol obtained from step-2 (Ig, 2.91 mmol) in xylene (15 ml) wadded p-toluene sulfonic acid (0.05 eqv) and the resulting reaction mixture was refluxed using a dean-stark apparatus for 5 hrs ( monitored by TLC) . Reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed successively with saturated sodium bicarbonate solution, water and brine. Organic layer was dried over sodium sulfate evaporated under reduced pressure to get the crude product that was purified by column chromatography (2% methanol in dichloromethane) . Yield : 56% Procedure for step-4:
A solution of the compound obtained from step-3 was taken in methanol (15 ml) and deoxygenated with argon. To it was added 10% Pd-C (150mg) and the resulting reaction mixture was hydrogenated under atmospheric pressure for 3hrs . It was filtered through celite bed, residue washed with methanol and the combined organic layer was evaporated to dryness to get the crude product which was used directly in the next step without any further purification. Yield : 80% (crude)
Preparation of the amine building block A42 tert-Butyl 6- (pyridin-3-yl) -3 , 4-dihydropyrrolo [1,2- a] pyrazine-2 (IH) -carboxylate
Figure imgf000127_0001
Procedure: To a solution of 3, 4-Dihydro-lH-pyrrolo [ 1 , 2-a] pyrazine-2- carboxylic acid tert-butyl ester ( 2g, 9 mmmol) in dry dimethyl acetamide ( 2 ml) was added cesium acetate (3 eqv) , diisopropyl amine (4 eqv) and 3-bromopyridine (2 eqv) under argon atmosphere. To this reaction mixture was then added Pd (OAc) 2 (0.15eqv) under inert atmosphere and the reaction was heated at 130°C for 16hrs. It was then diluted with ethyl acetate, filtered through celite bed and the organic layer was washed successively with water and brine. Evaporation of organic layer under reduced pressure gave the crude product that was purified by column chromatography . Yield: 40%
Preparation of the amine building block A43 tert-Butyl 6- (pyridin-3-ylmethyl) -3 , 4-dihydropyrrolo [1, 2- a] pyrazine-2 (IH) -carboxylate
Figure imgf000128_0001
Procedure for step-1: Same as step-1 of A41
Procedure for step-2:
To a solution of n-BuLi (1.57 M, 2.54 ml, 4 itunol) in dry ether (5 ml) at -78°C was added 3-bromo pyridine (4 mmol) and the reaction mixture was allowed to stir at the same temperature for 30 minutes. To it aldehyde (4 mmol) obtained from step-1 in dry ether (10 ml) was added drop wise and the resulting reaction mixture was allowed to stir at 25°C for 16 hrs (monitored by TLC) . Reaction was quenched with water, extracted with ethyl acetate, combined organic layer was washed with brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography (3% methanol in dichlormethane) . Yield: 30% Procedure for step-3:
2:1 mixture of AcOH-MeOH (16 ml) was added to the keto compound (3.6 mmol) and to it zinc dust (50 eqv) was added under stirring. The resulting reaction mixture was allowed to stir at 250C for 16 hrs (monitored by LCMS) and filtered through celite bed. Solvent was completely evaporated, residue was taken in ethyl acetate, organic layer was washed successively with sodium bicarbonate and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product that was purified by column chromatography (5% methanol in dichloromethane) . Yield: 35%
Preparation of the amine building block A44 tert-Butyl 6- (2- (pyridin-3-yl) ethyl) -3,4- dihydropyrrolo [1, 2 -a] pyrazine-2 (IH) -carboxylate
Figure imgf000129_0001
Step-3
Procedure for step-1: Same as step-1 of A41
Procedure for step-2 :
To an ice cold suspension of the wittig salt (4 mmol) in dry THF (25 ml) was slowly added n-BuLi (5 mmol) and the resulting reaction mixture was allowed to stir at that temperature for 30 minutes. To it aldehyde B (2 mmol) in dry THF (10 ml) was added at 0°C and allowed to stir for further lhr. Reaction was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. Organic layer was washed with water and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product that was unstable and used immediately without any further purification.
Procedure for step- 3 :
To a DMA solution (2ml) of the crude compound obtained from step-2 (9.12mmol) was added cesium acetate (3 eqv) , diisopropyl amine (4 eqv) and 3-bromopyridine (2 eqv) under argon atmosphere. To this reaction mixture was then added Pd (OAc) 2 (0.15eqv) under inert atmosphere and the reaction was heated at 130°C for lβhrs. It was then diluted with ethyl acetate, filtered through celite bed and the organic layer was washed successively with water and brine. Evaporation of organic layer under reduced pressure gave the crude product that was purified by column chromatography (5% methanol in dichloromethane) Yield: 15%
Procedure for step-4 :
A solution of the compound obtained from step-3 (400 mg) was taken in methanol (10 ml) and deoxygenated with argon. To it was added 10% Pd-C (200mg) and the resulting reaction mixture was hydrogenated under atmospheric pressure for 3hrs . It was filtered through celite bed, residue washed with methanol and the combined organic layer was evaporated to dryness to get the crude product which was used directly in the next step without any further purification. Yield : 80% ( crude )
Preparation of the amine building block A45 tert-Butyl 2- (pyridin-4-yl) -5, 6-dihydroimidazo [1,2- a] pyrazine-7 (8H) -carboxylate
Figure imgf000131_0001
Procedure for step-1: To a solution of 2-aminopyrazine (1.87g) in dry acetone (30 ml) was added potassium carbonate (3 eqv) , 4-bromoacetyl pyridine (2 eqv) and the resulting reaction mixture was heated at 6O0C for 20hrs. Reaction mixture was filtered through a celite bed, residue washed with DCM and combined organic layer was evaporated completely to get a brown residue. It was again dissolved in ethyl acetate, washed with water and brine and finally dried over sodium sulfate. Evaporation of organic layer gave the crude product which was purified by column chromatography (1% methanol in dichloromethane) .
Yield : 12%, 30% Starting material recovered.
Procedure for step-2:
To a dry dioxane solution ( 22 ml) of the compound obtained from step-1 (2.55 mmol) was added lithium borohydride (2 eqv) portion wise at 25°C and the resulting reaction mixture was stirred at this temperature for 10 minutes. It was then warmed to 600C and kept at that temperature for 30 minutes ( monitored by TLC) . Reaction was cooled to 0°C and acidified with 1 (N) HCl. Dioaxane was completely evaporated, dichloromethane (5 ml) , diisopropyl ethyl amine (2.5 eqv) and boc-anhydride (1.5 eqv) was added to the residue and the resulting reaction mixture was allowed to stir at 25°C for 16 hrs . It was diluted with dichloromethane, organic layer was washed with water and brine and finally dried over sodium sulfate. Evaporation of the organic layer gave the crude product which was purified by column chromatography (5 % methanol in dichloromethane) . Yield : 58%
Preparation of the amine building block A46 tert-Butyl 2- (pyridin-4-ylmethyl) -5, 6-dihydroimidazo [1, 2- a] pyrazine-7 (8H) -carboxylate
Figure imgf000133_0001
. NN
Q N NH,
Figure imgf000133_0002
Figure imgf000133_0003
Procedure for step-1 : To a THF solution (40 ml) of Diisopropyl amine (4.46 ml,
1.5 eqv) was added BuLi ( 1.88 M, 1.5 eqv) at -15°C and the resulting reaction mixture was allowed to stir at same temperature for 20 minutes. It was then cooled to -78°C and 2-chloro-3-iodopyridine (5g, 20.92 mmol) in THF (10 ml) was added dropwise at the same temperature and allowed to stir for 1 hr at -780C. Reaction was quenched with water ( 10 ml), stirred at ambient temperature for 15 minutes and extracted with ethyl acetate. Organic layer was washed successively with brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was immediately used in the next step without any further purification. Yield : 80% ( Crude )
Procedure for step-2 :
To a solution of 2-amino pyrazine (2Og, 210 mmol) in dimethoxy ethane (400 ml) was added ethyl bromopyruvate (32.8 ml) at 25°C and the resulting reaction mixture was allowed to stir at the same temperature for 4 hrs . It was then cooled to 0°C and stirred for 30 minutes. The separated solid was filtered and washed with ether. Solid residue was taken in ethanol (1000ml) and refluxed for 4hrs. Solvent was removed completely, residue taken in chloroform (1000ml), saturated sodium bicarbonate solution (700 ml) was added to it and the mixture was allowed to stir for 45 minutes. The mixture was filtered through celite bed, washed several times with chloroform and filtrate was dried over sodium sulfate. Evaporation of the organic layer under reduced pressure gave the crude mass, which was purified by crystallization using ether-methanol mixture. Yield : 20%
Procedure for step-3 :
To a well stirred suspension of the ester obtained from step-1 (1Og, 52.3 mmol) in dioxane (400 ml) was added lithium borohydride (2 eqv) at 25°C and the resulting reaction mixture was allowed to stir at the same temperature for 10 minutes. It was then warmed to 60°C and kept at this temperature for for 20 minutes (! Higher temperature and more reaction time reduce the yield and quality of reaction) . Reaction mixture was then cooled to 0°C, acidified with IN HCl and dioxane was completely evaporated under reduced pressure. Residue was taken in dichloromethane (200 ml) , TEA ( 4eqv) and Boc-anhydride ( 1.2 eqv) was added to it and the resulting reaction mixture was allowed to stir at 250C for 16 hrs . Organic layer was washed with water and brine and finally dried over sodium sulfate. Evaporation of organic layer gave the crude product which was purified by column chromatography (70% ethyl acetate in hexane) . Yield : 27%
Procedure for step-4 :
To a solution of the boc-ester (Ig, 3.38 mmol) obtained from step-3 in dry toluene (40 ml) was added DIBAL (IM, 3.7 mmol) at -780C and the reaction mixture was allowed to stir at this temperature for 5 hrs ( monitored by TLC) . Reaction was quenched with methanol (3.7 ml) and was slowly brought to 25°C. Brine (10 ml) was added to it and filtered through celite bed. Residue was washed with dichloromethane and combined organic layer was evaporated to get the crude aldehyde, which was used directly in the next step without any further purification.
Yield : 800 mg (crude)
Procedure for step- 5 :
To a ether solution (17ml) of 2-chloro-4-iodo pyridine (1 eqv) was added BuLi (1.2 eqv) at -78°C and the resulting reaction mixture was allowed to stir at the same temperature for 1 hr. To it was added the aldehyde (1 eqv) obtained from step-4 at -78°C and stirred for 1 hr at the same temperature. It was quenched with water, extracted with ethyl acetate and the organic layer was washed successively with brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography. Yield : 35%
Procedure for step-6 :
A solution of the compound obtained from step-5 was taken in methanol (10ml/ mmol) and deoxygenated with argon. To it was added 10% Pd-C (50% by wt of the alcohol) and the resulting reaction mixture was hydrogenated under atmospheric pressure for 16 hrs . It was then filtered through celite bed, residue washed with methanol and the combined organic layer was evaporated to dryness to get the crude product which was used directly in the next step without any further purification. Yield : 44% (crude)
Procedure for step-7 :
To a solution of the alcohol (1 eqv) obtained from step-6 in methanol (5ml/mmol) was added glacial acetic acid (10ml/mmol) , Zn dust ( 50 eqv) and the resulting reaction mixture was allowed to stir at ambient temperature for 16 hrs. Reaction mixture was filtered through celite bed, washed with methanol and combined organic layer was evaporated completely. It was then taken in ethyl acetate, washed with sodium bicarbonate, water and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product which was purified by column chromatography ( 2% methanol in dichloromethane) Yield : 26% Preparation of the amine building block A47 tert-Butyl 2- (2- (pyridin-4-yl) ethyl) -5,6- dihydroimidazo [1, 2 -a] pyrazine-7 (8H) -carboxylate
C Nl NH2
Figure imgf000137_0001
Figure imgf000137_0002
Procedure for step-1:
To a solution of 2-amino pyrazine (2Og, 210 mmol) in dimethoxy ethane (400 ml) was added ethyl bromopyruvate
;32.8 ml) at 25°C and the resulting reaction mixture was allowed to stir at the same temperature for 4 hrs . It was then cooled to 0°C and stirred for 30 minutes. The separated solid was filtered and washed with ether. Solid residue was taken in ethanol (1000ml) and refluxed for 4hrs. Solvent was removed completely, residue taken in chloroform
(1000ml), saturated sodium bicarbonate solution (700 ml) was added to it and the mixture was allowed to stir for 45 minutes. The mixture was filtered through celite bed, washed several times with chloroform and filtrate was dried over sodium sulfate. Evaporation of the organic layer under reduced pressure gave the crude mass, which was purified by crystallization using ether-methanol mixture. Yield : 20%
Procedure for step-2:
To a well stirred suspension of the ester obtained from step-1 (1Og, 52.3 mmol) in dioxane (400 ml) was added lithium borohydride (2 eqv) at 25°C and the resulting reaction mixture was allowed to stir at the same temperature for 10 minutes. It was then warmed to 600C and kept at this temperature for for 20 minutes (! Higher temperature and more reaction time reduce the yield and quality of reaction) . Reaction mixture was then cooled to 00C, acidified with IN HCl and dioxane was completely evaporated under reduced pressure. Residue was taken in dichloromethane (200 ml) , TEA ( 4eqv) and Boc-anhydride ( 1.2 eqv) was added to it and the resulting reaction mixture was allowed to stir at 25°C for 16 hrs . Organic layer was washed with water and brine and finally dried over sodium sulfate. Evaporation of organic layer gave the crude product which was purified by column chromatography (70% ethyl acetate in hexane) . Yield : 27%
Procedure for step-3:
To a solution of the boc-ester (Ig, 3.38 mmol) obtained from step-2 in dry DCM (40 ml) was added DIBAL (IM, 3.7 mmol) at -78°C and the reaction mixture was allowed to stir at this temperature for 5 hrs ( monitored by TLC) . Reaction was quenched with methanol (3.7 ml) and was slowly brought to 25°C. Brine (10 ml) was added to it and filtered through celite bed. Residue was washed with dichloromethane and combined organic layer was evaporated to get the crude aldehyde, which was used directly in the next step without any further purification. Yield : 800 mg (crude)
Procedure for step-4:
To a solution of 4-picoline (3 mmol) in dry THF (10 ml) was added n-BuLi (1.57M, 3 mmol) at -78°C and the resulting reaction mixture was allowed to stir at 25°C for 1 hr. It was again cooled to O0C and the aldehyde obtained from step- 3 (3 mmol) was added to the reaction mixture drop wise. After stirring at 25°C, reaction mixture was quenched with water (5ml), extracted with ethyl acetate and the combined organic layer was washed with brine. After drying over sodium sulfate, organic layer was evaporated under reduced pressure to get the crude alcohol that was purified by column chromatography (3 % methanol in dichloromethane) . Yield : 36%
Procedure for step-5:
To a solution of the alcohol obtained from step-4 (2.3 mmol) in xylene (12 ml) wadded p-toluene sulfonic acid (0.05 eqv) and the resulting reaction mixture was refluxed using a dean-stark apparatus for 5 hrs ( monitored by TLC) . Reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed successively with saturated sodium bicarbonate solution, water and brine. Organic layer was dried over sodium sulfate evaporated under reduced pressure to get the crude product that was purified by column chromatography (2% methanol in dichloromethane) . Yield : 59%
Procedure for step-6: A solution of the compound (1.38 mmol) obtained from step-5 was taken in methanol (15 ml) and deoxygenated with argon. To it was added 10% Pd-C (225mg) and the resulting reaction mixture was hydrogenated under atmospheric pressure for 3hrs . It was filtered through celite bed, residue washed with methanol and the combined organic layer was evaporated to dryness to get the crude product which was used directly in the next step without any further purification. Yield : 80% (crude)
Preparation of the amine building block A48 3- (Piperidin-1-ylmethyl) -5,6,7, 8- tetrahydro- [1,2,4] triazolo [4, 3 -a] pyrazine
HCl BoC2O Et3N Boc^
HN
I N I I N
CH2CI2 rt A48-1
Boc.
Figure imgf000140_0001
A48-1 A48-2
Figure imgf000140_0002
A48-3 A48
Procedure for step-1 : To a solution of 5, 6, 7 , 8-tetrahydro- [1, 2, 4 ] triazolo [4 , 3- ajpyrazine hydrochloride (1.0 g, 6.23 mmol) in CH2CI2 (25 inL) were added Et3N (2.17 mL, 15.57 mmol) and BoC2O (1.52 inL, 6.54 mmol) and the reaction was stirred at room temperature overnight. The mixture was extracted with aqueous 0.25 M KHSO4 (50 mL) . The organic layer was dried (Na2SCj) and evaporated to dryness to afford compound A48-1 (1.29 g, 92%) .
Procedure for step-2:
To a solution of compound A48-1 (1.29 g, 5.75 mmol) in dry THF (50 mL) was added a solution of 2.5 M n-BuLi in hexane (2.53 mL, 6.33 mmol) at -78 0C under argon. After 15 min ethyl formate (702 μL, 8.63 mmol) was added and the reaction mixture was stirred for 15 min at -78 °C.
Saturated aqueous NH4Cl (150 mL) was added and the mixture was extracted with CH2Cl2 (3 x 100 mL) . The combined organic layer was dried (Na2SO4) and evaporated to dryness to afford aldehyde A48-2 (1.21 g, 83%).
Procedure for step-3:
To a solution of aldehyde A48-2 (1.21 g, 4.80 mmol), piperidine (522 μL, 5.28 mmol) and AcOH (329 μL, 5.76 mmol) in CH2Cl2 (50 mL) was added NaBH(OAc)3 (1.53 g, 7.19 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with CH2Cl2 (50 mL) and washed with brine (50 mL) . The organic layer was dried (Na2SO4) and evaporated to dryness to afford amine A48-3 (1.53 g, 99%) .
Procedure for step-4:
To a solution of compound A48 - 3 ( 1 . 53 g , 4 . 76 mmol ) in
CH2Cl2 ( 30 mL ) wa s added TFA ( 18 . 3 mL , 238 mmol ) and the mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and co-evaporated twice with CH2Cl2 (50 mL) to afford amine A48 (3.18 g, λ302%').
General process for the preparation of the substituted sulfonamide derivatives according to the invention
Figure imgf000142_0001
N O p
The carboxylic acids N are converted in an amide formation process using primary or secondary amines O in the presence of water-removing agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC (optionally polymer-bound) , TBTU, EDCI, PyBOP or PFPTFA also in the presence of HOAt or HOBt and an organic base, for example DIPEA or pyridine in an organic solvent such as THF, dichloromethane, diethyl ether, dioxane, DMF or acetonitrile, at temperatures from 0°C to the reflux temperature, to yield the final products of the general formula P.
Parallel synthesis methods
Parallel synthesis method 1
Acid solution (0.05 M in DCM, 2 ml) was added to 105 μmole of CDI solution (0.105 M in DCM, 1 ml) and shaken for 1 hour at RT. 100 μmole of the amine solution (0.1 M in DCM) were then added at RT and shaken for a further 12 hours at RT. 3 ml of water were next added to the reaction mixture, shaken for 15 minutes, and the organic phase was separated. After distilling of the solvent the crude products were analysed by means of LC-MS and purified by HPLC.
Parallel synthesis method 2
EDCI (1.5 equiv.), HOBt (1 equiv.) and diisopropylethylamine (1.5 equiv.) were first of all added to a solution of the corresponding acid (1 equiv.) in DCM (3 ml/mmole) and stirred for 15 minutes at 25°C. The corresponding amine was dissolved in DCM (1 ml/mmole) in another reaction vessel, cooled to 00C, and diisopropylethylamine (4 equiv.) was added. The cooled solution was added to the acid solution and stirred for 16 hours at RT. For working-up, the mixture was first of all diluted with DCM and then washed in succession with ammonium chloride solution, sodium carbonate solution and saturated NaCl solution, and dried over Na2SO4. The solution was concentrated by evaporation to dryness. The product was purified using a purification system from Biotage operating in parallel. Parallel synthesis method 3
Figure imgf000144_0001
Figure imgf000144_0002
O
Stage 1. TFA (20% in DCM, 3 ml/mole) was added at 00C to the Boc-protected amine (1 equiv.)- The reaction mixture was heated to 25°C and stirred at this temperature for 2 hours (DC check) . The solvent was completely removed and the product was carefully dried in order to remove traces of TFA. The crude product was used without further purification .
Stage 2. EDCI (1.5 equiv.), HOBt (1 equiv.) and DIPEA (2.5 equiv.) were added to a solution of the acid building block (1 equiv.) in DCM (3 ml/mmole) and stirred for 15 minutes at 250C. The Boc-deprotected amine (1.5 equiv.) in DCM (1 ml/mmole) was cooled to 00C in another reaction vessel and DIPEA (4 equiv.) was added. The solution thereby obtained was added to the solution of the acid building block. The reaction mixture was stirred for 16 hours at 25°C and then diluted with DCM. The organic phase was washed in succession with aqueous ammonium chloride solution, aqueous sodium hydrogen carbonate solution and saturated NaCl solution. The organic phase was dried over Na∑SCU and concentrated by evaporation. The crude product was purified using a parallel purification system from Biotage . BIOTAGE PURIFICATION OF LIBRARY COMPOUNDS
Step-1: Before purification all the crude compounds were analyzed to get LCMS data of each compound. Thus, it is possible to determine the polarity of compounds .
Step-2 : Each compound was dissolved in minimum quantity of dichloromethane and loaded onto a Biotage column (Biotage Si 12+ M) and it was then placed in the 12 channel Biotage Quad-3 parallel purification system. At a time 12 compounds were purified.
Step-3 : Depending on the polarity of the compound (TLC was used to determine the eluent) specific solvent mixtures were run in 12 channel Biotage
Quad-3 purification system and the fractions were collected in test tubes. Pure fractions were combined after cheking the TLC of all the fractions . Step-4 : Combined pure fractions from each column were evaporated under reduced pressure, transferred to pre-tared glass vials using acetonitrile as solvent and dried in Speed Vac Thermo explorer to get dry pure compound. These were then submitted for final analysis.
LCMS Method for MONITORING
l.LC Parameters
Column = phenomenex GEMINI 5μm C18 IIOA (50*4.6 mm) U. V wavelength = 220 ran, 260nm
Shimadzu LC system injection volume = 1.00 to 5.00μl (Depending on concentration) Flow rate = 1.2 ml/min
Time Program:
A: 0.05 % TFA (pH 2.3)
B: Acetonitrile
Figure imgf000146_0001
2. MS Parameters
Scan Type: Ql MS (Ql) Polarity: Positive Scan Mode: Profile
Ion Source: Turbo Spray
Source Temperature (at setpoint; : 2000C
Figure imgf000146_0002
Detector Parameters): IS (Ion Spray Voltage) : 5500 Detector CEM: 2200.0 DP (Declustering Potential) : 50.00 EP (Entrance Potential): 10.00
HPLC : Schimadzu Prominance integrated with MS of API 2000 LCMS/MS of Applied Biosystems, and ELS Detector of Polymer labs (temperature 500C)
Example 1: N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3 , 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) - 4-methoxy-N, 2,3, 6- tetramethylbenzene sulfonamide
Figure imgf000148_0001
CDl (0.2 g, 1.23 mmole) was first added to a solution S3 (0.41 g, 1.18 mmole) in DCM (10 ml) and stirred for 1 hour at RT. The amine A18 (0.3 G, 1.18 mmole) dissolved in DCM (10 ml) was then added at this temperature and stirred for a further 16 hours at RT. After completion of the reaction the mixture was first washed with NH4Cl solution and then with saturated sodium carbonate solution. The organic phase was dried over Na2SO4, filtered, and the solvent was distilled off. The crude product was purified by column chromatography (silica gel, DCM/methanol 98:2). m/z=582.3
Example 3: N- (2- (2- (5, 6-dihydro- [1, 2 , 4] triazolo [4 , 3- a]pyrazin-7 (8H) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide
Figure imgf000148_0002
Stage 1. Oxalyl chloride (3.89 ml, 45.3 mmole) and 2 drops of DMF were added to a solution of the acid Sl (5.O g, 15.1 mmole) in DCM (100 ml) . The reaction mixture was stirred overnight at RT. After completion of the reaction the solvent was evaporated to dryness on a rotary evaporator. The residue was taken up in DCM and again evaporated to dryness. This was repeated a further two times . The crude product was used without further purification. Yield: 5.18 g, 98%.
Stage 2. Triethylamine (720 μl, 5.18 mmole) and 5,6,7,8- tetrahydro- [l,2,4]triazolo[4,3-a] pyrazine hydrochloride (238 mg, 1.48 mmole) were added to a solution of the acid chloride (518 mg, 1.48 mmole) in DCM (10 ml). The reaction mixture was stirred overnight at RT. After completion of the reaction the solvent was removed. Purification was first carried out by column chromatography (silica gel, DCM → DCM / 7 M NH3 in MeOH, 98:2) . The product obtained was taken up in DCM and washed with aqueous HCl (0.5 M, 10 ml) . The organic phase was dried over Na2SU4 and concentrated by evaporation. Yield: 210 mg, 32%. m/z=437.2
Preparation of 2- (piperidin-1-ylmethyl) -5, 6, 7, 8- tetrahydroimidazo [1, 2 -a] pyrazine
Figure imgf000150_0001
Stage 1. DMAP (0.75 g, 6.12 mmole) followed by BoC2O (1.34 g, 6.12 mmole) were added to a solution of the ethyl 5,6,7, 8-tetrahydroimidazo [ 1, 2-a] pyrazin-2-carboxylate hydrochloride (1.09 g, 4.70 mmole) in DCM (100 ml). The reaction mixture was stirred for 18 hours at RT. Since the reaction had still not gone to completion, further BoC2O (0.12 g, 0.53 mmole) was added and the mixture was again stirred overnight. After completion of the reaction the reaction mixture was washed with aqueous HCl solution (1 M, 100 ml) , and the organic phase was dried over Na2SC^ concentrated by evaporation in vacuo. The crude product was purified by column chromatography (silica gel, ethyl acetate) (Yield: 300 mg, 21%) .
Stage 2. A solution of 7-tert-butyl 2-ethyl-5,6- dihydroimidazo [ 1, 2-a] pyrazin-2, 7 ( 8H) -dicarboxylate (300 mg, 1.02 mmole) in THF (15 ml) was cooled to -78°C and DIBAL-H (1 M in hexane, 2.0 ml, 2.0 mmole) was slowly added under a N2 atmosphere. The reaction mixture was stirred for 1 hour at this temperature and Na2SO4 x 10 H2O was then added until the evolution of gas was no longer observed. Further Na2SO4 x 10 H2O was added, filtered, and the residue was washed with DCM (25 ml) . The filtrate was concentrated and the crude product obtained (450 mg) was used without further purification in the next stage.
Stage 3. The tert-butyl 2-formyl-5, 6-dihydroimidazo [ 1, 2- a] pyrazin-7 (8H) -carboxylate (400 mg, max. 0.91 mmole) and piperidine (158 μl, 1.59 mmole) were dissolved in DCM (8 ml) and NaBH(OAc)3 (506 mg, 2.39 mmole) was added in portions. The reaction mixture was stirred for 2 hours at RT and then hydrolysed with satd. sodium hydrogen carbonate solution (25 ml) . The phases were separated and the aqueous phase was extracted again with DCM (25 ml) . The combined organic phases were washed with satd. NaCl solution, dried over Na2SO4, and concentrated by evaporation in vacuo (Yield: 260 mg, 90% over 2 stages) .
Stage 4. TFA (2.83 ml, 36.7 mmole) was added to a solution of the tert-butyl 2- (piperidin-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazin-7 ( 8H) -carboxylate (235 mg,
0.73 mmole) in DCM (10 ml) and stirred for 3-4 hours at RT (DC check) . After completion of the reaction the solvent was first of all removed, DCM was added, and the reaction mixture was again concentrated by evaporation to dryness. The product was used without further purification for further reactions . Example 4: (R) -N- (3-oxo-l-phenyl-3- (2-piperidin-l- ylmethyl) -5, 6-dihydroimidazo [1, 2 -a] pyrazin-7 (8H) - yl) propyl) naphthalene-2-sulfonamide
Figure imgf000152_0001
The acid S8 (274 mg, 0.77 mmole) and the amine (0.73 mmole) were dissolved in DCM and cooled to 0°C. HOAt (10.01 mg, 0.07 mmole) diisopropylethylamine (0.64 ml, 3.68 mmole) and EDCI (155 mg, 0.81 mmole) were added at this temperature. The reaction mixture was stirred overnight at RT. After completion of the reaction (DC check) the mixture was diluted with DCM (15 ml) and the organic phase was washed in succession with aqueous KHSO4 solution (0.5 M, 25 ml), satd. NaHCO3 solution (25 ml) and satd. NaCl solution (25 ml) . The organic phase was then dried over Na∑SOή and concentrated. The crude product was purified by column chromatography (firstly silica gel, DCM / 7 M NH3 in MeOH, 9:1, then silica gel, DCM / 7 M NH3 in MeOH, 98:2 → 9:1). Yield: 105 mg . m/z=557.3
Example 2: Preparation of 4-methoxy-N, 2, 6- trimethyl-N- (2- (2-OXO-2- (2-piperidin-l-ylmethyl) -5, 6-dihydroimidazo [1, 2- a]pyrazin-7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide hydrochloride
Figure imgf000153_0001
The acid Sl (1.68 g, 5.06 mmol), HOAt (69 mg, 0.51 mole) , DIPEA (5.30 ml, 30.4 mmole) and EDCI (1.46 g, 7.59 mmole) were added to a solution of the amine (3.17 g, max. 3.48 mmole) in DCM (50 ml) . The reaction mixture was stirred overnight at RT. The mixture was then concentrated by evaporation to dryness. The crude product was purified by column chromatography on silica gel (DCM/7 M NH3 in methanol, 95:5). The product obtained was taken up in DCM (25 ml) and washed with aqueous HCl (0.1 M, 20 ml) . The organic phase was dried over Na2SU4 and concentrated. Yield: 210 mg, 11%
Preparation of 3 -chloro-2- (piperidin-1-ylmethyl) -5, 6, 7, 8- tetrahydroimidazo [1, 2-a] pyrazine
Figure imgf000153_0002
Bocv
Figure imgf000153_0003
Stage 1. Triethylamine (1.34 ml, 9.58 mole) and BoC2O (0.92 g, 4.22 mmole) were added to a solution of the ethyl- 3-chloro-5, 6,7, 8-tetrahydroimidazo [1, 2 -a] pyrazin-2- carboxylate hydrochloride (1.02 g, 3.83 mmole) in DCM (100 ml) and stirred for 18 hours at RT. After completion of the reaction (DC check) the reaction mixture was diluted with DCM and washed with aqueous 0.5 M KHSO4 solution (100 ml) . The organic phase was dried over Na2SO4 and the solvent was evaporated after filtration.
Stage 2. A solution of the Boc-protected ethyl-3-chloro- 5,6,7, 8-tetrahydroimidazo [1, 2-a] pyrazin-2-carboxylate (1.19 g, 3.62 mmole) in THF (25 ml) was cooled to -78°C and DIBAL-H (1 M in hexane, 7.24 ml, 7.24 mmole) was slowly added under a N2 atmosphere. The reaction mixture was stirred for 1 hour at -780C and hydrolysed with Na2SO4 x 10 H2O until the evolution of gas was no longer observed. An excess of Na2SO4 x 10 H2O was added and the mixture was then filtered. The solid was washed with DCM (2 x 25 ml) and the filtrate was then concentrated by evaporation to dryness. The crude product obtained was used further without further purification.
Stage 3. The aldehyde (720 mg, 2.52 mmole) and piperidine (249 μl, 2.52 mmole) were dissolved in DCM (15 ml) and sodium triacetoxy boron hydride (822 mg, 3.88 mmole) was added in portions. The reaction mixture was stirred for 4 hours at RT (LCMS check) . The reaction mixture was hydrolysed with saturated aqueous sodium hydrogen carbonate solution. The phases were separated and the aqueous phase was extracted once more with DCM (25 ml) . The combined organic phases were washed with saturated NaCl solution (25 ml), dried over Na2SC>4, and concentrated by evaporation to dryness.
Stage 4. TFA (2.61 ml, 33.8 mmole) was added to a solution of the Boc-protected amine (240 mg, 0.68 mmole) in DCM
(10 ml) and stirred for 4 hours at RT. After completion of the reaction (DC check) the reaction mixture was concentrated by evaporation to dryness, taken up in DCM (20 ml), concentrated by evaporation to dryness, taken up again in DCM (20 ml) and then concentrated by evaporation to dryness. The crude product was used further without further purification.
Example 5: Preparation of (R) -N- (3- (3-chloro-2- (piperidin- 1-ylmethyl) -5, 6-dihydroimidazo [1, 2 -a] pyrazin-7 (8H) -yl) -3- oxo- 1-phenylpropyl) naphthalene-2 -sulfonamide
Figure imgf000155_0001
The acid S8 (264 mg, 0.74 mmole) was dissolved in DCM (10 ml), DIPEA (1.18 ml, 6.75 mmole) was added, and the mixture was cooled to O C. HATU (282 mg, 0.74 mmole) and the amine (crude product, max. 0.68 mmole) were added and the mixture stirred overnight at RT (DC check) . The reaction mixture was concentrated by evaporation to dryness and the crude product was purified by column chromatography on silica gel (DCM / 7 M NH3 in methanol, 95:5). The product was taken up in DCM (10 ml) and washed with aqueous NaHCO3 solution. The organic phase was dried over Na2SU4 and concentrated. The product was re-purified via a flash column (silica gel, DCM/methanol, 9:1) Yield: 88 mg, 22% over 2 stages)
Example 6: Preparation of N- (2-2- (3-chloro-2- (piperidin-1- ylmethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,6- tr±methylbenzenesulfonamide
Figure imgf000156_0001
The acid Sl (218 mg, 657 μmole), HOAt (8.9 mg, 66 μmole) DIPEA (573 μl, 3.28 mmole) and EDCI (189 mg, 985 μmole) were added to a solution of the amine (695 mg, max. 722 μmole) in DCM (25 ml) and stirred overnight at RT. The reaction mixture was then concentrated by evaporation to dryness and purified by column chromatography on silica gel (flash, DCM / 7 M NH3 in methanol, 99:1). Yield: 319 mg, 86% over 2 stages .
Example No. 162: N- ( (IR) -3- (l-Ethyl-3 , 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene- 2- sulfonamide
Figure imgf000156_0002
Carboxylic acid S9 (120 mg, 0.338 mmol) and N-ethyl-N ' - (3- dimethylamino propyl) carbodiimide hydrochloride (EDCI) (96 mg, 0.507 mmol) were dissolved in CH2Cl2 (8 mL) . HOBt (49 mg, 0.372 mmol), 1-ethyl-l, 2 , 3, 4-tetrahydropyrrolo [ 1, 2- alpyrazine (76 mg, 0.507 mmol) and DIPEA (146 μL, 0.845 mmol) were added and the mixture allowed to stir overnight at room temperature. The reaction mixture was diluted with sat. sodium hydrogen carbonate solution and the aqueous layer extracted with CH2Cl2 (2 x) . The combined organics layers were dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, ethylacetate / hexane, 2:1) to afford screening compound 162 (150 mg, 91%) . LC/MS: Rt = 5.2 min; m/z = 488.2 [MH]+
Example No. 163: 4-Methoxy-N, 2, 6- trimethyl-N- (2- (2-oxo-2- (3- (piperidin-1-ylmethyl) -5, 6-dihydro- [1,2,4] triazolo [4,3- a]pyrazin-7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide
Figure imgf000157_0001
A48 S1 163
To a solution of amine A48 (795 mg, max. 1.19 mmol), carboxylic acid Sl (394 mg, 1.19 mmol) and DIPEA (1.66 mL, 9.52 mmol) in CH2Cl2 (20 mL) was added HATU (498 mg, 1.31 mmol) and the mixture was stirred overnight at room temperature. The mixture was evaporated to dryness and subjected to column chromatography (flash, silica, CH2Cl2/ (7 M NH3 in MeOH), 99:1 to 97:3). The product was then purified further by preparative LCMS twice to afford screening compound 163 (35 mg, 5.5%).
Example No. 164: (R) -N- (3-oxo-l-phenyl-3- (3- (piperidin-1- ylmethyl) -5, 6-dihydro- [1,2,4] triazolo [4, 3 -a] pyrazin-7 (8H) ■ yl) propyl) naphthalene-2 -sulfonamide
Figure imgf000158_0001
A48 S9 164
To a solution of amine A48 (1.59 g, max 2.38 mmol), carboxylic acid S9 (846 mg, 2.38 mmol) and DIPEA (3.32 mL, 19.0 mmol) in CH2Cl2 (40 mL) was added HATU (995 mg, 2.62 mmol) and the mixture was stirred overnight at room temperature. The mixture was evaporated to dryness and subjected to column chromatography (flash, silica, CH2Cl2/ (7 M NH3 in MeOH), 99:1 to 97:3). The product was then purified further by preparative LCMS twice to afford screening compound 164 (28 mg, 2.1%).
The synthesis methods (parallel syntheses) for the example compounds are listed in the following table.
The synthesised example compounds (1) to (161) were analysed inter alia according to their molecular weight. The molecular weights measured by means of ESI-MS are summarised in the following table:
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0002
Parallel synthesis method 4 :
Figure imgf000165_0001
DIPEA Step-2
Procedure for step-1 : Boc-protected amine BB (1 eqv) was treated with 20% TFA in DCM (10ml/ mol) at 00C and the resulting reaction mixture was allowed to stir at 25°C for 4 hrs ( monitored by TLC) . Solvent was completely evaporated, dried properly to remove traces of TFA and the residue was directly used in library synthesis.
Procedure for step-2 : To a dichloromethane solution (3 ml/mmol) of acid BBs (1 eqv) was added EDCI (1.5 eqv), HOBT (1 eqv), DIPEA (2.5 eqv) and the resulting reaction mixture was allowed to stir for 15 minutes at 25°C. In another R. B flask, Boc deprotected amine BB (1.5 eqv) in dichloromethane (1 ml/ mmol) was cooled in ice bath, treated with DIPEA (4 eqv) and it was added to the reaction mixture. Reaction mixture was allowed to stir at 250C for 16 hrs and diluted with dichloromethane. Organic layer was successively washed with aqueous ammonium chloride, sodium bicarbonate and brine and finally dried over sodium sulfate. Evaporation of organic layer under reduced pressure gave the crude product, which was purified by Biotage parallel purification system. Yield : 20-25%
Example compounds 165-179 were obtained according to parallel synthesis method 4 :
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
The following building blocks were used in the synthesis of example compounds 165-179
Figure imgf000168_0002
Figure imgf000169_0001
Figure imgf000170_0001
The purity (determined by UV) , the ESI-MS Results as well as the retention times are given in the following table:
Figure imgf000170_0002
Pharmacological data:
The agonistic and antagonistic action of the compounds according to the invention on the bradykinin 1 receptor (BlR) of humans and rats were determined as described above .
Antagonists lead to a suppression of the Ca2+ inflow. The % inhibition compared to the maximum achievable inhibition was calculated. The compounds according to the invention are highly effective on the human and rat receptor.
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001

Claims

Patent Claims
Substituted sulfonamide derivatives of the general formula 1
Figure imgf000175_0001
wherein
m and n independently of one another in each case denote 0, 1 or 2; p denotes 1 or 2 ;
Q denotes -0- or -CH2-;
X denotes N or CR5; Y denotes N or CR6; Z denotes N or CR7;
R1 denotes aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group;
R2 denotes H, Ci_6-alkyl, aryl or heteroaryl; or an aryl or heteroaryl bonded via a Ci_6-alkylene group, C2-6~ alkenylene group or C2-6-alkinylene group;
R denotes H, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2_6-alkenylene group or C2-6-alkinylene group; R4 denotes H, halogen, CN, NO2, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2_6-alkenylene group or C2_6- alkinylene group;
R5, R6 and R7 independently of one another in each case denote H, halogen, CN, Ci-6-alkyl, -NH (Ci-6-alkyl) , -N(Ci_6-alkyl)2, -Ci-6-alkylene-NH (Ci-6-alkyl) , -Ci-6- alkylene-N (Ci-6-alkyl) 2, C3-8~cycloalkyl, heterocyclyl, aryl or heteroaryl; or denote a heterocyclyl, aryl or heteroaryl bonded via a Cχ-6-alkylene group, C2_6~ alkenylene group or C2-6~alkinylene group;
wherein the aforementioned radicals Ci-6-alkyl, Ci-6~ alkylene, C2-6-alkenylene, C2-6-alkinylene, C3-8- cycloalkyl, heterocyclyl, aryl and heteroaryl can in each case be unsubstituted or monosubstituted or polysubstituted with identical or different radicals, and the abovementioned radicals Ci_6-alkyl, Ci-6- alkylene, C2_6-alkenylene, and C2-6-alkinylene can in each case be branched or unbranched;
in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in each case in the form of their bases and/or physiologically compatible salts .
2. Substituted sulfonamide derivatives according to claim 1, wherein m and n, independently of one another, in each case denote 0, 1 or 2; p denotes 1 or 2; Q denotes -O- or -CH2-;
X denotes N or CR5; Y denotes N or CR6; Z denotes N or CR7;
R1 denotes aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group;
R2 denotes H, Ci-6-alkyl, aryl or heteroaryl; or an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6~ alkenylene group or C2-6~alkinylene group;
R3 denotes H, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6-alkenylene group or C2-6-alkinylene group;
R4 denotes H, halogen, CN, NO2, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~ alkinylene group;
R5, R6 and R7 independently of one another in each case denote H, halogen, CN, Ci_6-alkyl, -NH (Ci_6-alkyl) , -N(Ci-6-alkyl)2, -Ci_6-alkylene-NH (Ci-6-alkyl) , -Ci_6- alkylene-N (Ci-6-alkyl) 2, C3-s-cycloalkyl, heterocyclyl, aryl or heteroaryl; or denote a heterocyclyl, aryl or heteroaryl bonded via a Ci_e-alkylene group, C2-6~ alkenylene group or C2-6-alkinylene group; wherein the aforementioned radicals Ci-6-alkyl, Ci_5- alkylene, C2-6-alkenylene, C2-6-alkinylene, C3-8- cycloalkyl, heterocyclyl, aryl and heteroaryl can in each case be unsubstituted or monosubstituted or polysubstituted with identical or different radicals, and the abovementioned radicals Ci-6-alkyl, C1-6- alkylene, C2-6~alkenylene and C2-6~alkinylene can in each case be branched or unbranched;
in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in each case in the form of their bases and/or physiologically compatible salts,
wherein
a substituted alkyl, alkylene, alkenylene, alkinylene or cycloalkyl is monosubstituted or polysubstituted with identical or different substituents selected from the group consisting of F, Cl, Br, I, CN, NH2, NH-C1-6- alkyl, NH-Ci-e-alkylene-OH, Ci-6-alkyl, N (Ci-6-alkyl) 2, N (Ci-6-alkylene-OH) 2, NO2, SH, S-Ci-6-alkyl, S-benzyl, O-Ci-6-alkyl, OH, O-Ci-6-alkylene-OH, =0, 0-benzyl, C (=0) Ci-6-alkyl, CO2H, CO2-Ci-6-alkyl or benzyl;
a substituted heterocyclyl is monosubstituted or polysubstituted with identical or different substituents selected from the group consisting of F, Cl, Br, I, -CN, NH2, NH-Ci-6-alkyl, NH-Ci-6-alkylene-OH, Ci-s-alkyl, N (Ci-6-alkyl) 2, N (Ci-6-alkylene-OH) 2, pyrrolinyl, piperazinyl, morpholinyl, NO2, SH, S-Ci-e~ alkyl, S-benzyl, O-Ci_6-alkyl, OH, O-Ci-6-alkylene-OH, =0, O-benzyl, C (=0) Ci-6-alkyl, CO2H, CO2-Ci-6-alkyl or benzyl;
and substituted aryl or heteroaryl is monosubstituted or polysubstituted with identical or different substituents selected from the group consisting of F, Cl, Br, I, CN, NH2, NH-Ci-6-alkyl, NH-C!-6-alkylene-OH, N(Ci-6-alkyl)2, N (Ci-6-alkylene-OH) 2, NH-aryl1, N (aryl1) 2, N (Ci-6-alkyl ) aryl1, pyrrolinyl, piperazinyl, morpholinyl, NO2, SH, S-Ci_6-alkyl, OH, O-Ci-6-alkyl, O-Ci-6-alkyl-OH, C (=0) Ci-6-alkyl, NHSO2Ci-6-alkyl, NHCOCi-6-alkyl, CO2H, CH2SO2-phenyl, CO2-Ci-6-alkyl, OCF3, CF3, -0-CH2-O-, -0-CH2-CH2-O-, -0-C (CH3) 2-CH2-, unsubstituted Ci-6-alkyl, pyrrolidinyl, imidazolyl, piperidinyl, benzyloxy, phenoxy, phenyl, pyridinyl, -Ci-5-alkylene-aryl1, benzyl, thienyl and furyl, wherein aryl1 denotes phenyl, furyl, thienyl or pyridinyl.
Substituted sulfonamide derivatives according to claim 1 or 2, wherein R1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably denotes phenyl, naphthyl, benzothiophenyl, benzooxadizolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, and particularly preferably denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or polysubstituted with identical or different substituents preferably selected from the group consisting of -O-Ci_3-alkyl, Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl .
4. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R1 denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or identically or differently polysubstituted, wherein the substituents are selected from the group consisting of methyl, methoxy, CF3, F, Cl, and Br.
5. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R2 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~ alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of Ci-6-alkyl, Ci-6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH.
6. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R2 denotes H, Ci-6-alkyl or phenyl; or denotes a phenyl bonded via a Ci-6-alkylene group, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH.
7. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R3 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C2-6~alkylene group or C3_6- alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of Ci-6-alkyl, Ci-6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH.
8. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH.
9. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein for
Q = -0- m and n are in each case 1, and for Q = -CH2- the sum m+n = 0 or 1.
10. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein p is 1.
11. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R4 denotes H, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci_6-alkylene group, C2_6- alkenylene group or C2-6~alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or identically or differently polysubstituted, the aryl or heteroaryl is preferably selected from the group consisting of phenyl, naphthyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_3-alkyl , unsubstituted Ci-6~ alkyl, F, Cl, Br, I, CF3, OCF3, OH and SH.
12. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein R5, R6 and R7 independently of one another in each case denote H, halogen, Ci_6-alkyl, -N (Ci_6-alkyl) 2, -Ci-6-alkylene- N (Ci-6-alkyl) 2, 5-, 6- or 7-membered heterocyclyl, 5- or 6-membered heteroaryl or denotes a 5- or 6-membered heteroaryl or 5-, 6- or 7-membered heterocyclyl bonded via a Ci-6-alkylene group, wherein heterocyclyl comprises one or two identical or different heteroatoms selected from the group consisting of N and O and is unsubstituted or monosubstituted or identically or differently polysubstituted with Cχ-6- alkyl.
13. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein
m and n in each case independently of one another denotes 0 or 1 ; p is 1;
Q denotes -0- or -CH2;
X denotes N or CR5; Y denotes N or CR6; Z denotes N or CR7;
R1 denotes phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) ; benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl) , preferably denotes phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, and particularly preferably denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or polysubstituted with identical or different substituents, preferably selected from the group consisting of -O-Ci-3-alkyl, Ci-6-alkyl, F, Cl, Br, I CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl;
R2 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C∑-β-alkenylene group or C2-6-alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of Ci_6-alkyl, Ci_6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH;
R3 denotes H, Ci-6-alkyl or aryl; or denotes an aryl bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~alkinylene group, wherein the aryl is in each case unsubstituted or monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of Ci_6-alkyl, Ci-6-alkyl-O-, F, Cl, Br, I, CF3, OCF3, OH and SH;
R4 denotes H, Ci-6-alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci-6-alkylene group, C2-6~alkenylene group or C2-6~alkinylene group, wherein the aryl or heteroaryl is in each case unsubstituted or monosubstituted or identically or differently polysubstituted, the aryl or heteroaryl is preferably selected from the group consisting of phenyl, naphthyl, pyridinyl, thienyl and furyl, and wherein the substituents are preferably selected from the group consisting of O-Ci_3-alkyl, unsubstituted Ci-6- alkyl, F, Cl, Br, I, CF3, OCF3, OH and SH;
R5, R6 and R7 independently of one another in each case denote H, halogen, Cχ-6-alkyl, -N (Ci-6-alkyl) 2, -Cχ-e- alkylene-N (Ci-6-alkyl) 2, 5-membered or 6-membered heterocyclyl, 5- or 6-membered heteroaryl or denote a 5- or 6-membered heteroaryl or a 5- or 6-membered heterocyclyl bonded via a Ci-6-alkylene group, wherein heterocyclyl comprises 1 or 2 identical or different heteroatoms selected from the group consisting of N and 0 and is unsubstituted or monosubstituted or polysubstituted identically or differently with Ci_6- alkyl;
in the form of an individual enantiomer or of an individual diastereomer , in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers and/or diastereomers, as well as in each case in the form of their bases and/or physiologically compatible salts .
14. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein
for Q = -O- m and n are in each case 1, and for Q = -CH2- the sum of m+n = 0 or 1; P is 1;
R1 denotes phenyl or naphthyl, in each case unsubstituted or monosubstituted or identically or differently polysubstituted, wherein the substituents are selected from the group consisting of methyl, methoxy, CF3, F, Cl and Br;
R2 denotes H, Ci_6-alkyl or phenyl; or denotes a phenyl bonded via a Ci-6-alkylene group, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, wherein the radicals are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH;
R3 denotes H or phenyl, wherein the phenyl is in each case unsubstituted or is monosubstituted or polysubstituted with identical or different radicals, the radicals being selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH; R4 denotes H, Ci-6-alkyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a Ci-3-alkylene group, wherein the phenyl, furyl, thienyl or pyridinyl are in each case unsubstituted or monosubstituted or identically or differently polysubstituted, the substituents being selected from the group consisting of -O-Ci-3-alkyl, unsubstituted Ci-6-alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH;
R5 denotes H;
R6 denotes H or a radical that is selected from the group consisting of
Figure imgf000186_0001
wherein R8 and R9 independently of one another in each case denote a Ci-6-alkyl radical, j is in each case 1, 2 or 3, and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH;
R7 denotes H, F, Cl, Br, I, Ci-6-alkyl, or denotes a radical that is selected from the group consisting of
Figure imgf000187_0001
-(CH2)J-N / O --(CH2)j- -N N-
Figure imgf000187_0002
wherein R8 and R9 independently of one another in each case denote a Ci-6-alkyl radical, j is in each case 1, 2 or 3, and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
15. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein
m = 1, n = 1 and Q denotes -0-, m = 1, n = 0 and Q denotes -CH2-, m = 0, n = 1 and Q denotes -CH2- or m = 0, n = 0 and Q denotes -CH2-; p denotes 1;
X denotes N or CR5;
Y denotes N or CR6; Z denotes N or CR7;
R1 denotes phenyl or naphthyl, which is unsubstituted or is monosubstituted or identically or differently disubstituted, trisubstituted, tetrasubstituted or pentasubstituted, wherein the substituents can be selected from the group consisting of methyl, methoxy, CF3, F, Cl and Br;
R2 denotes H, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl or phenyl; or denotes a phenyl bonded via a -CH2-, -(CH2)2~ or -(CH2) 3- group, wherein the phenyl is in each case unsubstituted or is monosubstituted or disubstituted, trisubstituted, tetrasubstituted or pentasubstituted with identical or different radicals, which are selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF3, OCF3 and OH,
R3 denotes H or unsubstituted phenyl,
R4 denotes H, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, furyl, thienyl or pyridinyl; or denotes a phenyl, furyl, thienyl or pyridinyl bonded via a -(CH2)-,
-(CH2) 2- or -(CH2) 3- group, wherein the phenyl, furyl, thienyl or pyridinyl is in each case unsubstituted or is monosubstituted, disubstituted or trisubstituted with substituents selected independently of one another from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, F, Cl, Br, I, CF3, OCF3, OH and SH,
R5 denotes H; R6 denotes H or a radical that is selected from the group consisting of
J-(CH2)J- f -j-(CH2)j-NN J
Figure imgf000189_0001
-(CH2)J-N J i-(CH2)j-Nv N-
Figure imgf000189_0002
wherein R8 and R9 in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH;
R7 denotes H, F, Cl, Br, I methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl or a radical that is selected from the group consisting of
-J-(CH2)J-
Figure imgf000189_0003
Figure imgf000189_0004
wherein R8 and R9 in each case denote a methyl radical, j is in each case 1, 2 or 3 and M1, M2 und M3 independently of one another each denote N or CH, whereby one of M1, M2 and M3 represents N and the other two of M1, M2 and M3 represent CH.
16. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein
X denotes N, YY ddeennootteess CCRR16, and Z denotes CR7
or
X denotes N, Y denotes N and Z denotes CR7
or
X denotes CR5 , YY ddeennootteess CCRR66,, and Z denotes CR7.
17. Substituted sulfonamide derivatives according to one or more of the preceding claims, wherein the sulfonamide derivative is selected from the group consisting of
(1) N- (2- (2- (6- ( (dimethylamino)methyl) -l-phenyl-3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 ( IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide, (2) 4-methoxy-N, 2, 6-trxmethyl-N- (2- (2-oxo-2- (2- (piperidm-1- ylmethyl) -5, 6-dihydroxmidazo [ 1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide,
(3) N- (2- (2- (5, 6-dihydro-[l,2, 4] tπazolo[4, 3-a] pyrazm-7 (8H)- yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(4) (R) -N- (3-oxo-l-phenyl-3- (2- (piperidm-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazm-7 (8H) -yl) propyl ) naphthalene- 2-sulfonamide,
(5) (R) -N- (3- (3-chloro-2- (piperidm-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazin-7 (8H) -yl) -3-oxo-l- phenylpropyl ) naphthalene-2-sulfonamide,
(6) N- (2- (2- (3-chloro-2- (piperidm-1-ylmethyl) -5, 6- dihydroimidazo [1, 2-a] pyrazm-7 (8H) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(7) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (morpholmomethyl) - 3, 4-dihydropyrrolo[l,2-a]pyrazm-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
( 8 ) N- ( 3 -oxo- 1 -phenyl- 3- ( 6- (pyrrolidm- 1 -ylmethyl ) - 3 , 4 - dihydropyrrolo [1, 2-a]pyrazin-2 (IH) -yl) propyl) naphthalene- 2-sulfonamide,
(9) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- ( (4-methylpiperazm- l-yl)methyl) -3, 4-dihydropyrrolo- [1, 2-a] pyrazin-2 (IH) -yl) - 2-oxoethoxy) -ethyl) benzenesulfonamide, (10) N- (3- (6- (morpholinomethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene-2- sulfonamide,
(11) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- ( 6- (pyrrolidin-1- ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(12) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (3- (4- methylpiperazin-1-yl) propyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(13) N- (3- (6- (3- (4-methylpiperazin-l-yl) propyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -3-oxo-l- phenylpropyl) naphthalin-2-sulfonamide,
(14) N- (2- (2- (6- ( (dimethylamino)methyl) -l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(15) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (l-phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(16) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (l-phenyl-6-
(piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(17) N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide, (18) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(19) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- (pyridin-3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzolsulonamide,
(20) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2 -a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(21) N- (2- (2- (5, 6-dihydroimidazo[l,2-a]pyrazin-7 (8H) -yl)-2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(22) N-isobutyl-4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -2, 3, 6-trimethylbenzenesulfonamide,
(23) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(24) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulonamide,
(25) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- (thiophen-2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide, (26) N-isobutyl-4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -2, 3, 6-trimethylbenzenesulfonamide,
(27) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(28) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(29) 4-methoxy-N, 2,3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (pyridin- 3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(30) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 5-tetramethylbenzenesulfonamide,
(31) 4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) -N, 2 , 3, 5-tetramethylbenzenesulfonamide,
(32) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-OXO-2- (1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(33) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [ 1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 5-tetramethylbenzenesulfonamide, (34) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 5-tetramethylbenzenesulfonamide,
(35) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 5-tetramethylbenzenesulfonamide,
(36) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen- 2-yl) -3, 4-dihydropyrrolo [1,2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl) benzenesulfonamide,
(37) 4-methoxy-N, 2,3, 5-tetramethyl-N- (2- (2-oxo-2- (1- (3-
(trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(38) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2 , 3, 5-tetramethylbenzenesulfonamide,
(39) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [1, 2-a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(40) N-benzyl-4-methoxy-2, 3, β-trimethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(41) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-OXO-2- (1-
(pyridin-3-yl) -3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl) benzenesulfonamide, (42) N-benzyl-N- (2- (2- (1- ( 6-chloropyridin-3-yl) -3, A- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(43) N-benzyl-N- (2- (2- (5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(44) N-benzyl-N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo
[ 1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy- 2, 6-dimethylbenzenesulfonamide,
(45) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2- (l-methyl-3, A- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(46) N-benzyl-N- (2- (2- (5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(47) N-benzyl-4-methoxy-N- (2- (2- (1- (4-methoxyphenyl) -3, A- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -2, 6-dimethylbenzenesulfonamide,
(48) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(49) N-benzyl-N- (2- (2- (l-(3, 4-dimethylphenyl) -3, A- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide, (50) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-
(thiophen-2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (1 H) yl) ethoxy) ethyl) benzenesulfonamide,
(51) N-benzyl-N- (2- (2- (1- (4-tert-butylphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(52) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(53) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(54) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (pyridin-3- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(55) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo-
[1, 2-a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy- N, 2, 6-trimethylbenzenesulfonamide,
(56) N- (2- (2- (5, 6-dihydroimidazo[l, 2-a] pyrazin-7 (8H) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(57) N- (2- (2- (1- (3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide, (58) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(59) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(60) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (thiophen-2- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl) benzenesulfonamide,
(61) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (1- (3-
(trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(62) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2 , 6-trimethylbenzenesulfonamide,
(63) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2 , 6- trimethylbenzenesulfonamide,
(64) N- (2- (2- (1- (4-tert-butylphenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(65) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide, (66) N, 2, 4, 6-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(67) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (1- (pyridin-3-yl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(68) N- (2- (2- (1- (6-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(69) N- (2- (2- (1- (4-methoxyphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(70) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(71) N-(2-(2-(l-(3, 4-difluorophenyl)-3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(72) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(73) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide, (74) N, 2, 4, β-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(75) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2-(l- (3-
( trifluoromethyl) phenyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(76) N- (2- (2- (1- (3-methoxyphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(77) N- (2- (2- (1- (2-fluoro-4- (trifluoromethyl) phenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2 , 4, 6-tetramethylbenzenesulfonamide,
(78) N- (2- (2- (1- (4-tert-butylphenyl) -3, 4-dihydropyrrolo [1, 2- a]pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2, 4, 6- tetramethylbenzenesulfonamide,
(79) N- (2- (2- (l-tert-butyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide,
(80) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2- (l-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(81) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- (pyridin- 3-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide, (82) N- (2- (2- (1- (β-chloropyridin-3-yl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(83) 4-methoxy-N- (2- (2- ( 1- (4-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 3, 6-tetramethylbenzenesulfonamide,
(84) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1-phenyl- 3, 4-dihydropyrrolo [1,2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(85) N-(2-(2-(l-(3, 4-difluorophenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(86) N- (2- (2- (1- (3, 4-dimethylphenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(87) N- (2- (2- (1- (3-fluorophenyl) -3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(88) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- (thiophen- 2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(89) 4-methoxy-N- (2- (2- (1- (3-methoxyphenyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2, 3, 6-tetramethylbenzenesulfonamide, (90) N- (2- (2- (1- (4-tert-butylphenyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3, 6-tetramethylbenzenesulfonamide,
(91) N- (2- (2-(6-( (dimethylamino) methyl )-l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(92) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(93) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (piperidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(94) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2- (6-
(morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(95) N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(96) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(97) N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(98) N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen-2-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(99) N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(100) N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) -N-isobutyl-4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(101) N-isobutyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- propyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl ) ethoxy) ethyl) benzenesulfonamide,
(102) N-isobutyl-N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(103) N- (2- (2- (l-ethyl-6-methyl-3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -N-isobutyl-4- methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(104) N-isobutyl-N- (2- (2- (l-isopropyl-6-methyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide, (105) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(106) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (1 H) -yl) ethoxy) ethyl) benzenesulfonamide,
(107) 4-methoxy-N, 2,3, 5-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(108) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2- (6- (morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1,2— a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide,
(109) N- (2- (2- (1-benzyl-β- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo[l, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(110) N- (2- (2- (6- ( (dimethylamino)methyl) -l-phenethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(111) N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide, (112) N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen-2-yl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(113) N- (2- (2- (6- ( (dimethylamino)methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,5- tetramethylbenzenesulfonamide,
(114) N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 5- tetramethylbenzenesulfonamide,
(115) 4-methoxy-N, 2, 3, 5-tetramethyl-N- (2- (2-OXO-2- (1-propyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(116) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(117) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2- (6- (morpholinomethyl) -1-phenyl-3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(118) N-benzyl-N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(119) N-benzyl-N- (2- (2- (6- ( (dimethylamino)methyl) -1-phenethyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3,6- trimethylbenzenesulfonamide,
(120) N-benzyl-N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2-oxoethoxy) - ethyl) -4-methoxy-2, 3, 6-trimethylbenzenesulfonamide,
(121) N-benzyl-N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen- 2-yl) -3, 4-dihydropyrrolo[l, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 3, 6- trimethylbenzesulfonamide,
(122) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolol [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethyl) ethyl) -4-methoxy-2, 3, 6- trimethylbenzenesulfonamide,
(123) N-benzyl-4-methoxy-2, 3, 6-trimethyl-N- (2- (2-oxo-2- (1- propyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(124) N-benzyl-N- (2- (2- ( l-isopropyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 3,6- trimethylbenzenesuIfonamide,
(125) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1- phenethyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl ) benzenesulfonamide,
(126) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -1-phenyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide, (127) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(128) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-phenyl- 6- (piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 ( IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(129) N-benzyl-N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2- (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(130) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -1- (thiophen- 2-yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(131) N-benzyl-N- (2- (2- (6- ( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(132) N-benzyl-N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(133) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- ( 1-phenethyl- 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(134) N- (2- (2- (l-butyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(135) N- (2- (2- (l-ethyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) ■ yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(136) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (l-propyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(137) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 6- trimethylbenzenesulfonamide,
(138) N- (2- (2- (l-ethyl-6-methyl-3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,6- trimethylbenzenesulfonamide,
(139) N- (2- (2- (6- ( (dimethylamino) methyl) -l-phenyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(140) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (pyrrolidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(141) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- ( l-phenyl-6-
(piperidin-1-ylmethy1) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(142) N, 2, 4, 6-tetramethyl-N- (2- (2- (6- (morpholinomethyl) -1- phenyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) benzenesulfonamide, (143) N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl ) -N, 2 , 4 , 6-tetramethylbenzenesulfonamide,
(144) N- (2- (2- (6- ( (dimethylamino)methyl) -1- (thiophen-2-yl) - 3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2 - oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(145) N- (2- (2-(6-( (dimethylamino) methyl) -l-ethyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -N, 2,4, 6-tetramethylbenzenesulfonamide,
(146) N, 2, 4, 6-tetramethyl-N- (2- (2-oxo-2- (l-propyl-3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(147) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [ 1, 2-a] pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -N, 2,4,6- tetramethylbenzenesulfonamide,
(148) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (1- phenethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl ) benzenesulfonamide,
(149) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2-oxo-2- (l-phenyl-6- (piperidin-1-ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide,
(150) 4-methoxy-N, 2, 3, 6-tetramethyl-N- (2- (2- (6-
(morpholinomethyl) -l-phenyl-3, 4-dihydropyrrolo [1,2- a]pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide, (151) N- (2- (2- (l-benzyl-6- ( (dimethylamino) methyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide,
(152) N- (2- (2-(l-ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH)- yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2,3,6- tetramethylbenzenesulfonamide,
(153) N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2-a]pyrazin- 2 (IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-N, 2, 3, 6- tetramethylbenzenesulfonamide,
(154) N-benzyl-4-methoxy-2, 6-dimethyl-N- (2- (2-oxo-2- (1-propyl- 3, 4-dihydropyrrolo [ 1 , 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(155) N-benzyl-N- (2- (2- (l-isopropyl-3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 ( IH) -yl) -2-oxoethoxy) ethyl) -4-methoxy-2, 6- dimethylbenzenesulfonamide,
(156) N- (3- (6- (2- (4-methylpiperazin-l-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) -3-oxo-l- phenylpropyl) naphthalin-2-sulfonamide,
(157) N- (3- (6- (2-morpholinoethyl) -3, 4-dihydropyrrolo [ 1, 2- a] pyrazin-2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalin-2- sulfonamide,
(158) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyrrolidin-1-yl) ethyl) -3, 4-dihydropyrrolo [1,2- a] pyrazin-2 (IH) -yl) ethoxy) ethyl) benzenesulfonamide, (159) N- (3-oxo-l-phenyl-3- (6- (2- (pyrrolidin-1-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) -yl) propyl) naphtha1in- 2-sulfonamide,
(160) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (2- (4- methylpiperazin-1-yl) ethyl) -3, 4-dihydropyrrolo [1, 2- a] pyrazin-2 (IH) -yl) -2- oxoethoxy) ethyl) benzenesulfonamide,
(161) 4-methoxy-N, 2, 6-trimethyl-N- (2- (2- (6- (2- morpholinoethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) -2-oxoethoxy) ethyl) benzenesulfonamide,
(162) N- ( (IR) -3- (l-Ethyl-3, 4-dihydropyrrolo [1, 2-a] pyrazin- 2 (IH) -yl) -3-oxo-l-phenylpropyl) naphthalene-2- sulfonamide,
(163) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (3- (piperidin-1- ylmethyl ) -5, 6-dihydro- [1, 2, 4] triazolo [4, 3-a]pyrazin-
7 (8H) -yl) ethoxy) ethyl) benzenesulfonamide,
(164) (R) -N- (3-oxo-l-phenyl-3- (3- (piperidin-1-ylmethyl) -5, 6- dihydro- [1,2,4] triazolo [4, 3-a] pyrazin-7 (8H) - yl) propyl) naphthalene-2-sulfonamide, (165) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-4- ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(166) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-3- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl ) ethoxy) ethyl ) benzenesulfonamide,
(167) N- (3-Oxo-l-phenyl-3- (6- (pyridin-3-yl) -3, 4- dihydropyrrolo [ 1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(168) N- (3-Oxo-l-phenyl-3- (6- (pyridin-4-yl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) propyl) naphthalene-2-sulfonamide,
(169) N- (3-Oxo-l-phenyl-3- (6- (pyridin-4-ylmethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl ) propyl ) naphthalene-2-sulfonamide, (170) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyridin- 3-yl) ethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(171) N- (3-Oxo-l-phenyl-3- (6- (2- (pyridin-3-yl) ethyl) -3,4- dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) propyl) naphthalene-2-sulfonamide,
(172) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (2- (pyridin- 4-yl) ethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl ) ethoxy) ethyl ) benzenesulfonamide, (173) N- (3-Oxo-l-phenyl-3- (6- (2- (pyridin-4-yl) ethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(174) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-3- ylmethyl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) ethoxy) ethyl) benzenesulfonamide,
(175) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (pyridin-4- yl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide,
(176) N- (3-Oxo-l-phenyl-3- (6- (pyridin-3-ylmethyl) -3, 4- dihydropyrrolo [1, 2-a] pyrazin-2 (IH) - yl) propyl) naphthalene-2-sulfonamide,
(177) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (6- (pyridin-4- yl) -3, 4-dihydropyrrolo [1, 2-a] pyrazin-2 ( IH) - yl) ethoxy) ethyl) benzenesulfonamide, (178) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (2- (pyridin- 4-yl) ethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide and
(179) 4-Methoxy-N, 2, 6-trimethyl-N- (2- (2-oxo-2- (2- (pyridin-4- ylmethyl) -5, 6-dihydroimidazo [1, 2-a] pyrazin-7 (8H) - yl) ethoxy) ethyl) benzenesulfonamide
in the form of an individual enantiomer or an individual diastereomer, in the form of the racemate, enantiomers, diastereomers, mixtures of the enantiomers or diastereomers, in each case in the form of their bases and/or physiologically compatible salts .
18. Process for the preparation of substituted sulfonamide derivatives according to one or more of the preceding claims,
Figure imgf000213_0001
N P
wherein carboxylic acids of the general formula N are reacted in an amide formation using amines of the general formula O in the presence of water-extracting agents such as sodium or magnesium sulfate, phosphorus oxide or reagents such as for example CDI, DCC, TBTU, EDCI, PyBOP or PFPTFA, also in the presence of HOAt or HOBt and an organic base, for example DIPEA or pyridine, in an organic solvent such as THF, dichloromethane, diethyl ether, dioxane, DMF or acetonitrile, at temperatures from 00C to the reflux temperature, to yield the final products of the general formula P.
19. Medicament containing at least one substituted sulfonamide derivative according to one or more of claims 1 to 17, optionally containing suitable additives and/or auxiliary substances and/or further active constituents.
20. Use of at least one substituted sulfonamide derivative according to one of claims 1 to 17 for the preparation of a medicament for treating pain, in particular acute, neuropathic or chronic pain.
21. Use of at least one substituted sulfonamide derivative according to one of claims 1 to 17 for the preparation of a medicament for treating pain, in particular acute, visceral, neuropathic, chronic pain and/or inflammatory pain.
22. Use of at least one substituted sulfonamide derivative according to one of claims 1 to 17 for the preparation of a medicament for treating migraine, diabetes, diseases of the respiratory tract, inflammatory intestinal diseases, neurological diseases, inflammations of the skin, rheumatic diseases, septic shock, reperfusion syndrome, obesity and as an angiogenesis inhibitor.
PCT/EP2009/000190 2008-01-17 2009-01-15 Substituted sulfonamide derivatives WO2009090054A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2712265A CA2712265A1 (en) 2008-01-17 2009-01-15 Substituted sulfonamide derivatives
JP2010542577A JP2011509961A (en) 2008-01-17 2009-01-15 Substituted sulfonamide derivatives
EP09702327A EP2229395A1 (en) 2008-01-17 2009-01-15 Substituted sulfonamide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08000840.2 2008-01-17
EP08000840 2008-01-17

Publications (1)

Publication Number Publication Date
WO2009090054A1 true WO2009090054A1 (en) 2009-07-23

Family

ID=39539534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000190 WO2009090054A1 (en) 2008-01-17 2009-01-15 Substituted sulfonamide derivatives

Country Status (8)

Country Link
US (1) US8263598B2 (en)
EP (1) EP2229395A1 (en)
JP (1) JP2011509961A (en)
AR (1) AR070187A1 (en)
CA (1) CA2712265A1 (en)
CL (1) CL2009000085A1 (en)
PE (1) PE20091436A1 (en)
WO (1) WO2009090054A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102229610A (en) * 2011-04-22 2011-11-02 中山大学 Method for synthesizing optical pure chiral 1,2,3,4-tetrahydropyrrole[1,2-a] pyrazine compound
CN102464661A (en) * 2010-11-16 2012-05-23 上海药明康德新药开发有限公司 Preparation method of 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid ethyl ester
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
JP2013527226A (en) * 2010-06-03 2013-06-27 サノフイ 3,4-Dihydropyrrolo [1,2-a] pyrazine-2,8 (1H) -dicarboxamide derivatives, their preparation and therapeutic use thereof
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
CN109956865A (en) * 2017-12-22 2019-07-02 浙江瑞博制药有限公司 A kind of preparation method of sitagliptin intermediate
CN114891004A (en) * 2017-12-23 2022-08-12 浙江九洲药业股份有限公司 Preparation method of sitagliptin intermediate compound

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
TW200944530A (en) * 2008-04-09 2009-11-01 Gruenenthal Chemie Substituted sulfonamide derivatives
CN103113324B (en) * 2013-02-07 2015-08-05 浙江工业大学 The preparation method of the tetrahydropyrrole compound that a kind of N-alkylsulfonyl replaces
CA3005353A1 (en) 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
KR102495650B1 (en) * 2017-04-12 2023-02-02 에프. 호프만-라 로슈 아게 Methods for Labeling Aldehyde-Containing Target Molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178360A1 (en) * 2003-03-25 2006-08-10 Laboratoires Fournier S.A. Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
US20060258646A1 (en) * 2003-05-14 2006-11-16 Tesfaye Biftu 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
WO2008046573A1 (en) * 2006-10-16 2008-04-24 Grünenthal GmbH Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE523926C2 (en) * 1999-06-15 2004-06-01 Hans Lundqvist stent Events

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178360A1 (en) * 2003-03-25 2006-08-10 Laboratoires Fournier S.A. Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
US20060258646A1 (en) * 2003-05-14 2006-11-16 Tesfaye Biftu 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
WO2008046573A1 (en) * 2006-10-16 2008-04-24 Grünenthal GmbH Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALIXTO ET AL., BR. J. PHARMACOL, 2004, pages 1 - 16
GABRA ET AL., BIOL. CHEM., vol. 387, 2006, pages 127 - 143
HESS ET AL., BIOL. CHEM, vol. 387, no. 2, 2006, pages 195 - 201
PESQUERO ET AL., BIOL. CHEM., vol. 387, 2006, pages 119 - 126

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527226A (en) * 2010-06-03 2013-06-27 サノフイ 3,4-Dihydropyrrolo [1,2-a] pyrazine-2,8 (1H) -dicarboxamide derivatives, their preparation and therapeutic use thereof
CN102464661A (en) * 2010-11-16 2012-05-23 上海药明康德新药开发有限公司 Preparation method of 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid ethyl ester
CN102464661B (en) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 Preparation method of 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid ethyl ester
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
CN102229610A (en) * 2011-04-22 2011-11-02 中山大学 Method for synthesizing optical pure chiral 1,2,3,4-tetrahydropyrrole[1,2-a] pyrazine compound
CN102229610B (en) * 2011-04-22 2014-10-29 中山大学 Method for synthesizing optical pure chiral 1,2,3,4-tetrahydropyrrole[1,2-a] pyrazine compound
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
CN109956865A (en) * 2017-12-22 2019-07-02 浙江瑞博制药有限公司 A kind of preparation method of sitagliptin intermediate
CN109956865B (en) * 2017-12-22 2022-09-13 浙江瑞博制药有限公司 Preparation method of sitagliptin intermediate
CN114891004A (en) * 2017-12-23 2022-08-12 浙江九洲药业股份有限公司 Preparation method of sitagliptin intermediate compound
CN114891004B (en) * 2017-12-23 2024-01-05 浙江九洲药业股份有限公司 Preparation method of sitagliptin intermediate compound

Also Published As

Publication number Publication date
US20090186899A1 (en) 2009-07-23
PE20091436A1 (en) 2009-10-08
AR070187A1 (en) 2010-03-17
CL2009000085A1 (en) 2009-03-20
CA2712265A1 (en) 2009-07-23
US8263598B2 (en) 2012-09-11
EP2229395A1 (en) 2010-09-22
JP2011509961A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
US8263598B2 (en) Substituted sulfonamide compounds
EP2403854B1 (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
US8178535B2 (en) Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments
CA2947338C (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
AU2007312557B2 (en) Substituted tetrahydropyrrolopyrazine compounds having affinity with the KCNQ 2/3 K+ channel and use thereof in medicaments
CN112601751B (en) Fused thiophene compounds
US10717736B2 (en) Pyrrole amides as alpha V integrin inhibitors
KR20070009699A (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
EA019192B1 (en) Piperidinyl derivatives as modulators of chemokine receptor activity
AU2005262330A1 (en) Piperidine derivatives as NK1 antagonists
SK9412002A3 (en) Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
JP2012506396A (en) Pyrimidine- and triazine-sulfonamide derivatives as bradykinin B1 receptor (B1R) inhibitors for the treatment of pain
EP3634955B1 (en) Piperidinone formyl peptide 2 receptor agonists
JP2012529448A (en) Substituted benzimidazoles, benzothiazoles and benzoxazoles
EP2617715A1 (en) Glycine transporter inhibitor
AU2002366801A1 (en) PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
KR20170129192A (en) A heterocyclic compound useful as an inhibitor of TNF
WO2014146249A1 (en) Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
KR20240013134A (en) Pyridine-sulfonamide derivatives as sigma ligands
CN114126713A (en) Substituted benzimidazolone compounds
TW202417435A (en) Targeted protein degradation of parp14 for use in therapy
JP2012516860A (en) Substituted indole compounds as bradykinin receptor 1 modulators
WO2023284703A1 (en) Protein degradation compound designed on the basis of bruton's tyrosine kinase ligand and application thereof
JP2013536812A (en) Substituted tetrahydropyrrolopyrazine derivatives
RU2778478C2 (en) Bicyclic dihydropyrimidinecarboxamide derivatives as rho-kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702327

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009702327

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2712265

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010542577

Country of ref document: JP